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ABSTRACT
Polymeric drug delivery systems have been widely used in the pharmaceutical industry.
Such systems can solubilize and sequester hydrophobic drugs from degradation, thereby
increasing circulation half-life and efficacy. However, there are still challenges in the
design of drug delivery vehicles to achieve efficient drug delivery in a site-specific
manner. In this thesis, an amphiphilic linear-dendritic block copolymer was designed,
synthesized, and applied as a new polymeric drug delivery platform.
First, to develop the drug delivery vehicle, an ABA dendritic-linear-dendritic block
copolymer consisting of poly(amidoamine) (PAMAM) and poly(propylene oxide) (PPO)
was synthesized. In order to determine the viability of the linear-dendritic block
copolymer as a drug delivery vehicle, the solution-phase self-assembly behavior and the
self-assembled structures were characterized experimentally and through molecular
dynamics simulations. The triblock self-assembles in aqueous media to form stable
micelles with low CMC values. Dynamic light scattering results and TEM indicate the
formation of particles ranging from 9 to 18 nm in diameter, with smaller diameters
exhibited at higher generations. Static light scattering also confirmed the trend where the
aggregation number decreased with higher generations. The experimental
characterization results indicated that the physical characteristics of the PPO-PAMAM
micelles were desirable and within the design specifications necessary for drug delivery.
The experimental results were utilized to set up simulations where further knowledge of
the microstructure of the micelles formed could be gained. It was found that the block
copolymers simulated formed micelles in the same size range that was seen
experimentally. However, the simulations indicated that the micelles displayed greater
asphericity than dendrimers. Backfolding of the terminal amine ends was encountered,
which would have implications for the configuration and spacing of any additional
targeting ligand attached to the dendritic ends. Further analysis revealed that with
increasing generation, the porosity of the micelles increased, which could affect the
diffusion rate of drugs released out of the system. Another important finding detailed the
preferential localization of a model hydrophobid drug, triclosan, in an equilibrated
micelle structure.
Additional experiments were performed to assess the feasibility of the nanoparticles for
drug delivery applications. Drug loading studies were performed with a model
hydrophobic drug, triclosan, resulting in high loading efficiencies. In comparison, linear
block copolymers were half as efficient in loading triclosan. It was determined that the
dendritic block synergistically increased the drug loading due to either acting as an
additional block capable of encapsulating drug or sterically favoring the seclusion of the
drug in the core. The linear-dendritic block copolymer synthesized was found to be a
promising candidate for drug delivery due to its relative stability in aqueous solution and
its drug encapsulation and release properties.
Overall, the linear-dendritic block copolymer displayed physical characteristics and self-
assembly behavior that satisfied the design criteria for a viable drug delivery vehicle. As
a further step, the potential benefits of the novel linear-dendritic architecture were
explored in two different drug delivery applications. First, PPO-PAMAM was explored
as a circulating nanoparticle with the capability of multivalently targeting to specific
cells, due to the presence of the dense functional groups on the dendritic block forming
the corona of the micelles. PPO-PAMAM was functionalized with galactose and targeted
to hepatocellular carcinoma cells. It was found that the polymer was not cytotoxic and
could bind to the asialoglycoprotein receptor. The galactose-functionalized micelles
were loaded with a chemotherapeutic, doxorubicin, and delivered to the carcinoma cells
more efficiently than non-functionalized micelles and bare doxorubicin. The results from
in vitro testing showed that PPO-PAMAM micelles with targeting capability are
promising circulating drug delivery vehicles.
In order to ensure success of subsequent testing in vivo of the targeted linear-dendritic
block copolymer system, some improvements to the system were explored. First, PPO-
PAMAM micelles were stabilized by physical entrapment of the hydrophobic core. An
emulsion polymerization of hydrophobic methacrylate monomers created an
interpenetrating polymer keeping the micelles intact at concentrations below the CMC
and in a solubilizing solvent, methanol. This improvement would ensure that once
injected into the bloodstream, the micelles would not destabilize and release high
concentrations of drug. Another improvement that was explored was the synthesis of a
new linear-dendritic block copolymer composed of a hydrophobic poly(amino acid) and a
polyester dendron. Additionally, poly(ethyleneglycol) (PEG) groups were attached to the
outer surface of the polyester dendron. The new system synthesized has a low CMC and
is thermodynamically slow to break apart in the bloodstream. Furthermore, the micelles
formed would be able to circulate for longer times with PEG aiding in evading the
reticuloendothelial system.
The second drug delivery application explored, which advantageously utilized the
dendritic blocks on the outer surface of the block copolymer micelles was as a localized
drug delivery coating created by the layer-by-layer (LbL) assembly approach. The
electrostatic LbL assembly approach offers large potential in the area of drug delivery
from thin films and surfaces; however, because the processing technique is aqueous-
based, there have been few strategies proposed to incorporate hydrophobic molecules into
these films. Here we created an LbL film that is capable of incorporating hydrophobic
drug at high loadings via encapsulation with linear-dendritic block copolymer micelles
and demonstrate for the first time release times of a hydrophobic antibacterial agent over
a period of several weeks--a significant improvement over reports of other micelle-
encapsulated thin films with release times of several minutes. The PAMAM block,
which is polycationic, enabled LbL deposition with negatively charged poly(acrylic acid)
(PAA). The stable PPO-PAMAM micelles incorporated into the LbL films encapsulated
a hydrophobic bactericide, triclosan. Film thickness and UV-vis measurements confirm
the formation of the LbL film and incorporation of triclosan into the film. Fluorescence
measurements of PPO-PAMAM/PAA films with pyrene indicated the presence of
hydrophobic domains in the film. GISAXS revealed regular spacing of approximately
10.5 nm in the direction parallel to the film substrate, which is approximately the same
size as the PPO-PAMAM micelles in aqueous solution. Volume fraction measurements
based on elemental analysis and TGA confirm the GISAXS data. An in vitro release
study revealed long release times of triclosan on the order of weeks, and a Kirby Bauer
test was performed on Staphylococcus Aureus demonstrating that the drug released was
still active to inhibit the growth of bacteria.
Linear-dendritic block copolymer micelles were successfully used in two different drug
delivery applications where the dendritic block could be fully utilized. It is hoped that
with the research and results presented in this thesis further development of this drug
delivery platform can result in a product successfully treating a serious disease.
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CHAPTER 1: INTRODUCTION
1.1 Motivation
Systemic drug delivery is a nonspecific treatment that can cause harmful side
effects. For example, chemotherapy kills cancer cells but also causes unwanted side
effects by destroying other healthy rapidly growing cells within the body. New
developments in localized or targeted drug delivery methods can be a promising
alternative. Currently, colloidal particles such as liposomes or block copolymers have
been designed and studied for use as drug carriers for delivering drugs to localized sites.
These colloidal particles can encapsulate a wide variety of drugs and isolate them from
the physiological environment where degradation can occur. Furthermore, they can
solubilize hydrophobic drugs at concentrations above the solubility limit of the drug in
aqueous solution. As a result of employing a nanoparticle, the half-life of the drug is
increased as it is sequestered from degradation reactions within the body, and the
distribution of drug within the body can be altered.' Primarily, drug delivery
nanoparticles are delivered parenterally, and the circulation times of these nanoparticles
can be increased by the use of polyethylene glycol (PEG) grafted to the exterior of the
nanoparticles. PEG creates a hydrodynamic barrier that prevents recognition, uptake, and
removal by the reticuloendothelial system (RES).2-4 Increased circulation times allow for
greater passive targeting to targeted sites through the enhanced permeability and retention
(EPR) effect.5 The EPR effect occurs in tumor tissue that have increased permeability of
blood vessels in tumor tissue and decreased lymphatic drainage.6
Although these studies have contributed to the development of promising drug
delivery vehicles targeting drugs to solid tumors, there are still challenges in the use of
colloidal particles for site-specific drug delivery. The first challenge is to develop a
nanoparticle that is stable in aqueous solution and does not break apart when it is
administered into the body.7 The second challenge is to control the biodistribution of the
drug delivery vehicle and have effective extravasation of the nanoparticles from the
vascular system into the treatment site.8 Once the particle enters the tumor, it must then be
taken up by the cancer cells and undergo endocytosis. The next challenge is to effectively
release the drug in a controlled manner while within the endosome or after escaping the
endosome. 9 Other challenges include the ability to increase drug-loading capacity, to vary
the size of the particle while maintaining stability, to prevent the aggregation of particles,
to introduce cell-specific targeting capability through the addition of targeting ligand, and
to vary ligand valency on the surface of the particle.
To address these issues, the scope of this thesis includes the design and creation
of a novel amphiphilic linear-dendritic block copolymer. As shown in Figure 1-1, the
linear-dendritic block copolymer consists of a hydrophobic linear block attached to a
hydrophilic dendron. These copolymers will undergo self-assembly in solution due to
thermodynamic driving forces that strive to isolate the hydrophobic linear block from the
surrounding media and to expose the hydrophilic dendron. In addition to synthesizing the
polymer, the aqueous phase self-assembly behavior of the linear-dendritic block
copolymer has also been studied to determine its feasibility as a drug delivery vehicle.
Molecular dynamics simulations of some of the linear-dendritic block copolymer micelle
systems also provided insight into the microstructure of the self-assembled micelles.
The linear-dendritic block copolymer micelles were then used in two different
drug delivery applications. The main application that was studied was exploring the use
of the linear-dendritic block copolymers as circulating nanoparticles for drug delivery. In
vitro studies were undertaken to evaluate the role of multivalency and the effectiveness of
the targeting ligand to deliver the drug-encapsulated colloidal particles to carcinoma
cells. Additional improvements were investigated including stabilizing the linear-
dendritic block copolymers through physical entrapment of the hydrophobic cores and
also developing a different linear-dendritic block copolymer system for future use.
The other application that was explored with the linear-dendritic block copolymer
micelles was to incorporate these micelles into a thin film as a coating for biomedical
implants. The block copolymer micelles were used to provide a hydrophobic
environment available as a hydrophobic drug depot in a film formed through the layer-
by-layer dipping process.
Figure 1-1. Linear-dendritic block copolymers self-assembling into a micelle.
1.2 Background: Colloidal Drug Delivery Systems
Colloidal drug delivery systems have shown a lot of promise in the effective
targeting of cytotoxic drugs to cancer tumors and areas of infarction by protecting the
drugs from degradation and prolonging circulation within the body. By encapsulating
drugs in a nanoparticle, the distribution of the drug is less determined by the properties of
the drug and more dependent on the size and surface properties of the drug carrier. There
are two different mechanisms that can be exploited to alter the biodistribution of the
nanoparticles circulating in the body. First, the size of the nanoparticles can be
manipulated to affect their passive accumulation at sites with arterial damage. Specific
targeting of the drug-encapsulating nanoparticles can be introduced through the
attachment of cell-specific targeting ligand to the outer surface of the particles.
1.2.1 Factors for Passive Targeting
The size of the circulating nanoparticles is a critical factor in controlling the
biodistribution of the drug. First, there are size restrictions that have to be met in order
for the nanoparticles to avoid removal from circulation. The nanoparticle must be larger
than 2-3 nm to avoid being filtered out by the kidney but smaller than 150 nm in order to
avoid the RES. 10 The RES is mainly composed of monocytes and macrophages in the
liver and spleen that have the ability to recognize microparticulate systems and remove
them from circulation. Recognition by the RES is aided by the adsorption of proteins,
called opsonins, onto the surface of the nanoparticles which promote phagocytosis.
,1
' 12
With an increase in size of the drug delivery vehicle, there is an increased rate of uptake
by the RES. 13
The size of the nanoparticle is important as it will determine the rate of
extravasation and uptake into the cells. Although macroparticles have a tendency to
accumulate in tumor tissue through the EPR effect, it has been found that as the size of
the particle increases, the time for extravasation exponentially increases. 14' 15 Once in the
tumor tissue, the size of the particle may also impede transport of the particle through the
solid tumor. There is high interstitial fluid pressure that is often present in tumor masses
which can decrease the ability of particles to penetrate the tumor as its size gets larger.16
Another consideration is that it is more difficult to internalize bulky particles by
nonphagocytic cells. 17  Typically, endocytosis can only occur for particles that are
smaller than 150 nm in diameter. Overall, an intermediate sized particle is necessary in
order to avoid the RES and facilitate extravasation and transport through the tumor.
The surface properties of the drug carrier are also crucial in determining the
biocompatibility, biodistribution, and retention within the circulatory system. It has been
found that neutrally charged liposomes have a lower tendency to be cleared by the RES
in comparison to positively or negatively charged liposomes. However, they have a
higher tendency to aggregate, which could also induce uptake by the RES.' 8 Cationic
particles are quickly removed from systemic circulation due to electrostatic interactions
with negatively charged cell membranes and the extracellular matrix.' Because of this
interaction, it has been found that particles with primary amine groups exposed can cause
haemolysis' 9 and are cytotoxic.20  Receptors found on macrophages can recognize
negative surface charges; thus, anionic particles are rapidly cleared from the body.2
To improve retention times and reduce immunogenecity, the surfaces of the drug
carriers can be modified with hydrophilic moieties that confer a hydration barrier around
the particle. The most common modification is the conjugation of short chains of PEG.
PEG has been well-characterized for biological use and parenteral applications.18 Other
polymers that have been used to form steric barriers include poly(acryloyl morpholine),
poly(acrylamide), poly(vinyl pyrrolidone), and polyvinyl alcohol. 9' 18 PEG is usually the
polymer of choice due to its high water solubility, low toxicity, low immunogenicity, and
high chain mobility.21 With the addition of PEG, the drug carriers have a reduced rate of
uptake by the RES, thus prolonging the circulation half-life.4' 22 Water molecules form a
sheath around the PEG chains, creating a particle with a large hydrodynamic radius that
prevents the adsorption of opsonins to the surface.2 3 The addition of the PEG palisade
also reduces the toxicity of the nanoparticle by decreasing interactions with the
physiological environment 20, 24 and alters the distribution of nanoparticles within the
body. For example, after conjugation of PEG to a cationic liposome, accumulation
dramatically decreased in the lung.2 5
By designing the drug delivery vehicle with an optimal size and the correct
surface properties, the blood circulation time of the drug can be dramatically improved.
With the increased circulation half-life and the EPR effect, more of the nanoparticles can
passively accumulate within leaky vasculature seen in tumors, inflammations, and
infarcted areas.
1.2.2 Active Targeting
To increase the retention of drug delivery nanoparticles in the affected sites
beyond what is offered by passive targeting, the attachment of various cell-specific
targeting ligands has been explored. In order for active targeting to be effective, there are
three key issues that have to be addressed. First, the drug delivery vehicle must circulate
within the system long enough for localization to the site of the tumor and for interaction
with the targeted cells. This is ensured through designing the nanoparticle with the
ability to passively accumulate at the tumor site in high concentrations as discussed
previously. The next consideration is that the ligand or the receptor to the targeted cells
should be highly specific. For example, rapidly growing tumor cells upregulate certain
receptors to allow for greater uptake of nutrients; therefore, tumor cells have a greater
density of specific receptors in comparison to healthy cells. The last consideration is that
the targeting molecule on the surface of the drug carrier should be stable in vivo and its
potential for opsonization is minimal. 18
There are several classes of targeting ligands that have been used for drug
targeting. This includes antibodies, carbohydrates, peptides, cell surface receptor ligands,
and oligonucleotide aptamers.26 For the treatment of tumor cells, ligands that are
recognized by cell surface receptors have been the most popular, including transferrin
and Apo E/Apo B.' 8 Transferrin receptors are overexpressed on the surface of many
tumor cells, and transferrin has been attached to liposomes to deliver drug to tumors and
into tumor cells.2 7' 28
1.2.2.1 Carbohydrates
Binding between carbohydrates and sugar binding proteins called lectins can be as
specific as enzyme-substrate or antigen-antibody interactions. Lectins have multiple
binding domains that bind to specific carbohydrate moieties. 29 Through multivalent
interactions, the strength of binding is increased dramatically from a Kd in the 10-3 M
range for monovalent interactions down to a Kd of 10-6 M and 10-9 M for divalent and
trivalent oligosaccharides, respectively. 2 9 There are two broad classes of lectins.30 C-
type lectins require calcium for binding, and this includes the hepatic asialoglycoprotein
receptor. S-type lectins, also known as galectins, are calcium independent. It has been
found that galectins-1 and -3 are overexpressed on the surface of colon cancer cells. 30
Targeting of carbohydrates to lectins have been applied in multiple applications
including gene therapy 31 and drug delivery.32  Drug delivery systems containing
asialofetuin, galactose, or N-acetyl-galactosamine have been able to bind and be
endocytosed by the asialoglycoprotein receptor present on hepatocytes. 33 Derivatives of
N-(2-hydroxypropyl)methacrylamide covalently bound to sugar ligands have been able to
deliver doxorubicin to colon adenocarcinoma and hepatic carcinoma cells.34' 35 The
higher the sugar content in the HPMA polymer, there was a higher extent of cell binding
due to the multivalent binding required with lectins. 34
1.2.2.2 Folate
Another popular targeting ligand is folate, a vitamin required in several metabolic
pathways and is essential for the biosynthesis of nucleotide bases. It is consumed in
elevated quantities by proliferating cancer cells. Folate is transported across the cell by
either of two membrane-associated proteins, a reduced folate carrier or the folate receptor
(FR). The reduced folate carrier is the primary pathway for uptake of folate while the
folate receptor is found mainly on polarized epithelial cells and activated macrophages.
FR has been found to be overexpressed in cancer cells. Furthermore, FR is only
accessible after the cells have been transformed into malignant cells. Normally, FR is
selectively expressed on the apical membrane surface (surface facing the body cavity) of
epithelial cells. After transformation into a malignant cell, the polarity is lost and FR on
the cells is accessible to drugs in circulation. 36 Because of these mechanisms for tumor
specificity, folic acid is a natural choice to be used as a molecule for targeting drugs to
cancer cells. The advantages to using folic acid is that it is nonimmunogenic, has a high
binding affinity (Kd -. 1 nM), has good stability, has simple and defined conjugation
chemistry, is available in large quantities, and is compatible with the use of organic
solvents.37
Folic acid is taken into cells by a process called potocytosis. Folate receptors
occur in dense clusters on the cell surface associated to caveolae, which are invaginated
pits that have a diameter of approximately 50 nm. Each cluster is composed of 700
receptor molecules. Once the caveolae are closed, the pH decreases to approximately 5.0
and the folate is released from the receptor.38 Due to the mechanism of folate uptake, it
has been found that folate binding is multivalent. The presence of multiple folates on a
single dendrimer decreases the Kd dramatically from about 2500 to 170,000-fold. 39
1.2.2.3 Targeting Challenges
Although there are several promising ligands that are being explored to target to
specific cells for drug treatment, extravasation to the tumor site has been found to be the
rate-limiting step for liposomes. For example, folate targeting has not increased the
concentration of liposomes in subcutaneously growing tumor implants.40 However,
targeting could be used for improved delivery and retention of therapeutics within tumor
tissue. Retrograde movement of drug-carrying nanoparticles may be hindered due to
binding of the nanoparticles to target cells, and retention of the drug is enhanced through
receptor-mediated endocytosis or potocytosis. The therapeutic index of the drug could
increase as the drug distribution shifts from the extracellular space of the tumor into the
intracellular compartments of the tumor cells-although, the relative contributions of
drug released in the extraceullular space and the intracellular space are unknown. In a
study of HER2-targeted immunoliposomes containing doxorubicin (DOX), there was
better tumor penetration, tumor cell uptake, and therapeutic efficacy.4 1
In several studies, the role of multivalency has shown to be dramatic.
Conjugation of a large number of ligand on the surface of the drug particle has increased
the avidity of the particle to the target cells. For polymeric systems, as the ligand density
on the surface of the particle was increased, binding increased exponentially. 34 Similarly,
the addition of 1000-fold greater concentration in free folate was necessary in order to
compete with the binding of folate-targeted liposomes to a folate receptor. 42 Therefore
another advantage for creating a targeted nanoparticle is that with greater affinity and
efficacy dosage could be lowered.
Although the use of a ligand may confer a greater affinity to targeted cell types,
the improved avidity and affinity may also negatively impact tumor penetration. It has
been demonstrated that antibody-free vesicles more readily permeate tumors than
immunoliposomes. This may be due to the high affinity of the antibody to the antigen
where the rate of transport into the tumor is smaller than the rate of binding to tumor
cells, thus retarding penetration into the tumor and binding occurs only at the periphery.43
Modeling of antibodies percolating through solid tumors shows that lower affinity
antibodies are able to penetrate into tumors more than higher affinity antibodies.44 Thus,
in the creation of a targeted nanoparticle, there is an optimal ligand density that will
balance the need for affinity to target cells and greater penetration into solid tumors.
1.2.3 Nanoparticles for Drug Delivery: Liposomes
Liposomes are phospholipid bilayer vesicles which can entrap hydrophilic drug
molecules in its aqueous interior or can incorporate hydrophobic molecules into its
bilayer as shown in Figure 1-2. The most common formulation of liposomes utilizes
phosphatidylcholine, which is neutrally charged, with fatty acyl chains of varying length
and degree of saturation. Cholesterol can also be added to modulate the rigidity and
stability of the liposome. In the mid-1990s, liposomes were approved by the FDA for use
as therapeutics in humans. Liposomal drug delivery systems have mainly been
developed for antifungal and anticancer therapies.18
Figure 1-2. Liposomes are composed of lipid bilayers that are able to encapsulate
hydrophilic drug in its aqueous core and hydrophobic drug in the lipid region.
Liposomes are characterized with long systemic circulation times in comparison
to the free drug. However, they are also characterized by efficient uptake by the RES. In
order to evade the RES and increase circulation times, liposomes have been modified by
adding PEG to their outer surface.45' 46 Liposomes modified with PEG have also been
approved by the FDA.
As an advancement, targeted liposomes have been developed. A lot of research
has been done to couple antibodies to liposomes primarily for cancer targeting. For
example, anti-HER2 liposomes to target HER2-overexpressing tumors47 and CC52
liposomes to target rat colon adenocarcinomas 48 have been efficacious. Liposomes have
also been developed with carbohydrates conjugated to the surface. For example,
mannosylated liposomes were developed to target macrophages49 and the brain.50
Asialofetuin, a protein that presents multiple galactose on its surface, has been conjugated
to liposomes for drug delivery and gene delivery to hepatocytes. Increased liver uptake
was seen in one study,51 while the addition of asialofetuin specifically delivered to
HepG2 cells and increased transfection in another study.52
Liposomes attached with folate molecules have been successfully targeted to cells
in vitro. In one experiment, folate was attached to a liposome via a PEG spacer of
molecular weight approximately equal to 3350, while smaller PEGs were attached to act
as the polymer brush to evade the RES. The PEG spacer was long enough to allow the
attached folate to extend away from the liposome surface and to avoid steric hindrance by
the PEG brush. These liposomes contained a fluorescent dye, calcein, as their cargo and
were incubated with KB cell monolayers, which are known to overexpress FR. It was
found that approximately 2.5x 105 liposomes were bound by each KB cell at saturation.
The authors also found that the folate-PEG liposomes displayed a much higher affinity
for the cells than free folate. Most likely, due to the length of the PEG spacer, more than
one folate on a liposome could bind to the cell.46
In another study, folate-PEG liposomes with doxorubicin as cargo were incubated
with cultured KB cells. It was found that cellular doxorubicin uptake with folate-
conjugated liposomes was 45-fold higher than that of non-targeted liposomes and 1.6
times higher than free doxorubicin. Furthermore, the cytotoxicity of these liposomes was
86 times and 2.7 times higher, respectively.53 These results indicate that the folate-PEG
liposomes are more effective towards targeting cells that overexpress FR than non-
targeted liposomes or free doxorubicin.
Liposomes conjugated to PEG-folate have also been tested in vivo.
Biodistribution studies have indicated that folate-targeted liposomes showed similar
patterns of distribution to non-targeted liposomes and did not improve uptake in tumors.4 1
Although in an ascitic tumor model, where the distribution between the tumor cell
compartment and extracellular fluid could be discerned, liposome levels that were
associated to the cells were significantly higher for folate-targeted liposomes.40 Other in
vivo studies examining the efficacy of folate-targeted liposomes have shown mixed
results. Studies were done in various tumor models, including M109-HiFR, M109R-
HiFR, and J6456-HiFR cells, indicating that active targeting improved treatment. In a
KB carcinoma model, folate-targeted liposomes showed significantly greater tumor
inhibition. 54
Although there are promising results for ligand-targeted liposomes, there are still
some challenges associated with the use of liposomes. If hydrophobic drug is
encapsulated in the bilayer region, the liposome could become destabilized. 55
Furthermore, as seen in the previous examples, liposomes need to be modified with PEG
in order to be stable in the circulation system. However, with the modifications there is a
trade-off. Receptor-ligand interactions can be blocked by the attached PEG. Lee was
able to avoid this problem by adding a PEG spacer, but other problems exist due to
stabilizing PEG modifications. The largest difficulty is liposome unloading efficiency
following endocytosis by a target cell.9' 36 Because of the need to balance stability and
solubility of the liposome, the density of PEG on liposomes is not closely packed. This
could lead to liposome aggregation or protein adsorption causing instability and cargo
release or elimination by the RES. Furthermore, high levels of PEG-liposomes can often
be found in the liver and the spleen or in tissues that are not the desired targets.56
Another disadvantage of liposomes is their size. Smaller liposomes have been
found to be more unstable, allowing more leakage of drug, 13 while larger liposomes can
not be internalized well.40 It has also been found that the permeation rates of liposomes
(which are approximately 100 nm up to 500 nm in diameter) into the targeted cellular
areas are lower than those of smaller nanoparticles due to the liposomes' large size. 57
Finally, liposomes are not a flexible system. For example, modifications to improve
interactions, such as hydrophobic, hydrogen bonding, and electrostatic interactions of the
drug molecules to the interior of the liposome can not be easily altered.
1.2.4 Nanoparticles for Drug Delivery: Dendrimers
Another class of nanoparticles that are being explored for targeted drug delivery is
dendrimers. 56 Dendrimers have an architecture that is globular and highly branched, with
regular molecular repeats created from stepwise synthesis as shown in Figure 1-3. They
have a dense exterior with porous interior regions that have the potential to store drug
molecules. Some of the advantages that dendrimers may have over linear polymers are
that dendrimers are monodisperse with respect to molecular weight, their size and
structure are highly controllable, and they have a high degree of functionality due to their
branched architecture.15 A variety of dendrimers have been created for drug delivery
applications, including polyamidoamine, poly(propyleneimine), ss polyether,59 and
polyester' dendrimers.
M-PEG-attached PAMAM dendrimer
Figure 1-3. A PAMAM dendrimer with conjugated PEG.20
The most widely studied and characterized dendrimer is the polyamidoamine
(PAMAM) dendrimer. However, in a toxicity study of dendrimers, it was found that
PAMAM dendrimers with terminal primary amine groups were quite cytotoxic and were
cleared rapidly from the circulation when administered intravenously.58 In order to
remediate this problem, PAMAM dendrimers are synthesized with PEG attached to the
outer surface to reduce the adsorption of proteins and to increase circulation times.
Additionally, with PEGylation, there is an increase in drug-loading capacity and a
decrease in hemolytic toxicity and drug release rate.24 In work done by Kojima,
PAMAM dendrimers with PEG grafted on were shown to be capable of encapsulating
two types of anticancer drugs, methotrexate and adriamycin. It was found that the
amount that could be encapsulated increased with dendrimer generation and PEG chain
length. The maximum amount of molecules encapsulated was 6.5 adriamycin molecules
or 26 methotrexate molecules per dendrimer. In drug release studies, the methotrexate
loaded dendrimers released the drug slowly in an aqueous solution of low ionic strength.
However, in isotonic solutions, the methotrexate and adriamycin were readily released,
indicating the need for more control in the drug release mechanism. 20
Dendrimers conjugated to targeting ligand have been synthesized and tested.
Extensive studies have been performed with carbohydrate ligands. For example, one
group has added lactose and maltose to the outer surface of PAMAM generation 2-4
dendrimers and have observed binding of a lectin, concavalin A, to the dendrimers.
Binding was reversible with the addition of excess glucose.60 Another group studied the
multivalent binding behavior of mannose-conjugated PAMAM dendrimers with
concavalin A. With the increase in the number of mannose ligand attached to the
PAMAM dendrimer, binding strength increased due to multivalent interactions.
However, a maximum was reached at 50% functionalization. Higher functionalization
values resulted in less binding strength due to greater steric hindrance of excess mannose
on the PAMAM dendrimer surface. 61, 62
Folate-targeted dendrimers have also been designed. One group has been able to
produce ester terminated polyether dendrimers, which are modified for the attachment of
folate. This group was able to attach 12.6 folates to a Generation 2 dendrimer with 16
available attachment sites. 59 Another group has gone one step further and has tested their
folate-targeted dendrimers in vitro. The dendrimer used was a PAMAM dendrimer of
generation 5. They attached folic acid and loaded methotrexate into the dendrimer. The
result of the in vitro study was that the targeted delivery improved the cytotoxic response
of the cells to methotrexate 100 fold over the free drug.63
Although the results for carbohydrate and folate-targeted dendrimers are
promising, there are some challenges and disadvantages associated with the use of
dendrimers. It has been observed that dendrimers seem to move out of tumor tissue
rather quickly, which prevents the drug from concentrating in the tumor.56 A similar
result has been shown in a polyester dendritic system where doxorubicin was covalently
bound to the dendrimer. It was found that two of their polyester dendrimer formulations
were excreted in 4-5 hours after intravenous injection of mice, while another compound
had significant accumulation in the liver. Their longest circulating compound had a half-
life of 72 minutes.1 In order for a macromolecular delivery system to be successful, its
circulation time must be long enough so that accumulation in tumor tissue can occur
through the EPR effect. The circulation times reported for the polyester dendrimers are
considerably shorter than those seen for block copolymer drug systems, which have been
reported as high as 98.3 hours. 64 Another disadvantage to using dendrimers is that the
size of the system is limited to the size of the interior of the dendrimer, which is
approximately 10 nm in diameter.15 The number of generations that the dendrimer can
reach is limited by the degree of crowding at the exterior, where the maximum number of
generations can range from 6 to 10 depending on the structure. Drug capacity is therefore
limited by steric constraints. Furthermore, the chemistry required to create dendrimers at
high generations can be a disadvantage, where the chemistry can often be extensive,
costly, and labor-intensive. Last, as seen in the example above, there have been issues
concerning the controllability of drug release from dendrimers, and improvements in
dendrimer chemistry and structure must be made in order to create an effective controlled
drug release system.
1.2.5 Nanoparticles for Drug Delivery: Block Copolymer Micelles
The last major group of polymers that have been explored as nanoparticle drug
delivery systems is block copolymer micelles. Block copolymer micelles are created
from copolymers composed of a hydrophilic segment and a hydrophobic segment, as
seen in Figure 1-4. When placed in an aqueous environment, micellization occurs where
hydrophobic segregation from the environment is the main thermodynamic driving
force.21
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Figure 1-4. The formation of micelles from a diblock
copolymer. 55
The advantages of a block copolymer system is that with the hydrophobic core,
the micelles have the ability to solubilize hydrophobic drugs while at the same time have
a hydrophilic surface to evade the RES.4  Micelles that are formed from the block
copolymers are also small, thus facilitating evasion from the RES. Additionally, there is
a lot of flexibility with a block copolymer system, where modifications in size,
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functionality, and stability can be made. Several block copolymer micelle systems have
been synthesized and reported such as poly(aspartic acid) and poly(f3-benzyl-L-aspartate)
as the hydrophobic block and PEG as the hydrophilic block.2 1' 65 Other systems include
poly(D,L-lactic acid-co-glycolic acid)-PEG, 66 poly(y-benzyl-L-glutamate)-PEG, 67 and
poly(E-caprolactone)-PEG. 68  All of the systems mentioned have used PEG as the
hydrophilic exterior in order to create a hydrodynamic barrier against the adsorption of
proteins and to evade the RES.
Block copolymer micelle systems have demonstrated to be stable and capable of
encapsulating hydrophobic drugs. For example, a poly(ethylene oxide)-poly(aspartic
acid) block copolymer with adriamycin, an anticancer drug, conjugated to aspartic acid
have been shown to form stable micelles.69 Another system composed of poly(ethylene
glycol) and conjugated doxorubicin-poly(aspartic acid), has been able to encapsulate free
doxorubicin (DOX) in particles approximately 40 nm in diameter. These micelles have
been tested against tumors inoculated subcutaneously and tumors implanted
intravenously in mice. Three out of six mice were cured of mouse colon 26 carcinoma
while two out of six mice were cured of human Lu-24 lung cancer. In comparison, free
doxorubicin injected into mice was not able to cure any of them. The authors were also
able to show that the block copolymer micelle accumulated in the tumor more effectively
than free doxorubicin. The results of this study were promising enough to warrant
clinical trials in Japan. 64
In a further step towards creating micelles that can target specific areas of the
body, some groups have explored the functionalization of the outer surface of block
copolymer micelles. The functional ligands that have been added have included folate,
biotin, monosaccharides, and peptides. 70  Specifically, one group has been able to create
galactose-, lactose-, and mannose-installed PEG-Poly(D,L-lactide) block copolymer
micelles averaging approximately 100 ligands on the surface. They found that the
galactose and lactose functionalized micelles specifically bound to RCA-1 lectin
immobilized beads while glucose-PEG-PLA micelles were eluted (RCA-1 lectin is a
plant lectin which specifically recognizes f-D-galactose residues). Also, the mannose
functionalized micelles specifically bound to concavalin A. Furthermore, they found that
there was a "cluster effect" in binding, where multiple sugar residues from one micelle
would bind to the beads. A 30-fold concentration of free galactose compared to the
micelle-conjugated galactose was required to elute the micelles from the column.65, 70
Mixed micelles of poly(L-histidine)-PEG and poly(L-lactic acid)-PEG conjugated to
folate have been tested in vitro, demonstrating that the targeted micelles were more
effective against tumor cells than non-targeted micelles.66' 71
1.3 Thesis Objectives
Block copolymer micelles have shown to be promising alternatives to liposomes
due to its flexibility. However, there is still much left to explore in this area, where many
design parameters can be investigated or optimized. For this thesis, a novel linear-
dendritic block copolymer has been designed. The linear-dendritic block copolymer is
composed of a hydrophobic linear block and a hydrophilic dendritic block, which will
self-assemble in aqueous solution into nanoparticles. The proposed drug delivery system
hopes to combine the advantages conferred from dendrimers, including its dense surface
functionality, with the increased capacity and chemical flexibility of a block copolymer
micelle. The system will be similar in size to block copolymer micelles, which are
approximately 20-60 nm. This system will be an improvement over liposome
nanoparticles with its smaller size--therefore the particle will have increased circulation
times and more facile extravasation into tumors. Also in contrast to liposomes, the
proposed system is easily fine-tuned to increase interactions between drug and drug
delivery vehicle. Additionally, because it is a polymer system, it will have the ability to
include a mechanism that will induce degradation of the nanoparticle system once it is in
the endosome. With the addition of the dendritic outer structure, the density of ligand
can be explored while maintaining approximately the same particle size. In comparison
to dendrimers, the proposed drug delivery vehicle will have one to two orders of
magnitude greater functionality with a large aggregation number (PEG-PBLA micelles
have shown aggregation numbers ranging from 200-400),72, 73 while for block copolymer
micelles, the functionality of the proposed system will be several times higher depending
on the dendron generation. An additional advantage of using the proposed system over
dendrimers is that mixed micelles with different ligands could be used to create multi-
functional systems or to manipulate the clustering density of ligands on the surface as
shown in Figure 1-5.
Figure 1-5. Formation of micelles with clustered or multifunctional ligands.
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As an improvement over diblock copolymer micelles, the linear-dendritic block
copolymers can be stabilized. It has been pointed out that after micelles are injected into
the bloodstream, thermodynamic fluctuations could occur causing the breakdown of the
micelle (because of the dilution effect leading to concentrations lower than the critical
micelle concentration) and the precipitation of hydrophobic drugs.4  Therefore, the
crosslinking of the dendritic micelles will prevent this from occurring. Overall, the
design of a new dendritic copolymer micelle will be able to address the issues that
previously studied nanoparticle systems have had and hopefully will exceed expectations
in performance.
Few linear-dendritic block copolymers have been synthesized and studied for
drug delivery.74 Additionally, those systems that have been explored self-assemble with
a hydrophobic dendritic block forming the core and a PEG linear block forming the outer
surface of the micelles. In this work, the first objective was to synthesize a linear-
dendritic block copolymer with a hydrophilic dendron and a hydrophobic linear block.
The second objective was to characterize and obtain a better understanding of the
aqueous phase self-assembly behavior of the linear-dendritic block copolymer to
ultimately determine its feasibility as a drug delivery vehicle. The third objective was to
develop drug delivery approaches that could determine whether the dendritic block could
confer advantages to the block copolymer micelles over conventional linear block
copolymer micelles. This includes using the linear-dendritic block copolymer micelles in
two different applications. The first application explored utilized the linear-dendritic
block copolymer micelles as circulating targeted drug delivery vehicles. The other
application studied was to incorporate these linear-dendritic block copolymers into films
as potential coatings for biomedical implants.
1.4 Thesis Overview
The remainder of this thesis is divided into 7 additional chapters. Chapter 2
discusses the synthesis of a linear-dendritic block copolymer. The solution-phase
characterization of the block copolymer was performed including critical micelle
concentration measurements, light scattering measurements, and TEM. Furthermore,
encapsulation of a model hydrophobic drug was investigated.
In Chapter 3, results of molecular dynamics simulations of the linear-dendritic
block copolymer micelles are detailed. Various micelle configurations are explored
based on experimental data obtained through static light scattering experiments used to
determine the aggregation number of the micelles. The simulations were performed to
get a better understanding of the microstructure of the micelles formed and the
thermodynamics of the micelle formation. Furthermore, locus of solubilization of a
model hydrophobic drug is studied.
Chapter 4 explores the use of the linear-dendritic block copolymer micelles as
circulating colloidal nanoparticles for targeted drug delivery. The linear-dendritic block
copolymer was functionalized with a carbohydrate targeting ligand. Its binding behavior
and drug delivery efficacy was determined in vitro.
Chapter 5 and Chapter 6 put forward methods to improve the linear-dendritic
block copolymer micelles for future testing in vivo. First, a stabilization technique is
explored in Chapter 5 to ensure that during administration into the body, the micelles
would not break apart. In Chapter 6, the synthesis of an improved linear-dendritic block
copolymer is detailed, and its solution-phase and encapsulation behavior is investigated.
Chapter 7 discusses the second application for the linear-dendritic block
copolymer micelles. The micelles are incorporated into a film created through a layer-
by-layer dipping method. The micelles create hydrophobic domains for encapsulation of
hydrophobic drugs. The films formed were characterized to ensure that the micelles
incorporated were not disrupted. Additionally, in vitro testing of the films were done as a
proof-of-concept for potential use as an antibacterial film on various biomedical implants.
Last, Chapter 8 includes the overall conclusions to the thesis project and suggests
future directions for the project.
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CHAPTER 2: Synthesis and Characterization of
Poly(propylene oxide)-b-Poly(amidoamine)
2.1 Introduction
Amphiphilic block copolymers have been studied extensively for applications that
can exploit their self-assembly behavior in aqueous media. Recently, amphiphilic linear-
dendritic block copolymers have emerged as a new class of amphiphilic block
copolymers with potential applications ranging from drug delivery and biomaterials to
molecular templating.1-3 The synthetic pathway used to make these block copolymers
permits low polydispersity and a great deal of control over molecular architecture.
Linear-dendritic block copolymers have been synthesized as both diblock4-8 and
dendritic-linear-dendritic triblock systems.9-13  Most of the linear-dendritic block
copolymers that have been studied are composed of a hydrophilic linear block, usually
poly(ethylene oxide) (PEO), attached to a hydrophilic dendritic block or to another
dendritic block that is relatively hydrophobic. These systems include a linear PEO block
attached to dendritic blocks of either poly(amidoamine) (PAMAM), 14, 15 poly(benzyl
ether),16-19 or poly(c,L-L-lysine). 4, 20 The amphiphilic systems display interesting solution
phase behavior with the ability to form multimolecular micelles that have critical micelle
concentrations (CMC) values well below the CMC values of low molecular weight
surfactants such as sodium dodecyl sulfate.19 Several groups have shown that the
hydrophobic dendritic block, such as poly(benzyl ether) or poly(a,s-L-lysine), forms the
core of the micelle, which increases in size with higher generations, while the PEO block
forms a protective corona around the micelle. 4' 19, 20 Because of the excellent
biocompatibility and stealth properties of PEO, these linear-dendritic block copolymer
systems have been proposed for drug delivery and gene therapy applications. 7' 11,20-23
Relatively few studies have been performed for linear-dendritic block copolymers
with a hydrophobic linear block and a hydrophilic dendritic block. For such systems, the
linear block forms the micelle core while the dendrimer block faces the aqueous media.
The Meijer group has performed extensive solution phase studies of polystyrene with
poly(propylene imine) dendrimers that have demonstrated the control of aggregation
morphology by changing the dendrimer generation and pH.24-27 Synthesis and self-
assembly behavior have been studied on more biocompatible systems such as block
copolymers of dendritic polyether with poly(N-isopropylacrylamide), 28 dendritic L-lysine
attached to poly(lactic acid) modified with cholesterol,29 and hyperbranched
poly(glycerol) (though not dendritic) and poly(propylene oxide) (PPO).30 These systems
formed varying morphologies in solution ranging from micelles to cylinders with low
CMCs. To the author's knowledge, extensive characterization studies have not been
performed on linear-dendritic or dendritic-linear-dendritic block copolymers containing a
hydrophobic linear block for drug delivery.
This chapter will discuss the synthesis of an ABA triblock consisting of PAMAM
as the A block and PPO as the B block, with varying generations of PAMAM. The series
of polymers created is well-defined due to the monodisperse nature of dendrimer
synthesis. The solution-phase behavior of the series of PPO-PAMAM has been studied.
Because of its amphiphilic nature, the triblock forms micelles in solution which have
been characterized as a function of the PAMAM generation. The drug encapsulation
efficiency and release rate were studied with a model hydrophobic drug to determine the
feasibility of the novel polymeric triblock as a drug delivery vehicle.
2.2 Experimental
2.2.1 Materials
Poly(propylene glycol) bis(2-aminopropyl ether) (MW -4000, Mw/Mn = 1.04),
methanol, diethyl ether, pyrene (sublimed, 99%), and 5-chloro-2-(2,4-
dichlorophenoxy)phenol (triclosan, ý97.0% purity) were purchased from Sigma-Aldrich
and used as received. Methyl acrylate and ethylenediamine were obtained from Sigma-
Aldrich and distilled over calcium hydride before use. MilliQ (18.2 MO) water was used
in all experiments requiring water.
2.2.2 Synthesis of PPO-PAMAM
Synthesis of PPO-PAMAM Generation 0.5
PPO-[N(aCH 2bCH2CO2cCH3)212. A 7 g sample of poly(propylene glycol) bis(2-
aminopropyl ether) (PPO) was dissolved in methanol and added dropwise to 200 times
molar excess of methyl acrylate (32 ml). The reaction mixture was stirred under nitrogen
for 3 days at room temperature. Excess methyl acrylate and methanol were removed with
a rotary evaporator leaving a viscous oil. The copolymer was redissolved in methanol
and removed by rotary evaporation three times thereafter and vacuum-dried overnight
(yield = 7.62 g, 100%). 'H NMR (CDC13): 8ppo(-OCH 2 CHCH3-) = 1.14 (t); 8PPO(-
OCH2CHCH3-) = 3.40 (m); 8ppo(-OCH 2CHCH3-) = 3.61 (m); 8PMAM = 3.66 (s, c);
8PAMAM = 2.77-2.81 (m, a); 8PAMAM = 2.42 (t, b). FTIR peak v cml': 1111, 1741, 2870,
2971.
Synthesis of PPO-PAMAM G1.0
PPO-[N(aCH 2bCH 2COcNHdCH 2eCH 2NH 2)2]2. PPO-PAMAM generation 0.5 (7.6 g)
was dissolved in methanol and added dropwise into 200 times molar excess
ethylenediamine (24 ml). The reaction was stirred under nitrogen for 4 days at room
temperature. Ethylenediamine and methanol were removed through rotary evaporation at
45 'C, leaving copolymer that was a viscous oil. To ensure complete evaporation of
ethylenediamine, an azeotropic mixture of toluene and methanol was used to dissolve the
copolymer and removed through rotary evaporation three times. Afterwards, the
copolymer was vacuum-dried overnight (yield = 7.7 g, 100%). 1H NMR (CDCl3):
8ppo(-OCH2CHCH3-) = 1.14 (t); 8ppo(-OCH 2CHCH3-) = 3.40 (m); 8PPO(-
OCH 2CHCH 3-) = 3.61 (m); 8PAMAM = 8.01 (Im, c); 8PAMAM = 3.25-3.32 (m, d); 8PAMAM =
2.6-3.0 (m, _e+a); 8PAMAM = 2.38 (m, b). FTIR peak v cm 1': 1111, 1557, 1651, 2870,
2971, 3292.
Synthesis of PPO-PAMAM G1.5
PPO-[N(CH2 bCH2COcNHdCH2eCH2N(CCH2H2CO2hCH3)2)212. PPO-PAMAM
generation 1.0 (7.7 g) was dissolved in methanol and added dropwise to methyl acrylate
(63 ml). Methyl acrylate was in 400 molar excess over the copolymer. The reaction
conditions and purification procedures were similar to the synthesis of generation 0.5
(yield = 8.5 g, 96%). 1H NMR (CDCl3): 8ppo(-OCH 2CHCH 3-) = 1.14 (t); 8ppo(-
OCH2CHCH3-) = 3.40 (m); 8ppo(-OCH 2CHCH 3-) = 3.61 (m); 8PAMAM = 8.01 (m, c);
8PAMAM = 3.66 (s, h); 8PAMAM = 3.28 (m, 4); 8PAMAM = 2.75-3.0 (m, a+f); 8PAMAM = 2.54
(t, e); 8PAMAM = 2.44 (t, g); 8PAMAM = 2.34 (t, b); FTIR peak v cm-': 1110, 1539, 1669,
1739, 2870, 2971.
PPO-PAMAM G2.0
PPO- [N(aCH2bCH2COcNHdCH2eCH2N('CH2gCH2COhNHCH2CH2NH2)2)212. The
synthesis, reaction conditions, and purification procedure was similar to the procedure
described for generation 1.0, with 8.5 g of generation 1.5 with 45 ml ethylenediamine.
An additional purification step was performed where the polymer dissolved in methanol
was run through a sephadex LH-20 column. The methanol in the collected fractions was
removed through rotary evaporation (yield = 8.12 g, 89%). 1H NMR (CDC13): 8ppo(-
OCH2CHCH 3-) = 1.14 (t); 8ppo(-OCH 2CHCH3-) = 3.40 (m); 8ppo(-OCH 2CHCH 3-)
3.61 (m); 8 PAMAM = 7.66-8.02 (bs, c+h); 8PAMAM = 3.31 (m, i); 8PAMAM = 3.24 (m, d);
8PAMAM = 2.74-2.89 (t, a+f+J); 8 PAMAM = 2.54 (t, e); PAMAM = 2.38 (t, g); 8PAMAM = 2.32
(m, b); FTIR peak v cm~': 1110, 1552, 1647, 2870, 2971, 3275.
PPO-PAMAM G2.5
PPO-[N(CH2bC H 2C O !N H dC H 2eC H 2N (fC H 2gC H 2C O hN H iCH 2jC H 2N
(kCH2'CH2CO 2mCH3)2)2)212. The synthesis, reaction conditions, and purification
procedure were similar to the procedure described for generation 1.5, with 8.12 g of
generation 2.0 copolymer with 113 ml methyl acrylate (yield = 9.6 g, 93%). 1H NMR
(CDC13): 8ppo(-OCH 2CHCH 3-) = 1.14 (t); 8ppo(-OCH 2CHCH3-) = 3.40 (m); 8ppo(-
OCH 2CHCH3-) = 3.61 (m); 8pAMAM = 7.66-8.02 (bs, c+h); 8pAMAM = 3.67 (s, m); 8PAMAM
= 3.28 (m, d+i); 8 MAMAM = 2.74-2.83 (m, a+f+k); 8PAMAM = 2.53-2.59 (m, _e+j); 8PAMAM =
2.44 (t, 1); 8PAMAM = 2.37 (t, b+g); FTIR peak v cm-': 1110, 1540, 1665, 1738, 2870,
2971.
PPO-PAMAM G3.0
PPO-[N(*CH2bCH2COcNHdCH2eCH2N('CH2gCH2COhNH'CH2CH2N
(kCH 2'CH2COmNHnCH 2oCH 2NH 2)2)2)212. A 9.6 g sample of PPO-PAMAM generation
2.5 was dissolved in methanol and added dropwise to 63 ml of ethylenediamine. The
reaction solution was stirred under nitrogen for 4 days. Ethylenediamine and methanol
were removed through rotary evaporation at 45 TC. Further purification involved
dissolving the polymer in an azeotropic mixture of methanol and toluene and removal
with a rotary evaporator 3 times. The resulting polymer was dissolved in methanol and
precipitated in 10 times excess diethyl ether. After decanting, the polymer was vacuum
dried (yield = 5.33 g, 54%). 'H NMR (CDCl3): 8ppo(-OCH 2CHCH 3-) = 1.14 (t); 8ppo(-
OCH2CHCH3-) = 3.40 (m); 8ppo(-OCH 2CHCH3-) = 3.61 (m); 8pAMAM = 7.73-8.09 (bs,
c+hr+m); 8PAMAM = 3.23-3.30 (m, d+i+n); 8PAMAM = 2.72-2.84 (m, a+f+k+o_); 8PAMAM =
2.53 (m, _e+); 8 PAMAM = 2.36 (t, 1); 8pAMAM = 2.33 (m, b+g); FTIR peak v cm': 1110,
1553, 1645, 2870, 2971, 3069, 3284.
PPO-PAMAM G3.5
PPO-[N(aCH2bCH2COcNHdCH2eCH2N( CH2 CH2CO'NH'CH2 CH2N
(kCH2'CH2COmNH"CH2CH2N(CH2 CH2CO2 CH3)2)2)2)212. The synthesis, reaction
conditions, and purification procedure were similar to the procedure described for
generation 1.5, with 3 g of generation 3.0 with 64 ml methyl acrylate (yield = 4.0 g,
95%). 'H NMR (CDC13): 8ppo(-OCH 2CHCH 3-) = 1.14 (t); 8ppo(-OCH 2CHCH3-) =
3.40 (m); 8PAMAM = 7.73-8.09 (bs, c+h+m); 8ppo(-OCH 2CHCH3-) = 3.61 (m); 8 PAMAM =
3.67 (s, r); 8PAMAM = 3.28 (m, d+i+n); 8pAMAM = 2.75-2.81 (m, a+f+k+p); 8 PAMAM = 2.53-
2.58 (m, e+j+o); 8PAMAM = 2.44 (t, q); 8PAMAM = 2.37 (m, b+g+l); FTIR peak v cm-1:
1110, 1542, 1652, 1738, 2870, 2971, 3293.
PPO-PAMAM G4.0
PPO-[N(aCH2bC H 2C O CN H dC H 2eC H 2N ('C H 2gC H 2C O hN H 'C H 2C H 2N
(kCH CH2COmNHnCH2 CH2N(CH CH'CH2CO NH'CH2CH2NH2)2)2)2)212. The
synthesis, reaction conditions, and purification procedure were similar to the procedure
described for generation 3.0, with 4.0 g of generation 3.5 with 45 ml ethylenediamine
(yield = 3.53 g, 85%). 'H NMR (CDC13): 8ppo(-OCH 2CHCH3-) = 1.14 (t); 8ppo(-
OCH2CHCH3-) = 3.40 (m); 8ppo(-OCH2CHCH 3-) = 3.61 (m); 8PAMAM = 7.63-8.07 (bs,
c+h+rm+r); 8PAMAM = 3.26 (m, d+i+n+s); 8PAMAM = 2.71-2.82 (m, a+f+k+p+t); 8 pAMAM
2.51 (bs, e+j+o); 8PAMAM = 2.32-2.37 (m, b+g+l+q); FTIR peak v cm-': 1110, 1554,
1647, 2870, 2971, 3069, 3279.
PPO-PAMAM G4.5
PPO-[N(aCH2bCH2COcNHdCH2eCH2NCH2N(CH 2CHCOhNHICHCH2N
(kCH2lCH2COmNHnCH2°CHzN(PCHzqCH2COrNHSCH2CH2N
("CH2'CH2CO2WCH3)2)2)2)2)212. Generation 4.0 (1.3 g) was dissolved in methanol and
added dropwise to excess methyl acrylate (38 ml). The reaction was stirred under
nitrogen for 3 days. Unreacted methyl acrylate and methanol were removed by rotary
evaporation. Subsequently, the polymer was redissolved in methanol and removed with
rotary evaporation 3 times. The polymer was dissolved in methanol and precipitated in
10 times excess diethyl ether. The ether was decanted and the polymer was dried by
vacuum (yield = 1.2 g, 58%). 1H NMR (CDCl3): 6ppo(-OCH2CHCH 3-) = 1.14 (t);
8ppo(-OCH 2CHCH 3-) = 3.40 (m); 8ppo(-OCH 2CHCH3-) = 3.61 (m); 8PAMAM = 7.63-8.07
(bs, c+h+m+r); 8PAMAM = 3.66 (s, w_); 8pAMAM = 3.27 (m, d+i+n+s); 8AMAM = 2.74-2.82
(m, a+f+k+p+u); 8pAMAM = 2.58-2.53 (m, e+j+o+t); 8PAMAM = 2.43 (t, v); 8PAMAM = 2.36
(bs, b+g+l+g); FTIR peak v cm-': 1110, 1542, 1647, 1736, 2870, 2971, 3287.
PPO-PAMAM G5.0
PPO-[N(aCH2bCH2CO'NHdCH2eCH2N( CH2 CH2COhNHCH2CH2N
(kCH2'CH2COmNHnCH2 CH2N(CH2CH2COrNH'CH2CH2N
(UCH 2VCH 2COWNHxCH 2YCH2NH2) 2)2)2)2)212. The synthesis, reaction conditions, and
purification procedure were similar to the procedure described for generation 3.0, with
ethylenediamine in excess at a molar ratio of 3200:1 compared to PPO-PAMAM
generation 4.5. 'H NMR (CDC13): 8ppo(-OCH2CHCH 3-) = 1.14 (t); 8ppo(-
OCH2CHCH 3-) = 3.40 (m); 8ppo(-OCH 2CHCH3-) = 3.61 (m); 8PAMAM = 8.07-7.97 (bs,
c+h+m+r-w); 8PAMAM = 3.27 (m, d+i+n+s+x); 8PAMAM = 2.82-2.74 (m, a+f+k+p+u+y);
8PAMAM = 2.54 (bs, e+i+o+t); 8pAMAM = 2.36 (bs, b+g+1++v_); FTIR peak P cm-l: 1110,
1552, 1643, 2870, 2971, 3071, 3280.
Synthesis of PPO-PAMAM G5.5
PPO-[N(aCH2bCH2COCNHdCH2eCH2N(fCH29CH2CONHICH2jCH2N
(kCH2'CH2COmNH nCH2CH2N( CH2 CH2COrNH'CH2tCH2N
(uCH 2vCH 2COWNHxCH 2YCH2N(zCH 2SaCH 2CO2abCH3)2)2)2)2)2)212. The synthesis,
reaction conditions, and purification procedure were similar to the procedure described
for generation 4.5. Methyl acrylate was present 6400 times in molar excess over the
copolymer. 1H NMR (CDCl 3): 8ppo(-OCH 2CHCH3-) = 1.14 (t); 8ppo(-OCH 2CHCH3-)
= 3.40 (m); 8ppo(-OCH 2CHCH3-) = 3.61 (m); 8PAMAM = 8.07-7.97 (bs, c+h+m+r+w);
8pAMAM = 3.66 (s, ab); 8pAMAM = 3.27 (m, d+i+n+s+x); 8pAMAM = 2.82-2.74 (m,
a+f+k+2+u+z); 8PAMAM = 2.59-2.53 (m, e+j+g+t+y); 8PAMAM = 2.43 (t, aa); 8PAMAM = 2.36
(bs, b+g+1+q+v); FTIR peak v cm-1 : 1199, 1544, 1648, 1736, 2840, 2951, 3071, 3291.
Synthesis of PPO-PAMAM G6.0
PPO-[N(aCH2bCH2CONHcCH2dCH2N(eCH2fCH2CONHgCH2hCH2N
(CH 2JCH2CONHkCH 2'CH2N(mCH 2DCH 2CONHoCH 2 CH2N
(CH2 CH2CONHsCH2tCH2N("CH2'CH2CONH'CH2CH2NH2)2)2)2)2)2)212. The
synthesis, reaction conditions, and purification procedure were similar to the procedure
described for generation 3.0. Ethylenediamine was present 6400 times in molar excess
over the copolymer. 1H NMR (D20): 8ppo(-OCH2CHCH 3-) = 1.12 (t); 8ppo(-
OCH2CHCH3-) = 3.51 (m); 8ppo(-OCH 2CHCH3-) = 3.66 (m); 8pAMAM = 3.24-3.17 (m,
c+g+k+o+s+w); 8PAMAM = 2.78-2.65 (m, a+e+i+m+q+u+x); 8PAMAM = 2.57 (t,
d+h +t); 8pAMAM = 2.36 (t, b+f+j+n+r+v); FTIR peak p cmi': 1199, 1544 (amide),
1643 (amide), 2840, 2951, 3291.
2.2.3 Characterization of PPO-PAMAM
Each synthesis step was confirmed through FTIR and 1H-NMR. FTIR spectra
were recorded on a Nexus 870 FTIR Spectrometer (Thermo Nicolet, Waltham, MA).
Samples were solvent cast onto KBr pellets and characterized. 'H-NMR spectra were
recorded on a Varian Inova-500 MHz spectrometer. Samples were dissolved in CDCl3 or
D20.
Fluorescence Studies. To determine the CMC of the dendritic block copolymer, pyrene
was used as a hydrophobic fluorescent probe.31, 32 The polymer was suspended in a stock
solution containing 10-7 M pyrene at concentrations ranging from 10-3 M to 10-7 M and
left overnight in the dark at room temperature to equilibrate. The solutions were
analyzed with a FluoroMax-2 Spectrometer (Horiba Jobin Yvon, Longjumeau France) at
25 'C. Emission spectra were recorded over a range of 355 nm to 500 nm with an
excitation wavelength of 333 nm, while excitation spectra were recorded from 300 nm to
360 nm with an emission wavelength of 390 nm.
Dynamic Light Scattering. Particle sizes were determined with dynamic light scattering
on a Brookhaven Instruments BI-200SM Research Goniometer System. A Coherent
Innova 90c (Santa Clara, CA) laser at 514.5 nm was used as the light source. Samples
were filtered with a 0.45 im polytetrafluoroethylene (PTFE) syringe filter (Pall, East
Hills, NY) and measured at 25 oC. Measurements were taken at multiple angles from 45
to 135 degrees with 15 degree increments, and autocorrelation functions were recorded at
each angle. A fit of the autocorrelation function was made to Equation 2-1 to obtain F,
the linewidth.33 F was plotted against the square of the scattering vector, q. A linear
least-squares fit of the data is used to obtain DT, the translational diffusion coefficient.
Equation 2-3 relates q to the scattering angle, 0, where n is the refractive index of the
solution and X is the wavelength of the laser. The Stokes-Einstein equation, as shown in
Equation 2-4, is used to relate the hydrodynamic diameter, dh, to DT for spheres, where k
is the Boltzmann constant, T is the temperature, and 11 is the viscosity of the solution. It
was assumed that all solutions were dilute, such that there were no interparticle
interactions and solution properties such as refractive index and viscosity were equivalent
to the properties of water at 25 OC.
C(r) = Ae - 2r t + B (2-1)
F = Dq 2  (2-2)
4rnSin {
q = (2-3)
kTdh = (2-4)
3r-DT
TEM. To confirm the presence of nanoparticles, polymer samples were visualized with a
JEOL 2011 TEM. Carbon coated grids, 400 mesh (Pacific Grid-Tech, Sugar Land, TX),
were dipped into dilute aqueous samples of polymer in phosphate buffered water and air-
dried overnight.
Drug Loading Studies. An oil/water emulsion technique with a model hydrophobic
drug, triclosan, was used for encapsulation with the copolymer. A solution of triclosan in
dichloromethane (5 ml, 2 mg/ml) was slowly added to a stirring solution of 1 mg/ml of
copolymer in water (10 ml). The solution was vigorously stirred overnight at room
temperature. To remove precipitated drug, the solution was centrifuged for 30 minutes at
4500 rpm. The supernatant, which contains the drug solubilized in micelles, was filtered
with a 0.45 jim PTFE syringe filter to remove any remaining precipitated drug.
To quantify the amount of drug encapsulated, 1 ml of the supernatant was added
to 9 ml of methanol in order to break up the micelles, and the solution was analyzed by
an Agilent 8453 UV-Visible Spectrometer System (Palo Alto, CA). The characteristic
absorbance of triclosan at 281 nm was recorded and compared to a calibration curve
generated from a 1:9 water:methanol mixture with triclosan concentrations varying from
0-100 1g/ml (Y = 60.90*X - 1.22, r2 = .9973). The percent efficiency of encapsulation
was calculated with Equation 5 while the weight percent of encapsulated drug was
calculated with Equation 6. Due to the 1:1 initial weight ratio of polymer to drug, these
two values are equivalent.
% drug loading efficiency weight of drug encapsulated% drug loading efficiency x 100 (2-5)
total weight of drug introduced
= weight of drug encapsulated x100 (2-6)
weight of polymer
Drug Release Studies. Solutions containing polymer-encapsulated drug were
lyophilized and resuspended in either 10 ml of phosphate buffered saline (PBS, pH = 7.4)
or acetate buffer (pH = 5.0) and placed into 3500 MWCO dialysis bags (Spectrum
Laboratories Inc., Rancho Dominguez, CA). The dialysis bag was placed in 1 liter of
buffer at 37 )C, which was changed every two days to maintain sink conditions. Samples
were taken out of the dialysis bag at various time intervals and analyzed by UV-vis. The
volume of solution in the dialysis bags were measured at each sampling time, so that
concentrations measured could be adjusted for volume changes due to osmotic pressure
differences and evaporation.
2.3 Results and Discussion
An amphiphilic linear-dendritic triblock copolymer was synthesized and characterized in
order to determine its feasibility as a self-assembling drug delivery vehicle with potential
targeting applications. The linear-dendritic triblock copolymer is composed of
poly(propylene glycol) bis(2-aminopropyl ether) (PPO), which after self-assembly forms
the core of the micelle, and hydrophilic poly(amidoamine) (PAMAM), which forms the
outer shell of the micelle. The PAMAM presents a dense outer shell of functional groups
that can be used for multivalent targeting.
2.3.1 Synthesis of PPO-PAMAM
A series of PPO-PAMAM polymers were synthesized from generation 2.0 (which
contains 8 amine ends) through generation 6.0 (containing 128 amine ends). The
copolymer was synthesized with a divergent approach starting from PPO with two
terminal amines as the core. Sequential steps of Michael addition of the free amine
groups with methyl acrylate to create half generations were followed with exhaustive
amidation with ethylenediamine to create full generations as shown in Figure 2-1.14, 15, 34
The amount of excess methyl acrylate and ethylenediamine was increased in proportion
to the number of reactive groups available at the ends of the dendrimer. Generally,
methyl acrylate and ethylenediamine were used in 50 times excess to the number of
reactive sites.
With increasing generations, the bulk morphology of the polymer changed,
becoming increasingly solid-like in nature. This is similar to the behavior observed in the
synthesis of PEO-PAMAM by Iyer et al. 14 At generation 2, the PPO-PAMAM polymer
became tacky. Beginning at generation 3.0 and at every reaction thereafter, the
NH2-(CH 3)CHCH2-(CH2CH(CH3))-'NH2
Poly(propylene oxide)
1) i
H2N 2) ii O ,NH 2
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Figure 2-1. Synthesis of PPO-PAMAM by reaction with excess i) methyl acrylate,
CH 2CHCOOCH3 and ii) ethylenediamine, NH2CH2CH2NH 2.
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method used to isolate and purify the product was slightly modified to take advantage of
the change in solubility of the copolymer. After the removal of excess reagent and
methanol, the polymer was redissolved in methanol and was precipitated in excess ether.
The precipitated polymer was vacuum-dried overnight. The synthesis of the triblock
copolymers was confirmed through FTIR and 1H-NMR.
2.3.2 Fluorescence Studies
Pyrene was used as a hydrophobic fluorescent probe to determine the critical
micelle concentration (CMC) of PPO-PAMAM from generations 2 through 6. Excitation
and emission spectra were recorded for each copolymer at varying concentrations. As the
concentration of the solution was increased above the CMC, pyrene was found to
segregate into the cores of the micelles causing changes in the photophysical properties
of pyrene.31' 32 The vibronic structure of pyrene changes due to its local environment.
For example, in the excitation spectrum, a red shift occurs in the system, and the band for
pyrene, which is at 335 nm in water, shifts to 340 nm. Ratios of fluorescence intensity
from the excitation spectrum at 340 nm to the intensity at 335 nm were plotted against the
logarithm of the copolymer as shown in Figure 2-2a. Emission spectra were also
obtained, and due to the changes in the local environment of the pyrene above and below
the CMC, the magnitude of the peak intensities at 373 nm and 393 nm change. Ratios of
fluorescence intensity at 373 nm to 393 nm were taken from emission spectra and plotted
as a function of the logarithm of the copolymer concentration in Figure 2-2b. For both
plots, lines were fit at low and high concentrations, and the CMC was determined by
identifying the point where the two fitted lines intersect. An average of the CMCs
obtained from the emission and excitation spectra is reported.
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Figure 2-2. a) (top) Ratios of the fluorescence intensity at 340 to 335 nm obtained from
the excitation spectra plotted against concentration for PAMAM generations 2, 4, and 6.
b) (bottom) Intensity ratios at 273 to 293 nm from emission spectra plotted against
concentration. Lines of the intensity ratio versus the concentration are shown to guide
the eye. The CMC line fit is shown for generation 4. The point of intersection of the two
lines in the CMC fit is given as the CMC value.
A AA
The CMC of PPO-PAMAM was measured in deionized water and phosphate
buffered saline (PBS) (with an ionic strength of 0.15 M) at approximate pHs of 5.5 and
2.5 to determine the dependence of PAMAM generation, solution pH, and ionic strength
on the CMC as shown in Figure 2-3. In one study, PAMAM has been reported to have
two pKa values at 3.9 and 6.9 due to the presence of tertiary and primary amines,35 while
another study suggested that the pKa values were approximately 6 and 9.36 The two
different pH values were chosen to determine the effects of protonation of these amines.
CMC values of the block copolymer are on the order of 1 gM to 10 pM. This was also
confirmed to an order of magnitude through surface tension measurements.
As seen in Figure 2-3, the CMC is a function of PAMAM generation number,
ionic strength, and pH. Molecular theory for the formation of micelles can be used to
qualitatively describe the trends. 37' 38 Equation 2-7 relates the mole fraction of micelles
(X,) with an aggregation number (n) to the mole fraction of unimers (XI) in solution and
the free energy of micellization (gmic). The mole fraction of micelles in solution is
proportional to the CMC.38
X n = X, exp(-gmic / kT) (2-7)
The term, gmic, is the change in the Gibbs free energy associated with transferring
n unimers from the aqueous solution to form a micelle. This free energy can be modeled
as the sum of five different free energy terms that take into account all of the free energy
changes that occur upon micelle formation. These terms are listed in Equation 2-8.
gmic = gtr + gint + gpack + gst + gelec
The first three terms, gtr, gint, and gpack, are associated with the hydrophobic block
copolymer. The free energy of transfer, gtr, reflects the free energy change associated
with transferring the hydrophobic block from the solution to the core of the micelle. The
interfacial free energy, gint, takes into account the change in free energy upon formation
of the interface between the core and the solution, while gpack involves the free energy
change associated with constraining the ends of the linear block (the point of attachment
to the hydrophilic block) to lie at the periphery of the core. These three terms could be
considered nearly equivalent for the series of block copolymers tested since the PPO
hydrophobic linear block is the same size. However, as the PAMAM generation changes
in the PPO-PAMAM block copolymers, both gst and gelec are affected. The steric
contribution, gst, takes into account the steric interactions between the PAMAM blocks of
the unimers. This is a function of the PAMAM block size. The term gelec, the
electrostatic free energy, is affected by the degree of charge and location of charge in the
PAMAM block.
As the PAMAM generation increases, the CMC was found to generally rise. This
can be explained by the growth in the PAMAM block with the increase in generation. As
the PAMAM block gets larger, there are higher steric penalties for transferring the large
head group into the micelle. Outside of the molecular theory of the formation of
micelles, the hydrophilic-lipophilic balance (HLB) also explains the rise in CMC with
increasing generation. The weight percent of the hydrophilic portion of the linear-
dendritic block copolymer rises with generation (from 23% to 86%), increasing the HLB.
(2-8)
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Figure 2-3. CMC of PPO-PAMAM Generations 2 through 6 in low (pH 2.2-2.7) or
medium pH (pH 5.2-5.5) with or without buffer. Buffer contains additional NaCI and
phosphate salts for a total ionic strength of 0.15 M while unbuffered solutions only have
added HCI to reduce the pH to the desired value. Note that the CMC value for the
polymer at low ionic strength, pH 5.5 was not significantly different from the CMC in
pure deionized water (the deionized water used has a pH of 5.5 due to absorbed carbon
dioxide). Lines are shown only as a guide for the eye.
In addition to PAMAM generation dependence, Figure 2-3 indicates that the
CMC is dependent on pH at high PAMAM generations and low ionic strengths. From
the reported pKa values, it is expected that at pH 2.7, the primary and tertiary amines
would be protonated, while at pH 5.5 the primary amines and some tertiary amines would
be protonated. For the solutions without buffer, the pH does not affect the CMC from
generations 2 through 4. For generations 5 and 6, there is an increase in CMC from pH
5.5 to pH 2.7 that is approximately a 2-fold increase. This result can be explained by the
change in the size and increased charge density of the dendrimer head (affecting both gst
and gelec). Simulations on the pH effects of dendrimers have shown that the dendrimer
radius of gyration (Rg) at low pH, where the tertiary and primary amines are protonated,
is larger than the Rg of the dendrimer at neutral or high pH.39, 40 The protonation of the
primary and tertiary amines increase intramolecular repulsion which results in expansion
of the PAMAM block. Increased protonation at low pH similarly increases electrostatic
repulsion intermolecularly between PAMAM blocks.
The CMC results for the copolymer in buffer were slightly different from
copolymer under low ionic strength conditions. For generations 2 through 4, the CMC
values are similar in magnitude indicating that pH does not have a significant effect. For
CMCs at generations 5 and 6, there are slight differences in CMC with pH. Studies have
shown that salt can screen out the effects of low pH,41 which results in significantly
smaller changes in the copolymer CMC as the pH is changed. With ionic shielding,
electrostatic repulsion within the PAMAM block is lessened, decreasing the steric effects
associated with the expansion of the PAMAM block thus decreasing the headgroup size
of the amphiphile. Enhanced water solubility is also anticipated in charged, unshielded
systems. Although there were slight effects of pH at generations 5 and 6 in the buffered
solutions, the CMC at higher pH (pH 5.2) was larger than in pH 2.2, which is opposite of
what would be expected. These surprising results may be due to specific phosphate and
chloride counterion complexation with the PAMAM block affecting its size and shielding
more of the electrostatic repulsions. Overall, it was found that pH does not seem to have
a large effect on the CMC in buffered salt solutions, but does measurably impact the
CMC of the high PAMAM generations at low ionic strength conditions.
In contrast, the effect of ionic strength of CMC is significant over most
generations. As anticipated, the CMC is smaller for high ionic strength solutions.
Reduction of the CMC is attributed to changes in gst and gtc. Monte Carlo simulations
of propyleneimine dendrimers reveal that with increasing ionic strength, the diameter of
the dendrimer decreases.42 With the addition of salt, counterions reduce the electrostatic
repulsion within the PAMAM block, resulting in a reduction in PAMAM size. With
electrostatic shielding, the electrostatic repulsion of the individual PAMAM blocks with
other PAMAM blocks is also reduced, enabling the packing of the dendron-amphiphiles
within the micellar aggregates.
2.3.3 Dynamic Light Scattering
PPO-PAMAM generations 2 through 6 suspended in PBS were tested with
dynamic light scattering. Similar to the CMC results in buffer, it was found that there
was little dependence of the particle diameter on pH due to ionic shielding effects. In
contrast, the PAMAM block generation affected the particle diameter as seen in Figure 2-
4 with particle sizes ranging from 19 nm down to 9 nm for generation 6.0. As the
generation of the PAMAM block increases, the diameter of the particles decreases. With
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Figure 2-4. Hydrodynamic diameter of PPO-PAMAM micelles as a function of
PAMAM generation tested in 0.15 M PBS solution. With increasing generation, the
diameter decreases due to the growing PAMAM block which lowers the number of
unimers per micelle.
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the growth in the head size of the PAMAM block at higher generations, there is
increased steric and electrostatic repulsion between the unimers. Therefore, fewer
unimers are able to pack into a micelle, and the core is composed of fewer PPO blocks.
This results in a reduction of the size of the core and an overall reduction of the micelle
size.43
2.3.4 TEM
Copolymer samples in PBS visualized with TEM confirm light scattering results.
The TEM samples were prepared by dipping the grid into a dilute polymer solution
followed by air-drying overnight. Based on TEM observations, the micelles that are
formed are relatively monodisperse. TEM results for generation 3.0 are shown in Figure
2-5. Based on TEM, generation 3.0 micelles are approximately 15 nm, similar to the
results obtained from dynamic light scattering. TEM results for generations 4.0 through
6.0 were also observed, indicating micelles present in the nanometer range. However,
due to the resolution of the TEM and the small size of the micelles, interpretation of the
true micelle diameter was difficult to ascertain for all generations. Overall, TEM was
able to confirm the formation of micelles for all block copolymer generations.
Figure 2-5. TEM micrographs of PPO-PAMAM generation 3.0 micelles air-dried on a
400 mesh carbon grid from phosphate buffered aqueous solutions.
2.3.5 Drug Loading Studies
Triclosan is a bactericide used as a model hydrophobic drug in these studies. It
has a log P (octanol-water) of 4.76 and a water solubility of 10-2 mg/ml. Triclosan was
encapsulated into the PPO-PAMAM micelles from generations 3.0 through 6.0 with the
oil/water emulsion technique. The polymers were able to encapsulate from 79% to 86%
w/w as shown in Table 2-1. An analysis of variance of the 4 polymer formulations
showed no statistically significant difference in the encapsulation efficiency (n = 3 for
each group, p = 0.57). However, the capacity of the micelles grows with increasing
generation. Figure 2-6 presents the normalized amount of triclosan encapsulated to the
amount of polymer present on a molar basis. There is an increase of this ratio indicating
that with the increase in PAMAM generation, each unimer within the micelle can retain
more hydrophobic drug.
Dynamic light scattering performed on the drug-loaded samples confirm that at
higher generations, more drug is encapsulated in the core. For generation 3.0, the
diameter of the particles increased by 5 nm upon drug loading. For generations 4.0
through 6.0, the concentration used for the polymer solutions were very close to the
CMC, where there is a mixture of micelles and unimers in solution. The concentration of
micelles present in the solution was too low to be detected from dynamic light scattering.
Upon the introduction of drug, stable micelles were formed for all generations. For
generations 5.0 and 6.0, there was a dramatic increase in the diameter of particles as
compared to previous light scattering measurements performed for empty particles
(shown in Figure 2-4). The generation 5.0 and 6.0 particles increased from
approximately 8 nm to approximately 50 nm. The growth in the diameter can be
Table 2-1. Drug encapsulation characteristics of PPO-PAMAM for generations 3
through 6 and control polymers.
% encapsulation Diameter After Drug
(w/w) Loading (nm)
PAMAM-PPO-PAMAM
Generation 3.0
PAMAM-PPO-PAMAM
Generation 4.0
PAMAM-PPO-PAMAM
Generation 5.0
PAMAM-PPO-PAMAM
Generation 6.0
F127
PAMAM 4.0
PAMAM 6.0
80+-4
86±11
84± 6
79± 7
42 + 13
517+2
17+6
30 1
33±5
57±6
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Figure 2-6. Drug encapsulation capacity of PPO-PAMAM generations 3.0 through 6.0.
As the generation increases, the amount of triclosan encapsulated to the amount of
polymer present increases.
attributed to the expansion of the hydrophobic core as more drug is encapsulated. For
generations 5.0 and 6.0, it is possible that the core is composed of solid drug with the
PPO core surrounding and stabilizing the solid drug center. If the unimers of the
generation 5.0 and 6.0 micelles were to be stretched out, the maximum diameter of the
micelle would be approximately 30 nm. The light scattering results indicate particles that
are larger than the maximum diameter. Therefore, the presence of a solid drug core
would allow the micelle to obtain sizes larger than its theoretical limit. The increased
PAMAM head size, arc length, and stiffness of the dendrimer block for generations 5.0
and 6.0 could also contribute to stabilizing this type of structure. With generations 3.0
and 4.0, there is only a slight increase in the core diameter. Either the encapsulated drug
is interspersed in the PPO core, or there is a small drug core in the middle of the micelle.
It is possible that the formation of a solid drug core could occur if a higher concentration
of drug was used during the encapsulation.
As a control, a Pluronic@, F127, and PAMAM dendrimers were processed with
the same encapsulation procedure. F127 was chosen as a control because it has been
used successfully for drug delivery by other groups.44' 45 F127 is structurally similar to
PPO-PAMAM, as a triblock copolymer with PEO hydrophilic outer blocks and a PPO
hydrophobic inner block. The PEO block length is roughly 100, while the PPO block
length is approximately 60. Compared to our block copolymer, the PPO block length is
similar, and the reported CMC of F127 is also in the micromolar range.46 Encapsulation
of triclosan with F127 was 42% efficient - half the efficiency of the PPO-PAMAM block
copolymer at generations 5.0 and 6.0.
Spherical PAMAM dendrimers generation 4.0 and 6.0 (Sigma-Aldrich) were also
used as controls. Drug loading with generation 4.0 PAMAM dendrimers showed very
little encapsulation, whereas with generation 6.0 PAMAM dendrimers, drug loading
efficiency was approximately 17 %w/w. Compared to PAMAM dendrimers, our block
copolymer is more efficient at encapsulating hydrophobic drug because the micelles
formed from the block copolymer are larger in size and have greater capacity.
Additionally, with the incorporation of the PPO hydrophobic block into the linear-
dendritic block copolymer, interactions with hydrophobic drugs are more favorable
compared to spherical PAMAM dendrimers. Although the encapsulation efficiency of
spherical PAMAM generation 6.0 was low, it was not negligible. It is possible that for
triblock copolymer generations 5.0 and 6.0 the PAMAM block also contributed to some
of the drug loading capacity. It is unknown how compact the PAMAM head group is in
the micelle and how well it can retain hydrophobic drug; thus, its independent
contribution cannot be determined. It is likely that encapsulation entails sequestration of
drug in the PPO core and the interior regions of the PAMAM block, leading to a
synergistic effect.
2.3.6 Drug Release Studies
Preliminary drug release studies were performed on PPO-PAMAM generation 3
micelles, since those micelles were the most stable as indicated by the CMC. Drug
release was performed in pH 7.4 PBS and pH 5.0 acetate buffer solution to simulate
physiological and endosomal conditions in the body, respectively. Figure 2-7 shows an
initial burst release over approximately the first day and then slow release afterwards.
The logarithmic release profile is indicative of drug diffusing out of the micelles.
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Figure 2-7. Release profile of triclosan from PPO-PAMAM generation 3.0 micelles at
pH 7.4 and pH 5.0.
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Furthermore, there was no pH dependence on the rate of drug release. This result was
expected since for generation 3 the CMC is not pH dependent.
2.4 Conclusions
A novel amphiphilic linear-dendritic block copolymer composed of PAMAM and
linear PPO blocks was synthesized up to generation 6.0. The block copolymers form
stable micelles in aqueous media with low CMC values, which can be controlled by
PAMAM generation, pH, or ionic strength. The ability to control the architecture and
properties of the PPO-PAMAM block copolymer makes it possible to create a system
that possesses the properties that are desirable for a drug delivery vehicle. The core is
biocompatible and has been used in Pluronics@ as drug delivery vehicles,44' 45 and
PAMAM is currently being studied as a drug delivery vehicle which can be made
biocompatible with simple modifications. 47-4 9 Because of its unique architecture, the
linear-dendritic block copolymer may be useful in targeted drug delivery, due to the
dense functionality of the dendrimer block. Targeting ligand can be attached to the
periphery of the dendrimer at high density and improve targeting efficiency through
increased affinity of multivalent interactions with receptors on the cell surface. In the
future, our group plans to study targeted drug delivery through multivalent
ligand/receptor interactions. It has been shown that micelles that are formed with and
without encapsulated drug are within the size limits that are desired for drug delivery
through endocytosis. 50 The PPO-PAMAM block copolymer encapsulates hydrophobic
drug at high efficiency and has sustained release of the drug. Although it was shown that
at generation 3.0 there was no pH dependence for drug release, it is possible that for
triblock copolymers at higher generations such as generation 5.0 or 6.0, there could be
pH dependence. Based on the studies performed, these block copolymers can be a viable
new type of drug delivery micelle.
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CHAPTER 3: Experiments and Molecular Dynamics
Simulations of PPO-PAMAM Linear-Dendritic Block
Copolymer Unimers and Micelles
3.1 Introduction
Linear-dendritic block copolymers are a new class of block copolymers that have
recently shown to have potential as biomaterials for tissue engineering,' gene therapy
delivery vehicles,2 and drug delivery vehicles. 3 4 When used for drug delivery, linear-
dendritic block copolymers are designed to be amphiphilic so that self-assembly into
colloidal particles (often times micelles) occurs, creating a hydrophobic compartment in
the micellar interior for drug encapsulation. Several groups have synthesized linear-
dendritic block copolymers with a hydrophilic linear block and a hydrophobic dendritic
block.3, 4 These block copolymers self-assemble with the dendritic block forming the
core. It is hypothesized that with the dendrimer forming the core, more hydrophobic drug
could be encapsulated due to the free volume created by the aggregated dendrimer
blocks. Recently, we reported the synthesis of a linear-dendritic block copolymer with a
hydrophilic dendritic block and hydrophobic linear block, so that in aqueous solution the
linear block forms the core while the dendrimer block forms the corona of the micelle.5
A potential advantage of our approach is that with the dendritic block located in the
corona region of the micelles, targeting ligand that can bind to receptors multivalently
can be presented for targeted drug delivery. In a previous study, we also found that the
dendritic block of the self-assembled micelles resulted in increased encapsulation of a
model hydrophobic drug, triclosan. The encapsulation efficiency for linear-dendritic
block copolymers composed of poly(amidoamine) (PAMAM) and poly(propyleneoxide)
(PPO) was approximately 82%. In comparison, the encapsulation efficiency for a
pluronic, F127, which has a similar PPO block length and similar CMC characteristics to
PPO-PAMAM had an encapsulation efficiency of 42%.
While our experimental results indicate that PPO-PAMAM linear-dendritic block
copolymer micelles have interesting and unexpected drug encapsulation properties and
show promise as drug-delivery vehicles, little is understood about the structure and
dynamics of these micelles (or even, more generally, for any linear-dendritic block
copolymer micelle) and the relationship between these characteristics and the micelles'
ability to deliver drug.
In order to understand structural characteristics of self-assembled dendritic
micelles, we have performed experiments to determine the aggregation number of these
micelles in aqueous solution, and performed atomistic molecular dynamics simulations to
determine the equilibrated structures of PPO-PAMAM block copolymer micelles with the
experimentally measured aggregation numbers. With these simulations, we are able to
better understand the structure and solubilization behavior of these drug delivery
vehicles, which may enable us to better design these block copolymers for drug delivery.
There have been numerous molecular dynamics studies on PAMAM dendrimers
examining PAMAM structure at various generations, 6-8 different solvation states,9-11 and
several ionically charged states.7' 10, 12, 13 There have also been a few coarse-grain
molecular dynamics studies on the formation of linear block copolymer micelles.
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However, there is only one cited instance of molecular dynamics simulations of a
Fr6chet-type linear-dendritic block copolymer unimer in various solvents.6 The block
copolymer was composed of linear poly(ethylene glycol) (PEG) and poly(benzyl ether)
dendron. Therefore, although prior simulations have provided further insight into the
behavior of linear-dendritic block copolymer unimers, molecular dynamics simulations of
linear-dendritic block copolymer micelles have never been reported. In this work in
collaboration with Brian Stephenson of the Blankschtein group, these simulations are
conducted for the first time.
3.2 Experimental Section
3.2.1 Materials
Poly(propylene glycol) bis(2-aminopropyl ether) (MW -4000, Mw/Mn = 1.04),
methanol, diethyl ether, and pyrene (sublimed, 99%), were purchased from Sigma-
Aldrich and used as received. Methyl acrylate and ethylenediamine were obtained from
Sigma-Aldrich and distilled over calcium hydride before use. MilliQ (18.2 MOZ) water
was used in all experiments requiring water.
3.2.2 Synthesis of PPO-PAMAM
The amphiphilic ABA linear-dendritic block copolymer was previously
synthesized.5  Briefly, the synthesis begins with poly(propylene glycol) bis(2-
aminopropyl ether) (PPO). The poly(amidoamine) (PAMAM) blocks are synthesized
from the amine ends of the PPO with alternating reaction steps of the first reaction,
Michael addition with methyl acrylate, and the second reaction, exhaustive amidation
with ethylenediamine. Generations 4.0 through 6.0 PPO-PAMAM were synthesized.
The synthesis of the block copolymer was confirmed through 1H-NMR and FTIR.
3.2.3 Aggregation Number Determination
For aqueous solutions of PPO-PAMAM generations 4.0 through 6.0, a BI-DNDC
differential refractometer (Brookhaven Instruments) was used to determine the specific
refractive index, dnldc, where n is the solvent refractive index and c is the concentration
of the polymer in solution. Polymer solutions ranging from 1 mg/ml to 10 mg/ml were
measured at 25 "C and 535 nm. Static light scattering was performed on a Brookhaven
Instruments BI-200SM Research Goniometer System. A Coherent Innova 90c (Santa
Clara, CA) laser at 514.5 nm was used as the light source. Static light scattering is used
to measure the angular dependence of the excess time-averaged scattered intensity known
as the excess Rayleigh ratio, R,(q). The Rayleigh ratio at dilute solution can be related
to the weight-average molecular weight, Mw, radius of gyration, Rg, and the second virial
coefficient, A2, in the following equation:
Hc 1 1l+( q2 + 2A2c (3-1)
R,,(q) M, 3
where H = 47tst2(dn/dc) 2 NA 4, q = 47rnk 4sin(0/2), nst is the refractive index of toluene,
NA is Avogadro's number, X is the wavelength of the laser, and 0 is the scattering angle. 17
Samples ranging from 1 to 10 mg/ml were measured at 10 degree increments from 40 to
140 degrees at 25 "C. Zimm plots were generated. To determine the Mw of the
aggregates, Rw(q), was extrapolated to zero scattering angle and zero polymer
concentration. The y-axis intercept was used to calculate the Mw. A2 and Rg are also
determined from the Zimm plot. As the scattering angle approaches zero, the slope is
equal to 2A2C, while at zero polymer concentration, the slope equals 167cn2 n2Rg2/(3Mw).' 7
3.2.4 Simulation Methodology and Parameters
All simulations were conducted using a 2006 developers' version of the
GROMACS software package. 18' 19 Each dendrimer and the hydrophobic solute triclosan
were simulated using the GROMACS forcefield, in which all atoms are simulated at an
atomistic level except hydrogens bound to carbon atoms.20 The GROMACS force field is
expected to be well-parameterized for the chemical structures present in each dendrimer
and triclosan, and has been applied by other researchers in simulating PAMAM
dendrimers with an ethylenediamine core and amine terminal ends.9 Water was
simulated explicitly using the simple extended point-charge model (SPC/E). 21 The
amines in each dendrimer were simulated as being unprotonated, a charge state
corresponding to an alkali solution (pH > 10). Using Gaussian '98, atomic charges were
assigned to each dendrimer molecule and triclosan using values predicted with the
Hartree-Fock method and the 6-31G(d) basis set.22
van der Waals interactions were modeled using a cutoff distance of 9 A, and
Coulombic interactions were evaluated using a cutoff distance of 14 A. A long-range
dispersion correction was applied to more accurately estimate the energy and pressure of
the system. In modeling short-ranged nonbonded interactions, a neighbor list of 9.0 A
was maintained and updated every 10 simulation timesteps. Each simulation was carried
out using fixed bond lengths, which allowed the simulation timestep to be increased to 3
fs. Bond lengths were constrained using the SHAKE algorithm.23
Simulations were conducted in the NPT (constant number of particles, constant
pressure, and constant temperature) ensemble. In each simulation, the cell temperature
was maintained at 298.15 K using a Berendsen temperature coupling algorithm, which
mimics weak coupling to an external heat bath with first-order kinetics.1 9 A Berendsen
pressure coupling algorithm was applied to maintain each simulation cell at the specified
pressure of 1.0 bar.19
To minimize the number of solvent molecules that must be included in each
simulation cell, each simulation was conducted in a rhombic dodecahedron simulation
cell. The volume of this geometry is 0.71 times that of a cubic simulation cell providing
the same separation distance between a solute and its periodic image. Details for each
simulation are given in Table 3-1.
3.2.5 System Preparation and Equilibration
Generations 4, 5, and 6 linear-dendritic block copolymers were simulated in both
unimeric and micellar states. In a separate simulation, ten molecules of the solute
triclosan were added to a generation 4 micelle to investigate the locus of its
solubilization. Initial energy minimization and simulation of both block copolymer
unimers and micelles were conducted in vacuum, but with the application of a dielectic
constant of 4.0 in order to roughly approximate the electrostatic shielding effects of
water.24 Each unimer or micelle was annealed at very high temperature and gradually
cooled to room temperature. Each system was then simulated at room temperature
(298.15 K) for the vacuo simulation time listed in Table 3-1. Initial simulation in
vacuum was conducted to permit rough equilibration of unimer/micelle structure with a
minimum of computational expense and was useful in this study because of the large size
of each linear-dendritic block copolymer system.
Next, explicit water molecules were added to each simulation cell. The number
of water molecules added is listed in Table 3-1. The number of added water molecules
was sufficient that the distance between the wall of each simulation cell and the closest
dendrimer atom was 1 nm in each direction. After placing each unimer or micelle in the
solvent box, an energy minimization was performed to remove close contacts. Next,
simulation in water was performed at 298.15 K for the water simulation time listed in
Table 3-1.
The equilibration of each system was monitored by evaluating the system
potential energy and the unimer or micelle radius of gyration. The potential energy of
each system appeared to stabilize within the first nanosecond of simulation in water.
However, changes in the radius of gyration occurred over much longer timescales. The
extent to which each system had equilibrated was quantified using the autocorrelation
function of the radius of gyration, CRg(t), which is evaluated using the following
equation:
CR, = ((R (Rg)Rg (0) - (R) (3-2)
(R 2 ) - R 2
Figure 3-1 shows the autocorrelation profiles for PPO-PAMAM generations 4, 5,
and 6 block copolymer unimers (Figures A, B, and C, respectively) and micelles (Figures
A', B', and C', respectively). Each autocorrelation profile drops to zero in less than the
total simulation time. We have used each autocorrelation profile for Rg to compute a
relaxation time, defined as the time at which CRg(t) = l/e. Each relaxation time is listed
in Table 3-1, and it ranges in time from 0.68 ns (generation 5 micelle) to 7.6 ns
(generation 4 micelle). We note that each relaxation time is significantly shorter than the
total simulation time, ranging from 4% of the total simulation time for the generation 5
Table 3-1. Simulation condition parameters for unimers and micelles of PPO-PAMAM
generations 4 through 6.
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Figure 3-1. Autocorrelation profiles for unimers of PPO-PAMAM generations 4, 5, and
6 (A, B, C, respectively) and for micelles of PPO-PAMAM generations 4, 5, and 6 (A, B,
C, respectively). The y-axis is a dimensionless number while the x-axis is time (ns). The
relaxation time, rRg, is determined from these autocorrelation profiles.
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micelle to 15% of the total simulation time for the generation 4 micelle.
3.3 Results and Discussion
A linear-dendritic block copolymer composed of a linear hydrophobic PPO block
and two outer PAMAM dendritic blocks was previously synthesized and characterized to
determine its viability as a drug delivery vehicle (shown in Figure 3-2). Interesting
properties were displayed in these studies including decreasing Rh with an increase in the
PAMAM generation and high drug loading capacity of triclosan due to the addition of the
PAMAM dendritic block. Further studies were needed to elucidate what was observed.
Additional experiments were conducted to determine the micelle aggregation number,
which would help to explain the micelle size trend. Furthermore, the results of these
experiments were the basis for subsequent molecular dynamics simulations of micelles in
order to determine micelle structure and the location of drug solubilization within the
micelles in the hopes that such understanding will guide future efforts towards
developing increasingly effective drug delivery vehicles.
Figure 3-2. Chemical structure of generation 4.0 PPO-PAMAM.
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3.3.1 Micelle Aggregation Number
The aggregation number of PPO-PAMAM micelles generations 4, 5, and 6 were
determined with static light scattering and a Zimm plot analysis. That data is
summarized in Table 3-2 and the Zimm plots are shown in Figure 3-3. The aggregation
numbers ranged from 8 to 6, where generally with increasing generation there was a
decrease in aggregation number. The trend observed closely follows the reduction in the
hydrodynamic radius previously reported with increasing PAMAM generation.5 With
less unimers in each micelle, the size of the micelle would decrease.
Table 3-2. Zimm plot results of PPO-PAMAM generations 4, 5, and 6 micelles in DI
water.
PPO- dn/dc A2  Average Aggregation RhPAMAM Micelle Mw
Generation (ml/g) (cm3.mol/g2) (g/mol) Number (nm)
4 1.26E-01 -1.68E-04 7.94E+04 ± 8 1 8 0.2
0.98E+04
1.39E-01 2.55E-04 9.14E+04 ±5 6 3.6 4.5 + 0.15.8E+04
6 -9.81E-02 1.09E-04 1.41E+05 ± 6 1 4.5 + 0.10.2E+04
The A2 values obtained from the Zimm plots indicate how well the solvent
solvates the polymer molecules. A2 is negative for generation 4 while it is positive for
generations 5 and 6. This trend is corroborated in the CMC of these linear-dendritic
block copolymers, where as the PAMAM generation increases the CMC increases due to
the rise in the overall hydrophilicity of the polymer. It was previously observed that the
CMC increased dramatically from generation 4 to 5 while it slightly decreased from
generation 5 to 6.5 The same trend is seen with A2.
101
Kcam
ad
I
hOA 
..
ibmPt
omo00o
Figure 3-3. Zimm plots(B), and 6.0 (C).
of miellar solutions of PPO-PAMAM generations 4.0 (A), 5.0+of micellar solutions of PPO-PAMAM generations 4.0 (A), 5.0
102
70.M
mom
The Rg values of the micelles in solution could not be determined accurately with
Zimm plots. As seen in Figure 3-3, the extrapolation to zero concentration does not fit
well with the actual data, since there is curvature at low and high angles. Furthermore, it
has been noted that static light scattering is not able to determine the Rg of particles with
Rg values smaller than 10 nm.17
3.3.2 Computer Simulation: Asphericity
Snapshots of the post-equilibration configurations of each simulated unimer and
micelle are shown in Figure 3-4. For clarity, water molecules are not shown. Hydrogen
atoms are depicted in white, carbon atoms cyan, nitrogen atoms blue, and oxygen atoms
red. As can be observed in the snapshots, in general, the micelles are less spherical and
more irregular in shape than the unimers.
In order to provide a quantitative measure of the asphericity of the simulated
unimers and micelles, we have computed the moment of inertia tensor. The average
values of the three principal moments of inertia Iz, I, and I,, where Iz, Iy, and I, are the
eigenvalues of the moment of inertia tensor in descending order, are given in Table 3-3
along with the time period used to generate the average results. Each time period
selected for averaging should be representative of the characteristics of the micelle after
reaching an equilibrium shape and size, and was chosen based on the radius of gyration
data shown in Figure 3-5. The average aspect ratios I11 and IzIIy, and the relative shape
anisotropy K2, which is equal to 1 for a linear set of atoms and 0 for shapes with high 3D
symmetry, are also reported in the table. The relative shape anisotropy is computed using
the following formula:
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Figure 3-4. Snapshots of PPO-PAMAM unimers and micelles post-equilibration.
Hydrogen atoms are depicted in white, carbon atoms cyan, nitrogen atoms blue, and
oxygen atoms red.
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3(I2)2 = 1 (3-3)
where I, and I2 are the first and second invariants of the radius of gyration tensor:
I] = Iy + I, 12 = IxIy + Iz + IxIz.
The aspect ratio Iz/Ix ranges between 1.52 and 2.26, while the ratio IzIy ranges
between 1.04 and 1.49. Both aspect ratios deviate significantly from 1.0 in most cases
for both unimers and micelles, indicating that the equilibrated configuration of the
simulated unimers and micelles are not very spherical. The relative shape anisotropy, K ,
ranges from 0.02 for the generation 5 unimer to 0.05 for the generations 4 and 5 micelles.
Although these values are relatively close to 0, which indicates a structure with high 3D
symmetry, they are significantly larger than values of K2 reported by other researchers
quantifying the shape anisotropy of PAMAM dendrimers in aqueous solution (ranging
between 0.015 for a generation 1 dendrimer and 0.005 for a generation 5 dendrimer), 9
indicating that the unimers and micelles considered in this study have a much higher
degree of shape anisotropy than simple dendrimers.
3.3.3 Computer Simulation: Radius of Gyration
The mass-weighted radius of gyration was computed for each unimer and micelle
over the course of simulation. Each radius of gyration was computed as follows:
(r - rcoM ) m2 i
R, = i (3-4)
i
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Table 3-3. Moments of inertia values for PPO-PAMAM unimers and micelles.
Time
Simulation Range for 2v(a.m.u. (a.m.u. (a.m.u. IJIx Izly 1 2Name Averaging nmz )  nm 2) nm 2)(ns)
ppog4uni 10-20 12198.0 11764.1 8034.2 1.52 1.04 0.03
ppog5uni 5-8.8 54734.8 36691.2 34827.5 1.57 1.49 0.02
ppog6uni 5-10 130100.4 110381.8 62032.2 2.10 1.18 0.03
ppog4mic 35-50 538095.4 458526.8 252791.2 2.13 1.17 0.05
ppog5mic 5-17 710767.1 609167.8 314532.9 2.26 1.17 0.05
ppog6mic 3-14.5 1870012 1596542 1053896 1.77 1.17 0.03
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where ri is the location of atom i, rcog is the location of the center of mass of the
unimer/micelle, and mi is the mass of atom i.
Figure 3-5 shows the radius of gyration profiles for PPO-PAMAM generations 4,
5, and 6 unimers in water (figures A, B, and C, respectively) and micelles (figures A', B',
and C', respectively) as a function of simulation time. The starting point for each profile
is the ending radius of gyration of the unimer/micelle after simulation in vacuo.
Although the magnitude of the radius of gyration values reported for each unimer and
micelle are different, to facilitate comparison of the results, the range of Rg values
reported on the y-axis is the same (0.2 nm) for each plot. Each unimer and micelle shows
change in the radius of gyration after the addition of explicit solvent molecules to the
simulation cell. Two of the micelles (generations 4 and 6) show gradual increases in Rg
over long periods of time, but in both cases the rate of change in Rg slowed significantly
by the end of the simulation. As reflected in the relaxation times reported in Table 3-1,
the timescale associated with stabilization of Rg is larger for the generation 4 micelle than
for the unimer, smaller for the generation 5 micelle than for the generation 5 unimer, and
larger for the generation 6 micelle than for the unimer. The radius of gyration values
recorded for each unimer and micelle appear to have roughly stabilized by the end of the
simulation time and to be fluctuating about an equilibrium value.
Table 3-4 summarizes the Rg values obtained from the simulations performed.
The unimer Rg values are in the same range that has been observed through simulations
and experimentation of PAMAM dendrimers (note that the PAMAM generation notation
is different between this paper and the references). 8' 25 Comparing the lowest generation
block copolymer (generation 4), the Rg value is very similar to the corresponding
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PAMAM dendrimer, indicating that the PPO block does not add much to the size of the
block copolymer unimer.8 However, as the PAMAM generation increases, the Rg values
increase as well due to the rise in the molecular weight of the PAMAM block. The rate
of increase is faster than what is observed with the PAMAM dendrimers, where
generation 6 is approximately 2-4 nm larger than the corresponding dendrimer.8 Most
likely for the block copolymer, the PPO block which separates the PAMAM dendrons
allows the PAMAM to spread out to a greater extent. In comparison, PAMAM
dendrimers are constrained due to crowding at the exterior, which limits their outgrowth.
For PPO-PAMAM micelles, the simulations revealed that the Rg increased with
increasing generation. Assuming that the micelles formed are similar in structure to each
other, the Rg/Rh ratio is constant. For a hard sphere, Rg/Rh = 0.77, and for a linear coil,
Rg/Rh = 1.8.17 Assuming a hard sphere, the theoretical Rg is presented in Table 3-4. The
calculated Rg data has the reverse trend observed from the simulations and is larger than
the simulated Rg data. The discrepancy could be explained due to how the Rh was
calculated from the Stokes-Einstein equation assuming a spherical particle. As discussed
in the previous section, the micelles were not particularly spherical in nature. It has been
observed that dendrimers are considered to be prolate ellipsoids.26 All of the micelles
simulated were quite anisotropic which would result in large Rh measurements.27 This in
turn would produce larger Rg calculations in comparison to the simulated results.
Generally, the Rg values obtained from the simulations and the Rg values
calculated from the experimental Rh values were of the same order of magnitude.
However, the differences in the values observed could also be explained through the
difference in the ionization state of the micelles. In the simulations, the micelles were not
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Figure 3-5. The time evolution of Rg for generations 4, 5, and 6 PPO-PAMAM unimers
(A, B, and C, respectively) and micelles (A', B', and C', respectively). The y-axis is Rg
(nm) while the x-axis is time (ns).
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Table 3-4. Rg values obtained from simulation and calculated through experimental data
for PPO-PAMAM unimers and micelles.
Simulation Name Simulation R, Rh (n Calculated Rg (nm)(nm) (hard sphere)
ppog4uni 1.28 ± 0.02 -- --
ppog5uni 1.67 ± 0.01 -- --
ppog6uni 2.24 ± 0.01 -- --
ppog4mic 2.83 ± 0.01 8 ± 0.2 6.2
ppog5mic 2.86 ± 0.01 4.5 ± 0.1 3.5
ppog6mic 3.54 ± 0.01 4.5 ± 0.1 3.5
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charged, while the experimental data is for micelles in a partially charged environment.
The radius of gyration expected for a partially protonated unimer or micelle would be
expected to be larger than the values recorded here, because electrostatic repulsions
among similarly charged nitrogen groups would be expected to cause swelling in aqueous
solution.
3.3.4 Computer Simulation: Monomer Density Distribution
To quantify the time-averaged structure of the simulated micelles, the radial
density profile of PAMAM monomers was computed with respect to the micelle center of
mass. The radial density profile was evaluated by counting the number of atoms within a
spherical shell between r and r + Ar, where r is the distance from the micelle center of
mass and dividing by the volume of the spherical shell. The value of Ar used was 0.1
nm, a value which is large enough to provide good statistics on the density values except
at small values of r (less than 0.5 nm9), where the volume of the spherical shell becomes
quite small and results in the density profile data becoming very noisy. The relationship
between the total number of atoms between the micelle center of mass and the value of r
is given by the following expression:
N(r) = 4x f r2p(r)dr (3-5)
Values of p(r) were computed for PPO-PAMAM generation 4, 5, and 6 micelles
using simulation data taken from 35-50 ns, 5-17 ns, and 3-14.5 ns, respectively (the same
time frames used in computing the asphericity data given in Table 3-3). Figure 3-6
shows p(r) as a function of r for the different micelles.
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Figure 3-6. PAMAM monomer radial density distribution of PPO-PAMAM micelles
generations 4 (blue circles), 5 (green diamonds), and 6 (red triangles).
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Before r becomes sufficiently small that the density profiles become unreliably
noisy, each of the p(r) profiles appears to trend slightly downward as r decreases below 1
nm. This decrease in density is consistent with the visual observation that the
hydrophobic PPO units tended to localize near the center of each micelle, displacing
PAMAM dendrimers. It is interesting to note that for each of the three generations the
decrease in p(r) as r increases is slow and fairly linear. The rate at which p(r) decreases
is distinctly slower than that observed by other researchers simulating dendrimers of
similar generation,8s-' and reflects the fact that each of the dendritic micelles simulated
here are more irregular in shape than unimolecular PAMAM generation 4, 5, or 6
dendritic molecules.
3.3.5 Computer Simulation: Terminal Group Distribution
Values of p(r) for the terminal amine groups in each dendritic micelle were
computed for generations 4, 5, and 6 (once again using simulation data taken from 35-50
ns, 5-17 ns, and 3-14.5 ns, respectively). Profiles of p(r) as a function of r are shown in
Figure 3-7. The location of terminal amine groups is important in the context of targeted
drug delivery, because targeting ligands are typically attached to terminal amine groups.
Furthermore, the extent to which terminal amine groups localize near the surface of the
micelle or in the interior of the micelle is important in understanding the composition of
the micelle/water interface.
At values of r less than 0.5, p(r) data becomes unreliably noisy. At values of r
greater than 0.5, values of p(r) for generation 4 are observed to be relatively level with no
general upwards or downwards trend up until about 3 nm. At this point p(r) begins to
decrease, and reaches zero at approximately 5 nm. The density data shows that rather
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than being localized only near the exterior of the micelle, terminal amine groups are
dispersed fairly evenly throughout the micelle interior, indicating that back-folding of
terminal amine groups is prevalent through the dendritic micelle. Such back-folding is
also observed in single dendrimer molecules9 The p(r) profiles for generation 5 and 6
show greater variation at small values of r, but once again the concentration of terminal
amine groups in both micelles is found to be quite high within the interior of the micelle.
3.3.6 Computer Simulation: Dendrimer/Water Interface
In drug delivery applications, the structure and composition of the micelle/water
interface plays an important role in determining the manner in which the dendrimer will
interact with cells and deliver drugs within the body. The density profiles discussed in
the previous two sections indicate that, due to the high degree of back-folding observed
within dendrimer unimers, both primary and terminal amine groups are present at the
micelle/water interface. Figure 3-8 plots the density of atoms comprising each micelle
(the solid line) and water atoms as a function of distance from the micelle center of mass
for the PPO-PAMAM generations 4, 5, and 6 systems.
For values ofr > 0.5 nm, where the p(r) profiles are reliable, the atom density of
water does not drop to zero within the interior of the generations 4 and 6 micelles, while
it does drop to essentially zero in the interior of the generation 5 micelle. Researchers
simulating dendrimer molecules have observed that the density of water does drop to zero
near the center of dendrimer molecules, even at low generation numbers, a finding which
stands in contrast to the results for generations 4 and 6 micelles observed here.
9
' 10
Although the interior of the PPO-PAMAM generations 4, 5, and 6 micelles simulated in
this article are expected to be more hydrophobic on average than the interior of a simple
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Figure 3-7. The radial density distribution of the terminal groups. Generation 4 is
shown as blue circles, generation 5 as green diamonds, and generation 6 as red triangles.
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Figure 3-8. The density of atoms comprising each micelle (the solid line) and water
atoms as a function of distance from the micelle center of mass for the PPO-PAMAM
generation 4 system (A), generation 5 system (B), and generation 6 system (C).
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dendrimer molecule because of the hydrophobicity of the PPO groups connecting each
PAMAM head, the shape of the micelles simulated in this article are much more irregular
and less spherical than that observed for simple dendrimers (see Section 3.3.2). The p(r)
profiles for water for generations 4 and 6 micelles are likely due to the observed
asphericity of the dendritic micelles. These results should not be taken to conclude that
water is adjacent to the hydrophobic PPO groups within the micelle core; however, due to
the irregular geometry of the micelle, water penetrates more closely to the micelle core
than is typically observed for surfactant micelles.
3.3.7 Computer Simulation: Locus of Hydrophobic Drug Solubilization
In Figure 3-9, density profiles are shown for PPO-PAMAM generation 4
dendrimer atoms, the atoms in 10 triclosan molecules, and water atoms. The p(r) profile
for triclosan has been scaled by the ratio of the total number of dendrimer atoms to the
total number of triclosan atoms (=38.44) to amplify the triclosan density profile and make
it more easily visible. The density profile appears to lie relatively evenly between the
dendrimer and water molecules. The post-equilibration locus of solubilization is similar
to the location where the triclosan was originally introduced during construction of the
generation 4/triclosan/water micellar system (at the micelle/water interface). None of the
10 triclosan molecules initially placed at the micelle/water interface diffused out into
aqueous solution, instead preferring to reside near the interface and remain in contact
with the more hydrophobic environment provided by the dendritic micelle. As discussed
in Section 3.2.4, 49.5 ns of equilibration of the ppog4drug system was conducted.
However, it is not clear whether this level of simulation was sufficient to permit diffusion
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Figure 3-9. Radial distribution density profiles are shown for PPO-PAMAM dendrimer
atoms (blue circles), the atoms in 10 triclosan molecules (green diamonds), and water
atoms (red triangles).
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of triclosan molecules to their thermodynamically preferred location within the micelle
because significant diffusion from their initial position was not observed. Simulation of
triclosan starting from different initial locations within each micelle is required to
conclusively identify the preferred locus of solubilization of triclosan in PPO-PAMAM
generation 4 micelles.
3.3.8 Computer Simulation: Solvent Accessible Surface Area
We have calculated the solvent accessible surface area (SASA) using the double
cubic lattice method as implemented in GROMACS. 20 A probe sphere of radius 0.14 nm
was used to compute the total (all atoms), hydrophobic (carbon and hydrogen bonded to
carbon), and hydrophilic (oxygen, hydrogen bonded to oxygen, nitrogen, and hydrogen
bonded to nitrogen) solvent accessible regions at each simulation time.28-30 SASA values
were computed for PPO-PAMAM generations 4, 5, and 6 micelles using simulation data
taken from 35-50 ns, 5-17 ns, and 3-14.5 ns, respectively. Average hydrophobic,
hydrophilic, and total SASA values are reported in Table 3-5, and the errors reported in
the table are the standard deviation associated with each SASA value. Hydrophobic
SASA values are much smaller than hydrophilic SASA values, indicating that the surface
of each dendritic micelle is largely hydrophilic.
We have computed SASA using spheres of radius 0.14, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7,
0.8, and 0.9 nm using the same simulation data used to generate Table 3-5 in order to
determine the dependence of SASA on probe sphere radius. Results for the square root
of the total solvent accessible surface area are shown in Figure 3-10 as a function of the
probe sphere radius for PPO-PAMAM generations 4, 5, and 6 micelles. Each SASA112
profile initially decreases as the probe radius increases. However, as the probe radius
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increases further this trend slows and is eventually reversed. At sufficiently large values
of the probe radius, SASA 1/2 begins to increase linearly with the probe radius. SASA 1/2
decreases with probe radius when the initial probe radius is smaller than the size of the
largest internal voids present in a micelle. When the probe radius is larger than the
largest internal voids, SASA /2 increases linearly with the probe radius. Evaluation of the
radius at which each system begins to show a linear increase in SASA 12 with the probe
radius allows us to determine that the largest voids in the generation 4, 5, and 6 micelle
systems are approximately 0.35 nm, 0.4 nm, and 0.6 nm, respectively. It is interesting to
note that the size of the largest void increases with the generation number of the
molecules comprising the micelle. This observation is in agreement with visual
observation of the equilibrated PPO-PAMAM generations 4, 5, and 6 micellar systems.
As shown in Figure 3-4, the irregularity of the micelle surface appears to increase as the
generation number increases (compare, in particular the irregularity of the generation 6
micelle's surface with that of generation 4 and 5). The effect of generation number on
the morphology of the self-assembled micelles observed here could be related to drug
delivery performance where the diffusion of drug through the micelle could be altered.
Additionally, the morphology of the outer surface of the micelles could affect how
targeting ligands are clustered on the surface and affect the binding characteristics of the
drug delivery vehicle.
Table 3-5. Average SASA values for PPO-PAMAM generations 4, 5, and 6 micelles.
System Hydrophobic Hydrophilic Total
SASA (nm2 ) SASA (nm2) SASA (nm2)
ppog4mic 53.4 ± 0.3 265.4 ± 1.9 318.8 + 2.5
ppog5mic 32.5 ± 0.3 273.0 ± 2.2 305.4 ± 2.4
ppog6mic 41.5 ± 0.4 464.6 ± 0.5 506.1 ± 0.5
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Figure 3-10. The square root of the total solvent accessible surface area, SASA/2, as a
function of the probe sphere radius for PPO-PAMAM micelles generation 4 (blue
circles), generation 5 (green diamonds), and generation 6 (red triangles).
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3.4 Conclusion
An amphiphilic linear-dendritic block copolymer system which displayed
interesting aqueous self-assembly behavior and high drug loading capacity was simulated
using the GROMACS software package in order to gain detailed information about the
structure of the micelles formed. Static light scattering experiments were used to explain
the trends in Rh values as a function of dendrimer generation previously observed
experimentally. Experimentally determined aggregation numbers were used to set up
simulations of a PPO-PAMAM generation 4 micelle (containing eight unimers), a
generation 5 micelle (containing six unimers), and a generation 6 micelle (containing six
unimers).
In some respects, the micelles were found to have structural characteristics similar
to PAMAM dendrimers. Rg values of the linear-dendritic block copolymer unimers were
found to be of the same order of magnitude as the corresponding dendrimer, and back-
folding of the PAMAM terminal amines was seen.8' 10 However, in contrast to
dendrimers, the micelles were quite a bit more irregular in shape and showed much more
asphericity than dendrimers with even a low number of generations.9 Simulations that
were also performed to determine where triclosan, a model hydrophobic drug, would
localize to in the block copolymer micelles showed the drug localizing in both the
PAMAM and PPO block and not diffusing out into the aqueous environment. Previous
experimental data confirms that triclosan can be encapsulated in PPO-PAMAM block
copolymer micelles as well as PAMAM dendrimers. 5  Evaluation of the post-
equilibration solvent accessible surface areas (SASAs) of each simulated micelle using
spheres of different probe radii permitted determination of the largest voids in the
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generation 4, 5, and 6 micelle systems. This could affect drug delivery performance by
altering the diffusion of drug and water in and out of the micelles. Additionally, the
spacing for drug delivery targeting would differ due to the different pore sizes.
The simulations performed provide a great deal of insight into the microstructure
of linear-dendritic block copolymer micelles than was previously available and the
manner in which these micelles encapsulate hydrophobic drugs for drug delivery. This
data is potentially useful for further design and improvement of the system. For example,
simulations could be used to predict the micelle equilibrium size as a function of the
block length, or it could be used to design drug delivery vehicles with the correct
targeting ligand spacing. Additionally, more information about the affinity of a drug to a
particular hydrophobic polymer could be gleaned from simulations. With the work
presented here, insight into the structural details of linear-dendritic block copolymer
micelles was gained and can be used to develop more efficient drug delivery systems.
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CHAPTER 4: PPO-PAMAM IN-VITRO TESTING
4.1 Introduction
Nanoparticle drug carriers can accumulate in targeted drug delivery areas that
display vascular permeability.' For example, extravasation of polymeric nanoparticles
into solid tumors occurs through a phenomenon called the enhanced permeability and
retention effect (EPR).2' 3 Recently, it has been shown that micellar particles can
accumulate in arteries that had sustained injury from angioplasty or stenting4 or in areas
of a myocardial infarction.5 Another region of polymeric micelle accumulation that has
been studied is at choroidal neovascularization sites in rat eyes. ' , 6
In order to further enhance targeting to the desired treatment sites, targeting
ligand can be attached to the outer surface of the polymeric nanoparticles. The ligand
used is often paired to a cell surface receptor that is only expressed or overly expressed in
the cells of interest. Therefore, utilizing targeting ligand can contribute to drug retention
through internalization of particles by receptor-mediated endocytosis. Ligands such as
folate,7-9 RGD, 10' 11 and transferrin 12 have been used with polymer nanoparticles and
liposomes.
Linear-dendritic block copolymers have previously been shown to be viable drug
delivery vehicles. 13  Amphiphilic linear-dendritic block copolymers may have an
advantage as a targeted drug delivery vehicle over conventional linear block copolymers
due to the dense functional groups presented on the surface of the hydrophilic dendritic
blocks forming the corona of the micelle. There are many multivalent targeting systems
within the body that require dense clustering of functional groups. For example,
129
carbohydrate/lectin systems have been demonstrated to be multivalent systems. 14' 15
Dendrimers conjugated to carbohydrates, such as mannose or lactose, have been shown to
have multivalent binding affinity with lectins. 16-18 Block copolymer micelles 19-21 have
been functionalized with galactose, and their binding affinity to RCA-1 lectin have been
studied. Studies with liposomes have been the most developed, where testing of
galactose-functionalized liposomes in vitro and in vivo have been done indicating
enhanced uptake by hepatic cells.22
To the author's knowledge, linear-dendritic block copolymer micelles have not
yet been functionalized with targeting ligand for cell-specific drug delivery. There have
been initial in vitro tests with amphiphilic linear-dendritic block copolymers composed of
a hydrophilic linear block and a hydrophobic dendritic block indicating comparable drug
efficacy as bare doxorubicin.23 However, the self-assembly behavior of the Frechet-type
linear-dendritic block copolymers uses the dendritic block as the hydrophobic core. In
contrast, the proposed linear-dendritic block copolymer system is composed of a
hydrophobic linear block and a hydrophilic dendritic block. This linear-dendritic block
copolymer self-assembles with the linear hydrophobic block forming the core and the
dendritic block forming the corona of the micelles formed. Here we can take advantage
of the dense functional groups presented on the outer surface of the micelles for
multivalent targeting.
In this chapter, experiments performed to determine the viability of linear-
dendritic block copolymer micelles as a targeted drug delivery vehicle will be presented.
The experiments include the synthesis of a targeted linear-dendritic block copolymer and
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in vitro experiments determining the binding efficiency and drug delivery efficacy of
these novel linear-dendritic block copolymer micelles.
4.2 Experimental
4.2.1 Materials
Chemicals including methanol, dimethylformamide (DMF), dimethylsulfoxide
(DMSO), triethylamine (TEA), N,N-diisopropylethylamine, 1-Amino-l -deoxy-g-D-
galactose (galactosylamine), phosphate buffered saline (PBS) and asialofetuin (ASF)
were acquired from Sigma Aldrich and used as received. BOP, HBTU, HOBT,
doxorubicin, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
were obtained from EMD biosciences. Dialysis bags were purchased from Spectrum
Laboratories. Alexa Fluor@ 488 carboxylic acid, succinimidyl ester was obtained from
Invitrogen. Water used in any experiments was from a MilliQ water purification system.
4.2.2 Synthesis of Galactose Functionalized PPO-PAMAM
Deprotection of PPO-PAMAM X.5 Generation. Generally, half generations of PPO-
PAMAM terminated with methyl ester groups were deprotected by base hydrolysis. For
example, PPO-PAMAM G3.5 (1.39 g, 0.2 mmol) was dissolved in 5 ml of methanol. 1.3
ml of 5 M aqueous NaOH was added dropwise to the stirring solution. The reaction was
monitored by FTIR. After completion, the solvent was removed by rotary evaporation
and dialyzed for 24 hours (3500 MWCO). The dialyzed solution was lyophilized until
dry (yield 63%).
PPO-PAMAM-COOH G2.5. 1H NMR (D6-DMSO): 8ppo(-OCH 2CHCH3-) = 1.14 (t);
8ppo(-OCH 2CHCH3-) = 3.40 (m); 8ppo(-OCH 2CHCH 3-) = 3.61 (m); 8PAMAM (-CONH-)
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= 7.66-8.02 (bs); 8PAMAM (-CH2CH2N-) = 3.28 (m); 8PAMAM (-CH2CH2CO-) = 2.74-2.83
(m); 8PAMAM (-CH2CH2N-) = 2.53-2.59 (m); 8 PAMAM (-CH2 CH 2CO-) = 2.37-2.44 (t);
FTIR peak v cm-': 1110, 1540, 1665.
PPO-PAMAM-COOH G3.5. 1H NMR (D6-DMSO): 8ppo(-OCH 2CHCH 3-) = 1.14 (t);
8ppo(-OCH2 CHCH3-) = 3.40 (m); 8ppo(-OCH 2CHCH3-) = 3.61 (m); 8PAMAM (-CONH-)
= 7.73-8.09 (bs); 8PAMAM (-CH2CH2N-)= 3.28 (m); 8PAMAM(-CH2CH2CO-) = 2.75-2.81
(m); 8PAMAM (-CH2 CH 2N-) = 2.53-2.58 (m); 8 PAMAM (-CH2CH 2CO-) = 2.37-2.44 (m);
FTIR peak v cm -': 1110, 1542, 1652.
PPO-PAMAM-COOH G4.5. 'H NMR (D6-DMSO): 8ppo(-OCH 2CHCH 3-) = 1.14 (t);
8ppo(-OCH 2CHCH 3-) = 3.40 (m); 8ppo(-OCH 2CHCH 3-) = 3.61 (m); 8PAMAM (-CONH-)
= 7.63-8.07 (bs); 8PAMAM (-CH2CH 2N-) = 3.27 (m); 8PAMAM (-CH2CH 2CO-) = 2.74-2.82
(m); 8PAMAM (-CH2CH 2N-) = 2.53-2.58 (m); 8PAMAM (-CH2 CH 2CO-) = 2.36-2.43 (m);
FTIR peak v cm-': 1110, 1542, 1647.
Synthesis of PPO-PAMAM-Galactose. As an example, PPO-PAMAM-COOH G3.5
(0.5 g) was dried by azeotropic distillation with toluene using the rotary evaporator at 45
'C. The polymer was dissolved in 20 ml of anhydrous DMSO. One molar equivalent of
DIPEA was added (0.24 g). Next, HOBT (1.16 g) and BOP (3.78 g) was added. The
solution was stirred for 5 minutes, and then 0.92 g galactosylamine was put into the
solution. After 2 days, water was mixed into the reaction to make approximately a 10%
DMSO solution. The solution was centrifuged for 10 minutes at 4000 rpm to collect the
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by-product precipitate. The solution was decanted and dialyzed (3500 MWCO) for 24
hours at room temperature. The dialyzed solution was lyophilized until dry (yield 59%).
PPO-PAMAM-COOH G2.5. 1H NMR (D6-DMSO): 8ppo(-OCH 2CHCH3-) = 1.14 (t);
8ppo(-OCH 2CHCH3-) = 3.40 (m); 8ppo(-OCH 2CHCH3-)= 3.61 (m); 8PAMAM (-CONH-)
= 7.66-8.02 (bs); PAMAM (-CH2CH 2N-) = 3.28 (m); 8pAMAM (-CH2CH2CO-) = 2.74-2.83
(m); 8PAMAM (-CH2CH 2N-) = 2.53-2.59 (m); 8PAMAM (-CH2CH 2CO-) = 2.37-2.44 (m);
6Gal = 3.8-4.0 (m).
PPO-PAMAM-COOH G3.5. 'H NMR (D6-DMSO): 8ppo(-OCH 2CHCH3-) = 1.14 (t);
8ppo(-OCH2CHCH3-) = 3.40 (m); 8ppo(-OCH 2CHCH3-) = 3.61 (m); 8 PAMAM (-CONH-)
= 7.73-8.09 (bs); 8•AMAM (-CH2CH 2N-)= 3.28 (m); 8PMAAM(-CH2CH2CO-) = 2.75-2.81
(m); 8PAMAM (-CH2CH2N-) = 2.53-2.58 (m); 8PAMAM (-CH2CH 2CO-) = 2.37-2.44 (m);
8Gal = 3.8-4.0 (m).
PPO-PAMAM-COOH G4.5. 'H NMR (D6-DMSO): 8ppo(-OCH 2CHCH3-) = 1.14 (t);
8ppo(-OCH 2CHCH3-) = 3.40 (m); 8ppo(-OCH 2CHCH3-) = 3.61 (m); 8PAMAM (-CONH-)
= 7.63-8.07 (bs); 8PAMAM (-CH2CH2N-) = 3.27 (m); 8PAMAM (-CH2CH2CO-)= 2.74-2.82
(m); GPAMAM (-CH2CH2N-) = 2.53-2.58 (m); 8PAMAM (-CH2CH2CO-) = 2.36-2.43 (m);
8Gal = 3.8-4.0 (m).
4.2.3 Polymer Characterization
IH NMR was used to characterize each polymer. 'H-NMR spectra were recorded
on a Varian Inova-500 MHz spectrometer. Samples were dissolved in deuterated DMSO.
FTIR spectra were recorded on a Nexus 870 FTIR Spectrometer (Thermo Nicolet,
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Waltham, MA). Samples were solvent cast onto polyethylene IR cards. MALDI-TOF
was performed by the MIT CCR Biopolymers Laboratory on an Applied Biosystems
Model Voyager DE-STR instrument. The samples were dissolved in 20 jtl of a 1:1
mixture of methanol:acetonitrile and 0.1% trifluoroacetic acid. 1 dtl of the solution was
mixed with 10 Al of a 2,5 dihydroxybenzoic acid matrix solution and analyzed.
4.2.4 In Vitro Testing
Drug Loading. PPO-PAMAM block copolymers were dissolved into DI water at a
concentration of 5 mg/ml. The pH of the solution was adjusted to 7.4 by addition of
either dilute HCI or dilute NaOH. 1 mg of doxorubicin-HCI was dissolved in 1 ml of
chloroform and 3 equivalents of triethylamine. The doxorubicin solution was added
dropwise to the stirred polymer solution and left open overnight in the dark. After the
chloroform evaporated, the solution was centrifuged at 4000 rpm for 10 minutes to
remove insoluble doxorubicin. The solution was filtered through a 0.20 Alm
polytetrafluoroethylene filter, and then using a centriprep centrifugal filter (Ultracel-YM
3, Millipore), ultrafiltration was performed in triplicate. The concentration of
doxorubicin in water was quantified by UV-vis (Agilent 8453 UV-Visible Spectrometer
System, Palo Alto, CA) by measuring the absorbance at 495 nm and compared to a
standard curve (concentration (Ag/ml) = 76.728*ABS 495-4.9553).
Drug Release. 5 ml of drug-loaded micelles in PBS were placed in dialysis bags (3500
MWCO) and put into a reservoir of PBS heated at 37 OC. A sample of the retentate was
measured by UV-vis at various time points at 495 nm. The PBS reservoir was replaced
every few days.
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Cell Culture. Hepatocellular carcinoma cells (Hep G2, ATCC HB-8065) were
maintained in Dulbecco's Modified Eagle Medium containing high glucose, 25 mM
HEPES, but no phenol red (DMEM, Invitrogen) supplemented with 10% fetal bovine
serum, 0.2 units/ml penicillin, and 100 gtg/ml streptomycin. The cells were kept in an
incubator at 37 'C in a 5% CO2 atmosphere. The media was changed every two days.
When the cells were confluent, trypsin-EDTA was added to the flask. After 15-30
seconds, the trypsin-EDTA was removed, and the flask was incubated at 37 OC for 10
minutes. The cells were subcultivated at a 1:6 ratio. Primary rat hepatocytes were
obtained from the Griffith Lab and seeded onto 6-well plates (0.4x106 cells/well, BD
Falcon) with serum-free hepatocyte growth media. The 6-well plates were first prepared
by incubating PBS solutions of 30 gtg/ml rat-tail collagen type I (BD Biosciences) for 1
hour at room temperature in each well. The cells were incubated for 3-4 hours at 37 'C
in a 5% CO2 atmosphere before use.
Binding Inhibition. ASF was modified with a reactive fluorescent tag, Alexa Fluor 488
succinimidyl ester. 7 mg of ASF was dissolved in 2 ml of water, and then 0.5 ml of 1 M
sodium bicarbonate solution was added to attain a solution with a pH of 8. 50 pl of a 10
mg/ml solution of Alexa Fluor 488 succinimidyl ester in DMSO was added to the ASF
solution and stirred at room temperature for 4 hours in the dark. The Alexa Fluor
modified ASF (ASF-AF488) was purified by dialysis at 4 OC for 2 days. Varying
concentrations of galactose-modified PPO-PAMAM or soluble ASF dissolved in DPBS
was introduced into 6-well plates of primary rat hepatocytes. 5 pl of ASF-AF488 was
introduced for every 1 ml of media. The solutions were incubated with the cells for 30
minutes. Afterwards, the cells were washed with PBS two times and then fixed with 2%
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paraformaldehyde in PBS at 4 OC overnight. The cells were then washed with PBS 3
times and then incubated with 1 mL/well of PBS. To stain the nucleus, 2 p•t of Hoescht
33342 (2 mM solution in water) was added to each well and incubated at room
temperature for 15 minutes. Afterwards, the cells were washed with PBS 3 times. The
cells were visualized with a fluorescent inverted microscope (Zeiss Axiovert 200) using
FITC and DAPI filters.
Cytoxocity Testing. Hep G2 cells were detached from the flask with trypsin-EDTA and
seeded into 96-well plates (BD Falcon) at 10,000 cells/well. The cells were incubated
overnight at 37 'C in a 5% CO 2 atmosphere. The media was aspirated and incubated in
100 ýtl of polymer dissolved in complete media for 24 to 48 hours. Afterwards, the
media was removed and replaced with 100 ýtl of complete media. 10 pl of MTT (5
mg/ml in PBS) was added to each well. The cells were incubated for 4 hours at 37 'C,
and then 50 pl of an extraction solution (20% sodium dodecyl sulfate in 1:1 DMF/Water
pH 4.7, adjusted with 0.5 N HC1/40% acetic acid) was added. The plates were left
overnight at 37 'C. A BioTek Powerwave microplate plate reader was used to get the
absorbance at 570 nm.
4.3 Results and Discussion
Linear-dendritic block copolymer micelles are promising polymeric nanoparticles
for drug delivery. 13' 23 Linear-dendritic block copolymer micelles with the dendritic
block forming the interface between the core and the aqueous environment may offer an
advantage over linear block copolymers due to the presentation of dense functional
groups on the surface of the nanoparticles. A representation of PPO-PAMAM generation
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4.0 was developed in Materials Studio, which was equilibrated in an environment with a
dielectric constant of 4.0 to simulate water (Figure 4-1). As seen in Figure 4-1, the length
scales of the PAMAM dendritic ends are approximately 1-3 nm apart. Multivalent
binding systems that have been previously studied exhibiting binding on similar length
scales are lectins. For example, asialoglycoprotein receptors bind to galactose in a
trivalent fashion with a triangular binding configuration that is approximately 2 nm
apart. 15  Therefore to determine whether PPO-PAMAM has the ability to bind
multivalently for targeted drug delivery, the system chosen for testing was the
asialoglycoprotein receptor and galactose as the binding ligand.
4.3.1 Synthesis of Galactose Functionalized PPO-PAMAM
In order to conjugate galactose to the dendritic ends of the linear-dendritic block
copolymer, half generations of PPO-PAMAM were used (Figure 4-2). The PPO-
PAMAM was synthesized as previously described in Chapter 2. The PPO-PAMAM half
generations, terminating in methyl ester groups, were deprotected in basic methanol. The
reaction was monitored by FTIR observing the disappearance of the ester peak at
approximately 1740 cm-1 as shown in Figure 4-3.
An amine derivative of D-galactose, galactosylamine, was attached to the
dendritic ends of the PPO-PAMAM block copolymers utilizing conventional amidation
chemistry. Due to the disparate solubility of each block, the best solvent to use was
DMSO. The coupling agents used were either BOP or HBTU with HOBT. These
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Figure 4-1. Model of PPO-PAMAM generation 4.0 generated in Materials Studio and
equilibrated by molecular dynamics in GROMACS.
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v
H OH
Galactosylamine
NH-Q
Figure 4-2. Synthesis of PPO-PAMAM-Galactose from a half-generation PPO-PAMAM
deprotected through base hydrolysis. Galactose is added through traditional amidation
chemistry.
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Figure 4-3. FTIR of PPO-PAMAM generation 2.5 before and after methyl ester
deprotection. The disappearance of the 1740 cm-1 indicates the deprotection of the
methyl ester group.
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coupling reagents were used in approximately 5 times excess of the reactive groups to
ensure completion of coupling. Additionally, the reactions were run for 2 to 4 days.
Reactions with PPO-PAMAM generations 2.5, 3.5, and 4.5 were performed. The
reaction products were analyzed with 1H-NMR and MALDI-TOF. 'H-NMR indicates the
presence of the galactosylamine after purification. MALDI-TOF was used to determine
the molecular weight of the polymer before and after the reaction. The amount of
galactosylamine was calculated based on the gain in mass. As seen in Table 4-1, the
percent functionalization ranged from 27% to 60%. It is possible that the percent
functionalization could be increased by reacting the galactose functionalized polymer
again, or it is possible that the functionalization with galactose plateaus due to steric
hindrance and crowding at the periphery of the dendrimer. Testing was performed on
polymers 2, 4 and 5 listed in Table 4-1.
4.3.2 In Vitro Testing
An initial test to gauge the targeting potential of the galactose-functionalized
polymers was performed with primary rat hepatocytes. Asialofetuin, a protein with 14
galactose and 2 N-acetyl-galactosamine, 24 was first modified with a fluorescent molecule
(Alexa Fluor 488 succinimidyl ester). When the fluorescent ASF (ASF-AF488) is
incubated with the primary rat hepatocytes, the ASF-AF488 binds multivalently to the
asialoglycoprotein receptors on the surface of the hepatocytes and is taken up into the
cells by receptor-mediated endocytosis. This can be seen by the bright spots, presumably
endosomes, as shown in Figure 4-4A. When ASF-AF488 is incubated with excess
soluble ASF, which would block the binding of fluorescent ASF, there is no uptake and
no punctuated bright spots present in the cells (Figure 4-4B). There is only nonspecific
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Table 4-1. Percent galactose functionalization of various generations of PPO-PAMAM.
-COOH -Galactose % Functionalized
Polymer Generation
MW (g/mol) MW (g/mol) (# attached/# available)
1 Gen 2.5 7001 8318 46 (7.4/16)
2 Gen 2.5 7001 9070 60 (9.6/16)
3 Gen 3.5 9338 11224 27 (8.7/32)
4 Gen 3.5 9338 12557 56 (18/32)
5 Gen 4.5 15173 18921 33 (21/64)
6 Gen 4.5 15173 21617 56 (36/64)
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Figure 4-4. A) Primary rat hepatocytes incubated with ASF-AF488 (25 ug/ml). B)
Primary rat hepatocytes incubated with ASF-AF488 (25 ug/ml) and excess ASF (1
mg/ml). C) Primary rat hepatocytes incubated with ASF-AF488 (25 ug/ml) and excess
PPO-PAMAM-Gal gen. 3.5 (0.5 mg/ml). D) Primary rat hepatocytes incubated with
ASF-AF488 (25 ug/ml) and excess PPO-PAMAM-Gal gen. 4.5 (0.5 mg/ml). For
treatment A, there is uptake of ASF-AF488 through receptor-mediated endocytosis. For
treatments B, C, and D, very little fluorescence indicates that uptake of ASF-AF488 was
blocked by excess reagent.
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binding (Figures 4-4C and 4-4D). When ASF-AF488 is incubated with galactose-
modified PPO-PAMAM generations 3.5 and 4.5, there is also only nonspecific binding.
Thus, the galactose-modified PPO-PAMAM binds to the asialoglycoprotein receptor and
prevents uptake of ASF-AF488.
Cytotoxicity testing was used to determine the useable polymer concentrations for
all in vitro testing. Hep G2 cells were incubated with polymers varying in concentration
and compared to cells with no treatment to determine the IC50, which is defined as the
concentration at which 50% of the cells are still viable. MTT tests indicate that all of the
polymers tested, PPO-PAMAM-COOH and PPO-PAMAM terminating in galactose,
except for PPO-PAMAM-Galactose G2.5 had IC50o values greater than 10 mg/ml (Table
4-2). Ideally, the working concentration of the polymer should be lower than the IC50
and higher than the CMC to ensure micelles are still present. Concentrations of 5 mg/ml
of polymer were chosen for subsequent tests since it is below the IC50 and well above the
CMC.
For targeting efficacy studies, doxorubicin was chosen as the model drug due to
its absorbance at 495 nm, its fluorescence properties, and its hydrophobicity. An
oil/water emulsion technique was used for the encapsulation of doxorubicin into PPO-
PAMAM micelles.25 The doxorubicin was prepared by dissolving it in chloroform and 3
molar excess amounts of triethylamine. The triethylamine is present to ensure
deprotonation of the amine group of the doxorubicin, which converts the doxorubicin to a
hydrophobic state. The doxorubicin solution was added dropwise to an aqueous solution
of preformed PPO-PAMAM micelles. The emulsion is stirred overnight in the dark, and
the chloroform is removed through evaporation. The amount of doxorubicin
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encapsulated is quantified by UV-vis and compared against a standard curve created in
the same solvent. The amount of doxorubicin encapsulated for all generations ranged
from 10-30 tg/ml.
Drug release studies of doxorubicin from PPO-PAMAM generation 4.0 micelles
were conducted. The release studies were done in PBS at 37 *C. As seen in Figure 4-5,
drug release is quite fast, with a half-life of approximately 1 hour. Ideally, drug release
should last over a period of at least a day, since the half life of micelles or other colloidal
particles circulating in the body has been observed as high as 98 hours.25' 26 However, for
the purposes of later studies, the release times are long enough to ensure that during the
duration of in vitro targeting efficiency studies most of the drug being delivered is still in
the micelles.
In vitro experiments to determine targeting efficiency were performed with PPO-
PAMAM generations 3.5 and 4.5 (polymers 4 and 5 from Table 4-1). PPO-PAMAM
generation 2.5 modified with galactose was too toxic to be used. PPO-PAMAM
generations 3.5 and 4.5 either terminating in carboxylic acid or galactose were used to
encapsulate doxorubicin. These micellar solutions were diluted with Opti-MEM media
modified with 2 mM Ca2+ to obtain doxorubicin concentrations ranging from 10 gLg/ml to
0.01 Jlg/ml. The micellar solutions encapsulating doxorubicin, bare doxorubicin as a
positive control, and only Opti-MEM were incubated with Hep G2 cells in 96 well plates
for 1 hour. Afterwards, the solutions were removed and replaced with complete media.
The cells were incubated for 48 hours. Cytotoxicity due to the doxorubicin delivered was
determined by MTT testing.
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Table 4-2. IC50 and CMC values for various generations of PPO-PAMAM modified
with galactose and unmodified.
Polymer IC50 (mg/ml) CMC (mg/ml)
PPO-PAMAM Gen 2.5-COOH >10 0.07
PPO-PAMAM Gen 2.5-Galactose 0.4 0.09
PPO-PAMAM Gen 3.5-COOH >10 0.09
PPO-PAMAM Gen 3.5-Galactose 8 0.11
PPO-PAMAM Gen 4.5-COOH >10 0.34
PPO-PAMAM Gen 4.5-Galactose >10 0.34
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Figure 4-5. Drug release of doxorubicin from PPO-PAMAM generation 4.0 micelles in
PBS at 37 oC.
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Figure 4-6 is an example of the results of the targeting efficacy studies. The cell
viability as compared to the negative control was plotted against the doxorubicin
concentration. The IC5o values were determined from these plots. Figure 4-7
summarizes the results obtained for PPO-PAMAM generations 3.5 and 4.5 in comparison
to bare doxorubicin. The ICso of doxorubicin was 4.2 + 2 ptg/ml. For PPO-PAMAM
generations 3.5 and 4.5 terminated with carboxylic acid, the IC 50 values were not
significantly different from bare doxorubicin (p = 0.15). For PPO-PAMAM generation
3.5 and 4.5 with galactose groups present, the IC 50 was lower than the non-functionalized
PPO-PAMAM micelles (p << 0.05 for both generations 3.5 and 4.5). This indicates that
the addition of targeting ligand increases the uptake of doxorubicin into the HepG2 cells.
For targeted generation 3.5 micelles, there was no significant decrease in cytotoxicity in
comparison to bare doxorubicin (p = 0.45). In contrast, for PPO-PAMAM generation 4.5
modified with galactose, the ICso was significantly smaller than bare doxorubicin (p =
0.03). It is possible that targeting with generation 4.5 micelles are much more efficient
than using generation 3.5 micelles due to several factors. With generation 4.5 PPO-
PAMAM's larger dendrimer head group, the end groups can sample a larger
configuration space that can bind to the asialoglycoprotein receptor. Although PPO-
PAMAM generations 3.5 and 4.5 had the same number of galactose attached to the
dendritic block, generation 4.5 performed much better. It is possible that for generation
3.5, the density of galactose was too high, where binding to the asialoglycoprotein
receptor was sterically hindered. In contrast, the generation 4.5 dendron was bigger and
had a lower density of galactose, which created a more ideal configuration of galactose
that would match the asialoglycoprotein binding sites. The improvement in the targeted
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Figure 4-6. Cell viability as a function of doxorubicin concentrations via different drug
delivery modalities.
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Figure 4-7. IC 50 values of doxorubicin for either bare doxorubicin delivery or
doxorubicin delivery via unmodified or galactose-functionalized micelles.
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generation 4.5 polymer compared to the control polymer is approximately 15-fold. In
comparison, other groups have seen improvements approximately 4 to 5 times better with
galactose functionalized linear polymers over non-targeted treatments.
27' 28
To ensure the results from the drug targeting efficacy experiments were due to
specific interactions, inhibition tests were performed. Similar to the primary hepatocyte
tests, varying concentrations of PPO-PAMAM generation 4.5 modified with galactose
encapsulating doxorubicin were incubated with increasing amounts of asialofetuin. As
shown in Figure 4-8, as the amount of asialofetuin increases, the IC 50 of the drug delivery
vehicle also increases. This indicates that the asialofetuin is blocking the binding and
delivery of the galactose-modified PPO-PAMAM micelles.
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Figure 4-8. Inhibition of PPO-PAMAM generation 4.5
containing doxorubicin with various concentrations of ASF.
galactose modified micelles
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4.4 Conclusions
Linear-dendritic block copolymer micelles have promise as a novel method to
incorporate multivalent targeting for drug delivery applications. Here we have shown
that micelles composed of linear-dendritic block copolymers are the proper size to bind
multivalently to lectins. Testing with primary rat hepatocytes and hepatocellular
carcinoma cells have demonstrated that galactose-functionalized PPO-PAMAM micelles
can bind to the asialoglycoprotein receptor specifically. Furthermore, these targeted
micelles can effectively deliver drug to the cells of interest. An application that was
explored in this work was delivering these micelles to cancer cells. Micelles are
particularly suited for delivery to solid tumors due to the EPR effect. Their size allows
for higher retention within the tumors, and with the addition of targeting ligand, retention
within the tumors and delivery into cells can be more effective. Therefore, large
improvements could be realized with targeted drug delivery vehicles that can bind in a
multivalent fashion.
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CHAPTER 5: Stabilization of PPO-PAMAM Micelles
5.1 Introduction
Colloidal drug delivery vehicles must be stable in solution for intravenous use in
vivo. It is possible for thermodynamically self-assembled structures, such as micelles or
vesicles, with high critical micelle concentrations (CMC) to break apart once introduced
into the bloodstream since dilution occurs and the concentration of the polymer falls
below the CMC. This results in dose dumping, in which high concentrations of drug,
which could be potentially toxic, are released prematurely.'
The most commonly used strategy to stabilize micelles is through crosslinking the
colloidal particle unimers to each other. Several crosslinking strategies have been
previously developed, including crosslinking the core of the micelle or crosslinking the
corona of the micelles. In order to crosslink the core, there are two different schemes.
The first strategy involves introducing a polymerizable group at the end of the
hydrophobic block. For example, the Kataoka group synthesizes poly(lactic acid)-b-
poly(ethyleneglycol) (PLA-PEG) block copolymers with a methacryloyl group at the end
of the PLA block. The polymerization is initiated with UV irradiation.2' 3 The other
method is to incorporate crosslinkable groups along the backbone of the hydrophobic
block such as poly(ethyleneoxide)-b-poly(butadiene) 4 and poly(2-cinnamoylethyl
methacrylate)-b-poly(acrylic acid)." The only drawback to this approach is that the free
volume in the core for hydrophobic drug encapsulation is reduced after crosslinking.
The other approach for directly crosslinking micelles is by crosslinking the blocks
forming the corona of the micelle. The Wooley group was the first to introduce shell
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crosslinked knedels. The corona of the micelles composed of poly(acrylic acid)-b-
poly(styrene) are crosslinked by introducing ethylene diamine.6-8
Much research has been performed on stabilizing micelles with available
functional groups. However, relatively few stabilization studies have been done with
block copolymers that do not have any functional groups. Three alternative strategies
have been explored for stabilizing pluronic systems: 1) stabilizing through direct
crosslinking of the core 2) stabilizing by introducing hydrophobic additives and 3)
stabilizing by physical entrapment. Direct stabilization of a pluronic was performed by
introducing a hydrophobic initiator, benzoyl peroxide into the micelle cores.9 It was
found that the free volume was dramatically reduced for drug loading. Experiments
using a hydrophobic additive, vegetable oil, showed increased stability of micelles below
the published CMC.9 The most developed method of stabilizing pluronic micelles is
through physical entrapment. Hydrophobic acrylamide9-11 or acrylate' 2 reactive
monomers are introduced into the core of the pluronic micelles by forming an emulsion.
The monomers are subsequently polymerized with either a heat-activated or UV-
activated initiator forming entangled polymer chains around the core of the micelle.
Stability tests, either using fluorescent probes or sonication, have shown this method to
work. However, in vitro testing of these systems has not been thoroughly performed.
There has been brief work exploring doxorubicin release through insonation, but very
little drug was released."
In this chapter we present a method to stabilize PPO-PAMAM micelles through
physical entrapment of the core with hydrophobic polymer. The stabilization is
performed through a UV-initiated emulsion polymerization, and the micelles are
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characterized after stabilization. The drug encapsulation and drug release behavior of
these micelles are explored. Additionally, the cytotoxicity of these stabilized micelles is
examined to determine whether this type of stabilization technique is viable to create
long-lasting circulating nanoparticles for drug delivery.
5.2 Experimental
5.2.1 Materials
Ethyl methacrylate, benzyl methacrylate, 1,3-butanediol dimethacrylate, 2,2
diethoxyacetophenone, 1,6-diphenyl-1,3,5-hexatriene (DPH), and phosphate buffered
saline (PBS) were obtained from Sigma-Aldrich and used as purchased. Water used in
all experiments is 18.2 Q MQ water.
5.2.2 Stabilization of Generation 4.5 PPO-PAMAM-COOH Micelles
Generation 4.5 PPO-PAMAM-COOH (5.0 mg/ml) was dissolved in water, which
had been purged with nitrogen for 1 hour, and the pH was adjusted to 7.4 with NaOH. A
dichloromethane solution containing mixtures of ethyl methacrylate, benzyl methacrylate,
1,3-butanediol dimethacrylate and 2,2 diethoxyacetophenone (1 ml) was added to the
aqueous solution to create an oil/water emulsion. The emulsion was stirred vigorously
overnight in a nitrogen environment in the dark to ensure the evaporation of the
dichloromethane. The solutions were placed in 6-well plates (BD Falcon) and stirred
while being exposed to UV light from a Blak-Ray UV lamp (Model B-100AP) for 2
hours. The solutions were lyophilized for later use.
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5.2.3 Characterization of Stabilized Gen. 4.5 PPO-PAMAM-COOH Micelles
Dynamic Light Scattering. Stabilized PPO-PAMAM micelles were dissolved in either
water or methanol (5 mg/ml). The solutions were filtered with 0.2 ýIm PTFE filters.
Dynamic light scattering was performed with a Brookhaven Instruments BI-200SM
Research Goniometer System. A Coherent Innova 90c (Santa Clara, CA) laser at 514.5
nm was used as the light source. The samples were measured at 900 and a quadratic
cumulants analysis was used.
Fluorescence Studies. DPH dissolved in tetrahydrofuran was added to scintillation
vials. The tetrahydrofuran was evaporated leaving behind 2 Rtg of DPH. Aqueous
solutions of stabilized and non-stabilized PPO-PAMAM micelles at varying
concentrations were incubated with the DPH and stirred overnight. The solutions were
analyzed with a FluoroMax-2 Spectrometer (Horiba Jobin Yvon, Longjumeau France) at
25 OC. Emission spectra were recorded over a range of 300 nm to 600 nm with an
excitation wavelength of 360 nm. The fluorescence intensity at 430 nm was used.
Drug Encapsulation. A solution of doxorubicin in 1 ml chloroform (1 mg/ml) and 3
molar equivalents of triethylamine were added dropwise to a vigorously stirred aqueous
solution of 5 mg/ml stabilized PPO-PAMAM micelles. The solution was left open to air
overnight in the dark. To remove unencapsulated doxorubicin, the solution was
centrifuged at 4500 rpm for 10 minutes, and the supernatant was filtered with a 0.2 gim
PTFE filter. The amount of doxorubicin encapsulated was determined with UV-vis
(Agilent 8453 UV-Visible Spectrometer System, Palo Alto, CA) by measuring the
160
absorbance at 495 nm and compared to a standard curve (Concentration (ptg/ml)
76.728*ABS 495-4.9553).
Drug Release. Stabilized PPO-PAMAM micelles (5 mg/ml) encapsulating doxorubicin
in PBS was placed into a dialysis bag (3500 MWCO, Spectrum Laboratories). The
dialysis bag was put into 1 L of PBS at 37 *C. Some of the micelle solution was removed
to measure the absorbance at 495 nm by UV-vis, and then placed back into the dialysis
bag. Measurements were taken at various time points.
Cell Culture. Hepatocellular carcinoma cells (Hep G2, ATCC HB-8065) were
maintained in Dulbecco's Modified Eagle Medium containing high glucose, 25 mM
HEPES, but no phenol red (DMEM, Invitrogen) supplemented with 10% fetal bovine
serum, 0.2 units/ml penicillin, and 100 pg/ml streptomycin. The cells were kept in an
incubator at 37 oC in a 5% CO2 atmosphere. The media was changed every two days.
When the cells were confluent, trypsin-EDTA was added to the flask. After 15-30
seconds, the trypsin-EDTA was removed, and the flask was incubated at 37 OC for 10
minutes. The cells were subcultivated at a 1:6 ratio.
Cytotoxicity Experiments. Hep G2 cells were seeded into 96 well plates (BD Falcon) at
a concentration of 10,000 cells/well. Varying concentrations of stabilized PPO-PAMAM
micelles were incubated with the cells for 48 hours in triplicate. After 48 hours, the
solution was removed, and 100 pl of complete media was added. 10 gl of MTT (5 mg/ml
in PBS) was added to each well. The cells were incubated for 4 hours at 37 'C, and then
50 pl1 of an extraction solution (20% sodium dodecyl sulfate in 1:1 DMF/Water pH 4.7,
adjusted with 0.5 N HCI/40% acetic acid) was added. The plates were left overnight at
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room temperature. A BioTek Powerwave microplate reader was used to get the
absorbance at 570 nm.
5.3 Results and Discussion
The linear-dendritic block copolymer composed of PPO-PAMAM forms micelles
in aqueous solution with a CMC of approximately 10- M.13 It is possible that when these
micelles are injected into the blood stream, dose dumping could occur (see Figure 5-1).
Therefore, a stabilization technique was explored for PPO-PAMAM-COOH Generation
4.5 micelles. The stabilization was performed by first introducing hydrophobic reactive
monomers into the core of the micelles. The monomers were polymerized creating
interpenetrating polymers that would entrap the hydrophobic PPO linear blocks together.
< CMC
Methanol
Figure 5-1. Amphiphilic linear-dendritic block copolymer micelles may break apart
upon dilution at concentrations below the CMC or in solvents that solubilize both
polymeric blocks.
5.3.1 Stabilization of Generation 4.5 PPO-PAMAM-COOH Micelles
The stabilization of PPO-PAMAM-COOH Generation 4.5 micelles were
performed with an emulsion polymerization. Three reactive monomers, ethyl
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methacrylate, benzyl methacrylate, and 1,3-butanediol dimethacrylate, were solubilized
in dichloromethane and introduced into the core of the PPO-PAMAM micelles (Figure 5-
2). The monomers were chosen because of their hydrophobicity, reactivity, and non-
cytotoxicity. 14 Ethyl methacrylate has been used in tissue engineering applications
previously. 15 Benzyl methacrylate was chosen because it had been shown previously that
doxorubicin is encapsulated better in the presence of benzyl groups due to pi bond
interactions between the drug and the polymer.16 A biodegradable crosslinker was used,
1,3-butanediol dimethacrylate, to ensure that the methacrylate polymer would degrade to
sizes amenable for removal by the kidneys.
The polymerization was initiated by UV-light. A hydrophobic photoinitiator, 2,2
diethoxyacetophenone, was introduced into the core of the micelles, and the emulsion
solution was exposed to UV-light while being stirred. The reaction was allowed to
proceed until completion and there was no discernible methacrylate odor. Furthermore,
the micelles were dialyzed to remove unreacted monomer.
-G<·ý7
UV
olymerizati
Ethyl Methacrylate/Benzyl Methacrylate
Butanediol Dimethacrylate
2,2 Diethoxyacetophenone
Figure 5-2. Methacrylate monomers are solubilized in the core of PPO-PAMAM
micelles through an emulsion. The monomers are polymerized with a UV-initiated
polymerization reaction, which forms polymers that interpenetrate the PPO core.
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The emulsion polymerizations were performed with either varying ratios of ethyl
methacrylate:benzyl methacrylate, methacrylate monomer:PPO-PAMAM polymer, and
crosslinker:methacrylate monomer. The initiator:methacrylate monomer ratio was kept
constant (see Tables 5-1 and 5-2).
5.3.2 Characterization of Stabilized Generation 4.0 PPO-PAMAM Micelles
In order to determine whether the micelles were stabilized after the emulsion
polymerization, dynamic light scattering was performed on the samples (formulation B
and C from Table 5-1). The stabilized micelles were measured either in water or in
methanol at 2 mg/ml. Generally, for both formulations in water, the hydrodynamic
diameter, Dh, was 22 nm. In contrast, the presence of micelles in methanol indicates that
the nanoparticles were stabilized. In methanol, unstabilized PPO-PAMAM micelles
would not form since both blocks are soluble in methanol, while stabilized micelles
maintained their structure. From DLS, the stabilized micelles had a Dh of 11 nm in size.
Both components of the PPO-PAMAM block copolymer are soluble in methanol, which
would induce swelling of the micelles. However, from the results, the micelles collapsed.
It is possible that the collapsed micelles were caused by the insolubility of the
methacrylate polymer in methanol.
In addition to dynamic light scattering, fluorescence was used to gauge the
stability of the stabilized micelles. Varying concentrations of aqueous solutions
containing PPO-PAMAM micelles either unstabilized or stabilized were incubated with
1,6-diphenyl-1,3,5-hexatriene (DPH). DPH is only fluorescent in hydrophobic
environments, and it can be detected at 430 nm. As seen in Figure 5-3, at below 1 mg/ml,
the unstabilized solution has a fluorescence intensity equal to the intensity of DPH in
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water, indicating that no stable micelles are being formed. In contrast, for the crosslinked
micelles, the DPH fluorescence emission intensity is well above the background level of
water at concentrations as low as 0.1 mg/ml. This suggests micelles are still formed at
concentrations below the CMC. Furthermore, the DPH fluorescence intensity of the
crosslinked micelles is higher at equivalent concentrations in comparison to the
uncrosslinked micelles indicating that the crosslinked micelles are also much more
hydrophobic.
Once determining that the emulsion polymerization worked to stabilize the
micelles, drug encapsulation was performed to explore how the methacrylate polymer
composition and concentration would affect the affinity of doxorubicin to the core. As
shown in Tables 5-1 and 5-2, the amount of doxorubicin encapsulated ranged from 10 to
20 jtg/ml. The amount of doxorubicin encapsulated by nonstabilized micelles was
approximately 6 gtg/ml. Generally, there did not seem to be an improvement in
doxorubicin encapsulation. However, it was observed that during the filtration step to
remove precipitated doxorubicin, there was quite a bit of polymer being removed from
the solution. During the encapsulation, the polymer had precipitated out along with the
drug due to increased hydrophobicity, which reduces the encapsulation efficiency. To
reduce aggregation, the amount of doxorubicin was decreased, as seen in Table 5-1. The
encapsulation efficiency increased for those formulations, but the doxorubicin
concentration encapsulated remained within the same range. Furthermore, in Table 5-1,
the amount of methacrylate monomer was reduced with each subsequent test, which
resulted in an increase in the amount of doxorubicin encapsulated. This is due to less
hydrophobic aggregation of the particles.
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Figure 5-3. Fluorescence measurements of DPH incubated with either uncrosslinked or
crosslinked PPO-PAMAM micelles.
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From Table 5-2, there did not seem to be a trend in the encapsulation efficiency
versus the composition and the amount of the methacrylate monomer. The formulations
that encapsulated the most doxorubicin (formulations 1, 4, and 8), either were composed
of 100% ethyl methacrylate, or 75% benzyl methacrylate. Generally, greater amounts of
crosslinker increased encapsulation efficiency. The differences between the amount of
doxorubicin are most likely not significant, and the largest factor to consider is the
amount of doxorubicin added for encapsulation and aggregation of the particles during
encapsulation.
A drug release study of doxorubicin from the crosslinked micelles was performed
at physiological conditions, in PBS buffer and at 37 'C. The formulation used for the
drug release profile was formulation B from Table 5-2. As seen from Figure 5-4, drug
release is much slower with crosslinked micelles. The drug release profile is more
relevant for clinical applications in comparison to the non-crosslinked micelles. The
slower drug release is most likely due to the increased hydrophobicity of the core. It is
also possible that increased affinity of doxorubicin to benzyl methacrylate could also
have slowed down the drug release.
Cytotoxicity testing of the crosslinked micelles was also performed. Various
concentrations of the crosslinked micelles (formulation B) were incubated with HepG2
cells for 48 hours. As seen in Figure 5-5, the IC50 is 2.2 mg/ml, which is lower than the
IC 50 of uncrosslinked micelles of >10 mg/ml. The addition of the methacrylate
monomers contributed to the increased cytotoxicity of the crosslinked micelles.
However, due to improved stability of the micelles, it is possible to use lower
167
Table 5-1.
concentration.
Formulation of methacrylate monomers by varying the monomer
Cone. EncapsulationEMA: Monomer: Crosslinker: Initiator: Doxorubicin
ormulation EfficiencyBMA Polymer Monomer Monomer Encapsulate Efficiency
(ug/ml)
Control -- -- -- -- 6 14.7
A 75:25 1:10 1:10 1:100 12 29.0
B 75:25 1:20 1:10 1:100 14 36.1
C 75:25 1:40 1:10 1:100 16 39.7
Fable 5-2. Various formulations of methacrylate monomers.
Cone. EncapsulationEMA: Monomer: Crosslinker: Initiator: Doxorubicin capsulation
ormulation EfficiencyBMA Polymer Monomer Monomer Encapsulated (%)
(ug/ml) %
1 100:0 1:20 2:10 1:100 18 14.5
2 75:25 1:20 2:10 1:100 14 11.0
3 50:50 1:20 2:10 1:100 n/a n/a
4 25:75 1:20 2:10 1:100 20 15.7
5 0:100 1:20 2:10 1:100 10 8.1
6 50:50 1:20 1:10 1:100 13 10.4
7 50:50 1:20 5:10 1:100 14 11.4
8 25:75 1:20 5:10 1:100 18 14.0
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Figure 5-4. Drug release of doxorubicin from crosslinked and uncrosslinked micelles in
PBS at 37 oC.
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Figure 5-5. Cytotoxocity of crosslinked PPO-PAMAM micelles with HepG2 cells.
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concentrations of polymer, although the limit would be around 0.1 mg/ml to 1 mg/ml as
determined by Figure 5-3. At these concentrations, the cell viability is only 60 to 70%,
which is not high enough to ensure biocompatibility.
5.4 Conclusions
For efficient drug drug delivery into the bloodstream, self-assembled micelles
must be stable and retain drug within the core before reaching the target site. Here we
have explored one method to stabilize PPO-PAMAM micelles through physical
entanglement of the core with hydrophobic poly(methacrylate)-type polymers. The UV-
initiated emulsion polymerization was performed on Generation 4.5 PPO-PAMAM-
COOH micelles. From dynamic light scattering and fluorescence measurements, it was
confirmed that the micelles were stabilized. It was also found that these micelles
encapsulated drug at higher amounts than unstabilized micelles. Furthermore, due to
increased hydrophobicity of the core and affinity of the drug to the core, drug release of
doxorubicin was considerably slowed. However, the increased hydrophobicity of the
micelles also increased the cytotoxicity of the micelles. In order to continue on with this
stabilization process, less cytotoxic monomers must be used. For example, either the
monomer composition could be entirely composed of methyl methacrylate or ethyl
methacrylate, or a different system entirely could be used, such as acrylamide systems.
The parameter space for these types of model systems need to be explored, but overall,
the stabilization process looks promising if cytotoxicity can be reduced.
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CHAPTER 6: Synthesis and Characterization of
Poly(j-Benzyl-L-Aspartate)-b-Polyester Dendron
6.1 Introduction
Poly(ethylene glycol) (PEG) is the most commonly used polymer to attach to
drugs,' the surface of liposomes,2-4 or block copolymer micelles5-7 to allow these drug
delivery vehicles to circulate for longer amounts of time within the body. PEG creates a
hydrodynamic barrier that prevents proteins from sticking to the surface (opsonization) of
these drug delivery vehicles and their removal through phagocytosis.
Recently, in the Hammond group, a novel linear-dendritic block copolymer was
developed with PEG attached to the outer surface of the dendron block.8, 9 This block
copolymer is comprised of a linear hydrophobic polypeptide block of co-1-dodecyl-L-
glutamate and a hydrophobic polyester dendritic block. The addition of the PEG groups
creates an amphiphilic polymer. The design of this linear-dendritic block copolymer is
quite tunable and flexible, where the alkane side groups on the polypeptide block can be
changed to either introduce polymerizable groups or other groups to increase
hydrophobicity or chemical affinity to certain drugs. Encapsulation of the block
copolymer with triclosan showed high loading efficiency. However, attempts at loading
more relevant drugs, such as doxorubicin were not successful.
Here in this chapter, a modification of the linear-dendritic block copolymer that
was developed is presented, which allows for greater affinity to doxorubicin.
Furthermore, the solution phase behavior of this block copolymer was examined to
determine its feasibility as a drug delivery vehicle.
175
6.2 Experimental
6.2.1 Materials
All chemicals including p-toluenesulfonic acid, 4-di(methylamino)pyridine
(DMAP), dimethoxypropane, 2,2-bis(hydroxymethyl)propionic acid (DMPA), N,N-
diisopropylcarbodiimide (DIPC), N-hydroxysuccinimide (NHS), and 1,1 -
carbonyldiimidazole (CDI) were obtained from either Sigma-Aldrich or VWR and were
used as purchased. Some solvents, such as dichloromethane and tetrahydrofuran, when
indicated by the word "dry" were obtained from a solvent still and were HPLC grade.
MilliQ (18.2 MC) water was used in all experiments requiring water
6.2.2 Synthesis
DPTS.'O 60 g (0.315 mol) of p-toluenesulfonic acid monohydrate was dried by
azeotropic distillation (130-150 0C) in a toluene solution (300ml) by using a Dean-Stark
trap setup. The distillation was run for approximately 3-5 hours. 40 g of 4-
(dimethylamino)pyridine (0.327 mol) was dissolved in warm dry toluene. The DMAP
solution was added to the p-toluenesulfonic acid monohydrate solution and stirred until
the solution reached room temperature. The crude solid was collected by suction
filtration. The product was recrystallized in 1200 ml of dichloroethane.
Isopropylidene-2-2-bis(methoxy)propionic Acid. 60 g (0.447 mol) of DMPA, 82.5ml
(0.671 mol) of dimethoxypropane, and 4.37 g (0.023 mol) of p-toluenesulfonic acid
monohydrate were dissolved in approximately 250 ml of acetone. The mixture was
stirred for 6 hours and then 6.0 ml of ammonium hydroxide was added to neutralize the
solution. The solvent was removed by rotary evaporation at room temperature. The
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crude product was dissolved in 800 ml of dichloromethane, and an extraction was
performed with water saturated with NaCi (100 ml, 3 times). The dichloromethane was
dried over magnesium sulfate. The magnesium sulfate was filtered through vacuum
filtration. The solvent was removed by rotary evaporation and vacuum dried overnight to
give white crystals (yield: 74%). '1H NMR (CDCl3): 81.19 (s, 3H, -CH 3), 81.43 (s, 3H, -
CH3), 61.47 (s, 3H, -CH3), 83.71 (d, 2H, -CH20), 84.18 (d, 2H, -CH 20).
Benzyl-2-2-bis(methylol)propionate. 18.0 g of DMPA (0.134 mol) and 8.60 g (0.153
mol) of potassium hydroxide were dissolved into 100 ml of DMF. The reaction was
stirred for 1 hour at 100 'C, and then 27.6 g (0.161 mol) of benzyl bromide was added.
After 15 hr, the DMF was evaporated off by rotary evaporation at 80 OC. The residue
was dissolved in 400ml of dichloromethane, and then washed with 100 ml water
saturated with NaCI 3 times. The solvent was then dried over magnesium sulfate. The
magnesium sulfate was removed through vacuum filtration. The solvent was removed by
rotary evaporation at room temperature. The crude product was dissolved in
approximately 30 ml dichloromethane and precipitated in 700 ml of hexane. After the
precipitated solution was stored overnight at -40 OC, the solvent was decanted. The
remaining solid was collected and vacuum dried overnight (yield: 88.2%). 1H NMR
(CDC13): 81.08 (s, 3H, -CH3), 63.75 (d, 2H, -CH20), 63.92 (d, 2H, -CH20), 65.20 (s, 2H,
-CH2Ar), 87.35 (m, 5H, -ArH).
B4 Dendron Generation 2. 10.0 g (0.0446 mol) of benzyl-2-2-bis(methylol)propionate,
16.3 g (0.0935 mol) of isopropylidene-2-2-bis(methoxy)propionic acid, and 5.25 g
(0.0178 mol)of DPTS were dissolved in approximately 120.0 ml of dry dichloromethane
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over nitrogen. The solution was stirred for 10 minutes, and then 15.6 ml (0.1 mol) of
DIPC was added into the reaction flask dropwise. The reaction was stirred overnight.
After stirring overnight, the solution was vacuum filtered to remove the precipitate. The
solvent was removed by rotary evaporation leaving thick oil. The crude product was
purified by column chromatography using silica gel and 1:1 ethyl acetate:hexane eluant.
The product was collected and dried by rotary evaporation and then vacuum dried (yield:
84.4%). 1H NMR (CDC13): 81.09 (s, 6H, -CH3), 81.30 (s, 3H, -CH3), 81.34 (s, 6H, -
CH3), 81.41 (s, 6H, -CH3), 83.58 (d, 4H, -CH20), 84.10 (d, 4H, -CH20), 84.34 (s, 4H, -
CH20), 85.16 (s, 2H, -CH 2Ar), 87.26-7.35 (m, 5H, -ArH). TLC (silica): Rf = 0.56 (1:1
ethyl acetate:hexane).
B4-COOH Dendron Generation 2. 9.0 g of B4 was dissolved in 100 ml of ethyl
acetate, and then 0.90 g of Pd/C catalyst was added to the reaction vessel. The solution
was placed under 15-20 psi of hydrogen gas and shaken for 8-10 hours. The solution was
vacuum filtered to remove the catalyst. The solvent was removed by rotary evaporation
leaving an oily product (yield: 96.5%). 1H NMR (CDCl3): 81.15 (s, 6H, -CH 3), 81.32 (s,
3H, -CH 3), 81.36 (s, 6H, -CH 3), 81.42 (s, 6H, -CH 3), 83.63 (d, 4H, -CH20), 84.16 (d, 4H,
-CH 20), 84.34 (s, 4H, -CH20).
B4-OH Dendron Generation 2. B4 (5.34 g, 9.95 mmol) was dissolved in 75 ml of
methanol. Approximately 1.4 teaspoons of Dowex HI catalyst was added to the reaction
vessel. After 3 hours stirring at room temperature, the Dowex H+ was removed by
vacuum filtration. The solvent was removed through rotary evaporation. The crude
product was dissolved in 150 ml of ethyl acetate. An extraction was performed on the
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solution with saturated salt water (70 ml, 3 times). The organic solution was dried over
magnesium sulfate. The magnesium sulfate was filtered off, and the solvent was
removed by rotary evaporation. The product was vacuum dried overnight producing
white crystals (yield: 77.3%). 1H NMR (CDCl 3): 81.09 (s, 6H, -CH 3), 81.30 (s, 3H, -
CH3), 83.58 (d, 4H, -CH20), 84.10 (d, 4H, -CH20), 84.34 (s, 4H, -CH20), 85.16 (s, 2H, -
CH 2Ar), 87.26-7.35 (m, 5H11, -ArH).
B16 Dendron Generation 4. 12.0 g of B4-COOH (0.0269 mol), 3 g of B4-OH (6.57
mmol), and 2.7 g of DPTS (9.17 mmol) were dissolved in approximately 150 ml of dry
dichloromethane. The clear solution was stirred under nitrogen for 10 minutes, and then
5.3 ml of DIPC (0.034 mol) was added dropwise. The reaction was stirred overnight.
After stirring overnight, the solution was vacuum filtered to remove the precipitate. The
solvent was removed by rotary evaporation at room temperature, leaving a thick oil. The
crude mixture was purified with a silica gel column running an 8:2 mixture of ethyl
acetate:hexane. The appropriate fractions were collected, and the solvent was removed
by rotary evaporation and vacuum dried overnight (yield: 60.3%). 1H NMR (CDCl3):
81.12 (s, 24H, -CH3), 81.18 (s, 6H, -CH 3), 81.27 (s, 12H, -CH3), 81.30 (s, 3H, -CH 3),
81.35 (s, 24H, -CH 3), 81.41 (s, 24H, -CH 3), 83.62 (d, 16H, -CH20), 64.13-4.16 (m, 16H,
-CH20), 84.19-4.30 (m, 28H, -CH20), 85.16 (s, 2H, -CH2Ar), 87.39-7.59 (m, 5H, -ArH).
TLC (silica): Rf = 0.65 (8:2 ethyl acetate:hexane).
B16-COOH Dendron Generation 4. B16 dendron (13.0 g, 5.99 mmol) was dissolved in
100 ml of ethyl acetate. 1.30 g of Pd/C catalyst was added to the reaction flask. The
solution was hydrogenated under 15 PSI of hydrogen gas and shaken for 8-10 hours. The
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Pd/C catalyst was removed by vacuum filtration. The solvent was removed by rotary
evaporation and dried overnight under high vacuum (yield: 93.6%). 1H NMR (CDCl3):
81.12 (s, 24H, -CH3), 61.18 (s, 6H, -CH 3), 81.27 (s, 12H, -CH 3), 81.30 (s, 3H, -CH3),
81.35 (s, 24H, -CH 3), 81.41 (s, 24H, -CH 3), 83.62 (d, 16H, -CH 20), 84.13-4.16 (m, 16H,
-CH20), 64.19-4.30 (m, 28H, -CH20).
B16-NH 2 Dendron Generation 4. Dissolve 12.0 g of B16-COOH (5.77 mmol) and 1.89
g of CDI in 150ml of dry THF and stir under nitrogen gas for 4 hours. After stirring for 4
hours, add 3.07 ml of diaminopropane (0.0364 mol) into the reaction vessel as quickly as
possible. The reaction was stirred for 1 day. The precipitate was removed by vacuum
filtration, and the solvent was removed by rotary evaporation. The crude product was
dissolved in approximately 500 ml of dichloromethane. The solution was washed first
with water saturated with sodium bicarbonate (100 ml) and then with 100 ml of saturated
salt water (3 times). The solvent was dried over magnesium sulfate removed through
rotary evaporation. The crude product was purified with silica gel column
chromatography using 9:1 CH2C12:MeOH. The solvent was removed through rotary
evaporation and vacuum dried overnight (yield: 12.9%). 'H NMR (CDC13): 81.12 (s,
24H, -CH 3), 61.27 (s, 21H, -CH3), 81.35 (s, 24H, -CH 3), 81.41 (s, 24H, -CH 3), 61.84 (m,
2H, -CH 2-), 82.98 (m, 2H, -CH2N-), 83.42 (m, 2H, -CONCH 2-), 83.62 (d, 16H, -CH20),
64.14 (d, 16H, -CH20), 64.25-4.35 (m, 28H, -CH20). TLC (silica): Rf = 0.4 (9:1
CH 2C12:MeOH).
P-Benzyl-L-Aspartate N-Carboxyanhydride (BLANCA). B-benzyl-L-aspartate (3 g,
0.0134 mol) was dissolved in 30 ml of dry tetrahydrofuran. 1.40 g (4.69 mmol) of
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triphosgene was added to the solution. The solution was stirred at 50 oC. After
approximately half an hour, the solution was clear. The solution was stirred for a total of
3-4 hours, and then precipitated into 10 times excess hexane. The white precipitate was
collected by vacuum filtration and vacuum dried for approximately 5 hours (yield: 85%,
m.p. = 125-127 'C). '1H NMR (CDCl3): 82.84 (d, 1H, -COCH2-), 83.08 (d, 1H, -
COCH2-), 84.59 (m, 1H, -CHNH-), 65.19 (s, 2H, -CH 2Ar), 67.34-7.41 (m, 5H, -ArH).
FTIR (cm-'): 1736 (-COOBn), 1789 (-COO-), 1857 (-COO-).
Poly(3-Benzyl-L-Aspartate)-B16 (PBLA-B16). 2.45 g (9.84 mmol) of BLANCA was
dissolved in 30 ml of dry dichloromethane, while in a separate reaction flask, 1.6 g (0.76
mmol) of B16-NH2 was dissolved in 20 ml of dry dichloromethane. The B16-NH 2
solution was added to the BLANCA solution, and then 5 ml of DMF was added. The
reaction was stirred at 40 'C and monitored until the anhydride peaks (1790 and 1820 cm
1) disappeared. Most of the solvent was removed through rotary evaporation and then
precipitated in 10 times excess diethyl ether. The precipitate, white powder, was
collected through vacuum filtration and vacuum dried overnight (yield: 67%). 'H NMR
(CDC13): 81.12 (m, 24H, -CH3), 81.25 (m, 21H, -CH 3), 81.33 (s, 24H, -CH 3), 81.39 (s,
24H, -CH 3), 82.67-3.06 (bs, -COCH2-), 83.60 (d, 16H, -CH 20), 84.13 (d, 16H, -
CH 20), 64.24-4.32 (m, 28H, -CH20), 64.56 (m, -CHNH-), 85.03 (bs, -CH2Ar), 67.22 (bs,
-ArH. FTIR (cm-'): 1539 (-CONH-), 1671 (-CONH-), 1737 (-COOR-).
Poly(3-Benzyl-L-Aspartate)-B16-OH (PBLA-B16-OH). 1.6 g of B16-PBLA was first
dissolved in 100 ml of THF, and then methanol was added. 3 g of Dowex IW was added
to the stirred solution. The reaction was run under argon for up to 48 hours. The reaction
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was monitored by NMR. After completion, the Dowex was removed by gravity
filtration. The solvent was removed by rotary evaporation and then redissolved in
chloroform. An extraction was performed with saturated salt water (2 times). The
organic phase was dried over magnesium sulfate and run through gravity filtration. The
solvent was removed by rotary evaporation. 'H NMR (CDCl 3): 81.12 (m, 24H, -CH3),
61.25 (m, 21H, -CH3), 82.67-3.06 (bs, -COCH2-), 83.60 (d, 16H, -CH20), 84.13 (d, 16H,
-CH 20), 64.24-4.32 (m, 28H, -CH 20), 64.56 (m, -CHNH-), 65.03 (bs, -CH 2Ar), 67.22
(bs, -ArH).
Poly(3-Benzyl-L-Aspartate)-B16-PEG (PBLA-B16-PEG). Poly(ethylene glycol)
bis(carboxymethyl) ether (10.92 g, 18.2 mmol) was dried through an azeotropic
distillation with toluene via rotary evaporation. PBLA-B16-OH (2.1g, 0.38 mmol) was
first dissolved in 20 ml of dry THF and then 120 ml of dry DCM was added. The
dissolved solution was added to the round bottom flask containing the dried PEG, and the
whole solution was stirred. 2.82 ml of DIPC (18.2 mmol) and 1.32 g (4.6 mmol) of
DPTS was added. The reaction took place for 3 days at room temperature. Afterwards,
insoluble precipitate was removed through gravity filtration. The organic solvent was
removed by rotary evaporation, and then DI water was added to the polymer. The
polymer was dialyzed for 1 day (MWCO 15k) at 4 OC, and then the solution was
concentrated by ultrafiltration with a centriprep centrifugal filter (Ultracel-YM 10,
Millipore). The polymer was lyophilized. Last, the polymer was dissolved in DCM and
precipitated in ethyl ether. 'H NMR (CDCl3): 61.12 (m, -CH 3), 61.25 (m, -CH3, -CH 2),
62.67-3.06 (bs, -COCH2-), 63.65 (m, -CH 2), 64.13 (m, -CH2), 64.32 (m, -CH20), 64.56
(m, -CHNH-), 65.03 (bs, -CH 2Ar), 67.22 (bs, -ArH).
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Poly(j3-Benzyl-L-Aspartate)-B16-PEG-NHS (PBLA-B16-PEG-NHS). PBLA-B 16-
PEG (0.3 g, 6.6 itmol) was dissolved in dichloromethane (10 ml), and DIPC (0.048 ml,
0.48 mmol) and NHS (0.055 g, 0.48 mmol) were added to the stirred solution. The
reaction took place for 2 days at room temperature. The solution was precipitated with
ethyl ether, and the polymer was collected by centrifugation. 1H NMR (CDCl 3): 81.12
(m, -CH3), 81.25 (m, -CH 3, -CH2), 82.67-3.06 (bs, -COCH2-), 82.83 (i, -CH 2), 83.65 (m,
-CH2), 84.13 (m, -CH2), 84.32 (m, -CH20), 84.56 (m, -CHNH-), 85.03 (bs, -CH2Ar),
87.22 (bs, -ArH).
Poly(j3-Benzyl-L-Aspartate)-B16-PEG-Galactose (PBLA-B16-PEG-Gal). PBLA-
B16-PEG-NHS (0.2 g) was dissolved in DMSO (5 ml) and 3 times molar excess of
galactosylamine was added. The reaction took place for 2 days. Afterwards, the reaction
solution was diluted 10 fold with DI water and dialyzed (MWCO 3500) for 1 day at 4 OC.
The solution was concentrated by ultrafiltration with a centriprep centrifugal filter
(Ultracel-YM 10, Millipore) and lyophilized. 1H NMR (CDCl3): 81.12 (m, -CH3), 81.25
(m, -CH3, -CH2), 82.67-3.06 (bs, -COCH2-), 83.65 (m, -CH 2), 63.8-84.0 (m, -CH2), 84.13
(m, -CH 2), 84.32 (m, -CH 20), 64.56 (m, -CHNH-), 85.03 (bs, -CH2Ar), 87.22 (bs, -ArH).
6.2.3 Polymer Characterization
During the synthesis, all of the polymers were characterized with 1H NMR, which
was performed on a 500 Mhz Varian Inova spectrometer. FTIR was done on a Nexus
870 FTIR Spectrometer (Thermo Nicolet, Waltham, MA). Samples were solvent cast
onto KBr disks.
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Fluorescence Studies. To determine the CMC of the PEG-modified linear-dendritic
block copolymer, a hydrophobic fluorescent probe, pyrene, was used.11' 12 The polymer
was suspended in a stock solution containing 10-7 M pyrene at concentrations ranging
from 1 mg/ml to 10-7 mg/ml and left overnight in the dark at room temperature to
equilibrate. The solutions were analyzed with a FluoroMax-2 Spectrometer (Horiba
Jobin Yvon, Longjumeau France) at 25 OC. Emission spectra were recorded over a range
of 355 nm to 500 nm with an excitation wavelength of 333 nm, while excitation spectra
were recorded from 300 nm to 360 nm with an emission wavelength of 390 nm.
Dynamic Light Scattering. Particle sizes were determined with dynamic light scattering
on a Brookhaven Instruments BI-200SM Research Goniometer System. A Coherent
Innova 90c (Santa Clara, CA) laser at 514.5 nm was used as the light source. Samples
were at 0.5 mg/ml and were filtered with a 0.45 Am polytetrafluoroethylene (PTFE)
syringe filter (Pall, East Hills, NY) and measured at 25 OC. Measurements were taken at
multiple angles from 45 to 135 degrees with 15 degree increments, and autocorrelation
functions were recorded at each angle. A fit of the autocorrelation function was made to
Equation 6-1 to obtain F, the linewidth.' 3 F was plotted against the square of the
scattering vector, q. A linear least-squares fit of the data is used to obtain DT, the
translational diffusion coefficient. Equation 6-3 relates q to the scattering angle, 9,
where n is the refractive index of the solution and X is the wavelength of the laser. The
Stokes-Einstein equation, as shown in Equation 6-4, is used to relate the hydrodynamic
diameter, dh, to DT for spheres, where k is the Boltzmann constant, T is the temperature,
and 11 is the viscosity of the solution. It was assumed that all solutions were dilute, such
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that there were no interparticle interactions and solution properties such as refractive
index and viscosity were equivalent to the properties of water at 25 'C.
C(r) = Ae -2 r + B (6-1)
F = Dq 2  (6-2)
4;nSin -2q =4 (6-3)
kTdhi = T (6-4)
3mlD,
6.2.4 In Vitro Testing
Drug Loading Studies. An oil/water emulsion technique with a model hydrophobic
drug, doxorubicin, was used for encapsulation with the copolymer. A solution of
doxorubicin in chloroform (0.5 ml, 1 mg/ml) and 3 molar excess of triethylamine was
slowly added to a stirring solution of 0.5 mg/ml of copolymer in water (5 ml). The
solution was vigorously stirred overnight at room temperature. To remove precipitated
drug, the solution was centrifuged for 10 minutes at 4500 rpm. The supernatant, which
contains the drug solubilized in micelles, was filtered with a 0.20 gim PTFE syringe filter
to remove insoluble doxorubicin. To remove soluble doxorubicin, the aqueous solution
was purified through ultrafiltration using a centriprep centrifugal filter (Ultracel-YM 10,
Millipore). Ultrafiltration was performed in triplicate. The concentration of doxorubicin
in water was quantified by UV-vis (Agilent 8453 UV-Visible Spectrometer System, Palo
Alto, CA) by measuring the absorbance at 495 nm and compared to a standard curve
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(concentration (tg/ml) = 76.728*ABS495-4.9553). The percent efficiency of
encapsulation was calculated with Equation 6-5 while the weight percent of encapsulated
drug was calculated with Equation 6-6.
weight of drug encapsulated% drug loading efficiency = weight of drug encapsulated x 100 (6-5)
total weight of drug introduced
% encapsulation = weight of drug encapsulated% encapsulation = x 100 (6-6)
weight of polymer
Drug Release Studies. The micellar solution encapsulating doxorubicin was lyophilized
and resuspended in phosphate buffered saline (PBS, pH = 7.4) and placed into 3500
MWCO dialysis bags (Spectrum Laboratories Inc., Rancho Dominguez, CA). The
dialysis bag was placed in 1 liter of buffer at 37 'C, which was changed every two days
to maintain sink conditions. Samples were taken out of the dialysis bag at various time
intervals and analyzed by UV-vis. The volume of solution in the dialysis bags were
measured at each sampling time, so that concentrations measured could be adjusted for
volume changes due to osmotic pressure differences and evaporation.
Cell Culture. Hepatocellular carcinoma cells (Hep G2, ATCC HB-8065) were
maintained in Dulbecco's Modified Eagle Medium containing high glucose, 25 mM
HEPES, but no phenol red (DMEM, Invitrogen) supplemented with 10% fetal bovine
serum, 0.2 units/ml penicillin, and 100 gg/ml streptomycin. The cells were kept in an
incubator at 37 'C in a 5% CO2 atmosphere. The media was changed every two days.
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When the cells were confluent, trypsin-EDTA was added to the flask. After 15-30
seconds, the trypsin-EDTA was removed, and the flask was incubated at 37 'C for 10
minutes. The cells were subcultivated at a 1:6 ratio.
Cytoxocity Testing. Hep G2 cells were detached from the flask with trypsin-EDTA and
seeded into 96-well plates (BD Falcon) at 10,000 cells/well. The cells were incubated
overnight at 37 OC in a 5% CO2 atmosphere. The media was aspirated and incubated in
100 tld of polymer dissolved in complete media for 24 to 48 hours. Afterwards, the
media was removed and replaced with 100 gll of complete media. 10 gl of MTT (5
mg/ml in PBS) was added to each well. The cells were incubated for 4 hours at 37 'C,
and then 50 ll of an extraction solution (20% sodium dodecyl sulfate in 1:1 DMF/Water
pH 4.7, adjusted with 0.5 N HCI/40% acetic acid) was added. The plates were left
overnight at 37 'C. A BioTek Powerwave microplate plate reader was used to get the
absorbance at 570 nm.
6.3 Results and Discussion
A variation of a linear-dendritic block copolymer was synthesized based on previous
work done in the Hammond group.8' 9 The linear-dendritic block copolymer is composed
of a linear hydrophobic block of poly(13-benzyl-L-aspartate) (PBLA), which was chosen
to interact better to the encapsulated drug, doxorubicin. 14 It is thought that the aromatic
groups in the PBLA would be able to interact with doxorubicin through pi-stacking
interactions.5, 15 The dendritic block is composed of a polyester dendron that is
biodegradable. The addition of the PEG groups on the outer periphery of the polyester
dendron transforms the block copolymer into an amphiphilic polymer. The addition of
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the PEG group allows for the self-assembled nanoparticles to avoid being taken up by the
reticuloendothelial system and allow for longer circulation times within the body.16', 17
6.3.1 Synthesis of PBLA-B16-PEG-Gal
The linear-dendritic block copolymer was synthesized first with the synthesis of
the polyester dendron block through a convergent synthetic method.' 8 The dendron block
was then used to initiate the polymerization of the poly(amino acid) block through a
pseudo-living polymerization reaction as shown in Figure 6-1.19 The degree of
polymerization was typically chosen from 10-15 monomeric units. Afterwards, the PEG
groups were added to the outer dendritic block through an esterification reaction. The
amount of PEG used was 3 molar excess of the reactive groups present in the dendron to
ensure that the PEG attached would not react at both ends and crosslink the dendrons.
The PEG groups had a degree of polymerization of approximately 10-15 units. It has
been shown that densely packed PEG groups can create an effective hydrodynamic
barrier against proteins.20 Due to the hydrophobicity of the PBLA-B16-PEG polymer,
any reactions in aqueous solution would be difficult. Therefore, the PBLA-B16-PEG
polymer was activated first with NHS in dichloromethane, and then galactosylamine was
added to the activated polymer in DMSO to be conjugated to the linear-dendritic block
copolymer (Figure 6-2). The synthesis was confirmed through 'H-NMR and FTIR.
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Figure 6-1. Synthesis of PBLA-B16-PEG composed of a hydrophobic linear block of
poly(f3-benzyl-L-aspartate), a polyester dendron, and PEG on the outer periphery of the
dendron.
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Figure 6-2. Functionalization of PBLA-B16-PEG with galactosylamine. First, the PEG
group was activated with NHS, and then the polymer was further reacted with
galactosylamine.
190
6.3.2 Characterization of PBLA-B16-PEG
To ensure that the block copolymers that were synthesized were amphiphilic and
would self-assemble in aqueous solution, the critical micelle concentration (CMC) of
PBLA-B16-PEG was determined through a pyrene fluorescence method. Constant
concentrations of pyrene were incubated with varying concentrations of polymer in DI
water. The ratio of the emission intensities at 373 and 393 nm were plotted as a function
of the polymer concentration to determine the CMC as shown in Figure 6-3. It was
determined that the CMC was 3.6e-8 M (5.5e-4 mg/ml), which is orders of magnitude
lower than the CMC found from pluronics21 and from the CMC of PPO-PAMAM linear-
dendritic block copolymers. 22 This indicates that these linear-dendritic block copolymers
would be more stable when introduced into the body for in vivo applications. In addition
to the extremely low CMC values found, the crystallinity and the low Tg of the PBLA
blocks thermodynamically slow down the disintegration of the micelles formed upon
dilution in the body.12' 23
To further probe the self-assembly behavior of PBLA-B16-PEG, dynamic light
scattering was used. Aqueous solutions of PBLA-B16-PEG were measured, and it was
found that the average hydrodynamic diameter of the aggregates formed were 70 ± 6 nm.
The correlation function of the samples displayed only one decay time, indicating that the
samples were monodisperse. 13 The hydrodynamic diameter indicates the presence of
micellar structures that may not necessarily be spherical in nature, but more cylindrical.
To produce smaller structures that are spherical, either the size of the linear block would
have to be reduced, or the size of the PEG groups would have to be increased according
to the Israelachvili model.24
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Figure 6-3. Ratio of the emission intensity of pyrene at 373 nm and 393 nm at various
concentrations of PBLA-B16-PEG. The CMC is determined as 3.6e-8 M (5.5e-4 mg/ml).
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6.3.3 In Vitro Testing
Doxorubicin was loaded into PBLA-B16-PEG micelles through an oil/water
emulsion technique. Due to the increased hydrophobicity of the polymer, the polymer
concentration and the amount of doxorubicin added was critical to ensure that the
polymer and drug would not aggregate. Aggregation and precipitation would reduce the
loading efficiency. It was determined that the loading efficiency was 36 ± 6% with a
loading capacity of 6 w/w%. In comparison the PBLA-PEG block copolymers, the
loading capacity of the linear-dendritic block copolymers was lower. The PBLA-PEG
block copolymers had a loading efficiency ranging from 39-43 w/w% and a loading
capacity of 12-22 w/w%.25 The difference could be due to the purification procedure,
where the linear-dendritic block copolymers were filtered before ultrafiltration. During
filtration, polymeric aggregates containing doxorubicin were removed, which would
lower the drug loading capacity value. Additionally, the presence of aggregates in the
solution could potentially stabilize the formulation, creating less destabilization and drug
release during the ultrafiltration step.
A drug release study on the linear-dendritic block copolymer micelles
encapsulating doxorubicin was performed. The test was done in a sink of PBS at 37 "C
to simulate physiological conditions. As seen in Figure 7-4, there were two phases of
drug release, with an initial burst and then delayed drug release which was more linear in
nature. The tl/2 of release was approximately 15 hours, which indicates that these
nanoparticles interact with doxorubicin better than PPO-PAMAM micelles either through
greater hydrophobic interaction or chemical affinity between the aromatic rings present in
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Figure 6-4. Release profile of doxorubicin from PBLA-B16-PEG micelles in PBS at 37
oC.
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F
the drug and polymer structure. Furthermore, the overall release of the drug was
sustained for a period of weeks, which is relevant for clinical applications.
PBLA-B16-PEG was tested for cytotoxicity on HepG2 cells. Figure 6-5 indicates
that the polymer is not toxic for a large range of concentrations, up to the solubility limit
of the polymer in PBS. Most likely, the presence of the PEG groups makes the polymers
less toxic.
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Figure 6-5. Cytotoxicity of PBLA-B16-PEG on HepG2 hepatocellular carcinoma cells.
The polymer is non-toxic over a large concentration range.
6.4 Conclusions
A linear-dendritic block copolymer, PBLA-B16-PEG, has been synthesized and
characterized. This block copolymer composed of a linear hydrophobic polyaspartate-
based polypeptide, a polyester dendron, and PEG groups forms stable micelles in
solution. The CMC is in the 10-8 M region. Furthermore, the hydrophobic block has a
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low T,. Therefore, when administered into the body, the block copolymer micelles
would be less apt to break apart, and the kinetics of the micelle destabilization would also
be slow. The block copolymer also exhibited good in vitro properties, with its ability to
encapsulate doxorubicin and had an extended release profile. Moreover, the polymer was
not toxic, and would be degradable at the ester bonds through hydrolysis and at the amide
bonds through enzyme-catalyzed hydrolysis. The block copolymer was also
functionalized with a targeting ligand, galactose. The reactivity of the block copolymer
allows for functionalization with other targeting ligands as well. This linear-dendritic
block copolymer offers a lot of flexibility in tuning the polymer for a specific drug
delivery purpose. Additionally, with the presence of the PEG groups on the outer
periphery of the nanoparticles formed, the block copolymer micelles would be able to
circulate in the body for longer amounts of time, to allow for accumulation at solid tumor
sites through the EPR effect and also through receptor binding. The linear-dendritic
block copolymer synthesized has a lot of promise as a targeted drug delivery vehicle,
especially in the area of multivalent targeting.
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CHAPTER 7: Incorporation of PPO-PAMAM Linear-
Dendritic Block Copolymer Micelles Into Extended
Release Antibacterial Layer-by-Layer Films
7.1 Introduction
The layer-by-layer (LbL) method of assembling thin films has drawn a great deal
of attention because of its versatility' and potential use in many applications, including
cell patterning,2 controlled drug release,3 and biosensors.4 In this chapter we demonstrate
the use of charged linear-dendritic block copolymer micelles as a building block for LbL
films, providing a matrix for the incorporation of hydrophobic drug into ionically
crosslinked LbL assemblies at high concentrations. The micelles remain intact within the
LbL films, providing hydrophobic microenvironments. Drug release lasts over a
clinically relevant period of weeks in an active form, which has previously not been
demonstrated with hydrophobically encapsulated molecules in LbL films.
LbL films are easily fabricated by exposing charged substrates sequentially to
baths of oppositely charged polyions; in some cases, hydrogen bonding acceptors and
donors are also used.5 The films are able to conformally coat substrates of nearly any
geometry, making them useful as coatings for medical devices such as implants or stents.
Several common strategies for using LbL films for drug delivery have been
demonstrated. The first general area involves coating microparticles with an LbL film.
The film can act as a diffusion barrier when coating a hydrophobic drug microparticle,3
or hollow LbL microcapsules can be fabricated and loaded with water-soluble drug.6' 7
These types of LbL systems rely on diffusion of the drug through the LbL layer, which is
often only slowed down by a matter of hours. An alternative approach is to integrate the
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drug directly into the thin films during the fabrication process. For example, our group
has previously shown that LbL films composed of drug and a degradable polymer, can be
used to release the drug gradually as the film comes apart.8' 9 The drawback to using the
drug as one of the building blocks of the film is that it has only included drugs which are
polyionic and water soluble. This method excludes drugs without the necessary
functionality and water solubility, such as small, hydrophobic molecules. A solution to
this limitation has been offered by the use of prodrugs to integrate hydrophobic
molecules into the LbL assembly.'0 However there are also limitations with this
approach. Drugs with no functional groups may not be used, and for drugs with multiple
functional groups, the synthesis of the prodrug would require many steps. Another
method to incorporate hydrophobic drugs is to use porous multilayers to take up
hydrophobic molecules and then release them in aqueous solution." A disadvantage of
this approach is that it requires the use of organic solvents to dissolve the drug, which
may still be present in the films and cause toxicity. Furthermore, the amount of drug
loaded may be limited by diffusion and poor interaction and wetting of the multilayer
with the organic solvent. Interactions between the drug and the multilayer, such as
electrostatics or other secondary forces may also prevent the drug from being released.
Our approach to incorporating drug molecules that would otherwise exhibit poor
integration into LbL films is to use amphiphilic block copolymers. This method is more
universal than other previous approaches because amphiphilic block copolymers, which
self-assemble in solution, can be designed to solubilize and encapsulate any hydrophobic
molecule within the hydrophobic core of the self-assembled structure. Encapsulation can
be achieved at high concentrations. Incorporation into micelles provides an environment
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isolated from the rest of the film, which protects the drug from adversely interacting with
other components of the LbL structure. The only requirement is that the hydrophilic
block be polyionic; thus, this approach is quite flexible and can be adapted to include a
number of biocompatible materials. The hydrophobic block can be tuned to interact with
the encapsulated hydrophobic drug for greater encapsulation efficiency and for
adjustment of release times. The amount of drug in the film can be adjusted either by the
amount of drug encapsulated by the block copolymer micelles or by altering how many
bilayers of polymer are deposited.
Other groups have explored incorporating charged micelles into LbL assemblies.
Some of these micelles need to be stabilized through crosslinking prior to assembling in a
LbL film,12, 13 while others are directly incorporated into the film with no modification. 14-
16 There are limitations to these films, as the release times of representative hydrophobic
molecules in all of these systems were quite short, on the order of several minutes for 10
to 16 bilayer films.14' 16
This early progress, though encouraging, did not indicate a route toward greater
control of the drug release profile or delivery times. This study is the first to investigate
LbL/micelle thin films as a viable sustained release drug delivery device. We have
integrated linear-dendritic block copolymer micelles encapsulating a hydrophobic
antibacterial drug into LbL films. Dendritic polymers have recently been shown to have
potential for use as biomaterials and as drug delivery agents. 1719 Our group has recently
synthesized a linear-dendritic block copolymer,20 using hydrophilic poly(amidoamine)
(PAMAM) dendritic blocks, and a hydrophobic poly(propylene oxide) (PPO) linear
block. The copolymer assembles in water such that the linear block forms the
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hydrophobic interior of the micelle, with the positively charged dendrons on the exterior.
It has been shown that the polymers form micelles in solution and have a significantly
higher encapsulation capacity for a model hydrophobic bactericide, triclosan, over
pluronic micelles. 20 These micelles incorporated into the LbL films have a long release
time, and the drug released is still active, providing the possibility for the film to be
utilized as an antibacterial coating for implants.
7.2 Experimental
7.2.1 Materials
Poly(acrylic acid) (PAA) (M, - 90,000, 25% aqueous solution) was obtained from
Polysciences. Pyrene (sublimed, 99%) and 5-chloro-2-(2,4-dichlorophenoxy)phenol
(triclosan, ;97.0% purity) were purchased from Sigma-Aldrich and used as received.
Quartz slides were obtained from Chemglass and silicon was purchased from Silicon
Quest International.
7.2.2 Synthesis of PPO-PAMAM
The synthesis and complete characterization of the amphiphilic ABA linear-
dendritic block copolymers have been previously published.20  Briefly, the synthesis
begins with poly(propylene glycol) bis(2-aminopropyl ether) (a,o-amino-PPO). The
poly(amidoamine) (PAMAM) blocks are synthesized from the amine ends of the PPO
with alternating reaction steps of 1) Michael addition with methyl acrylate, and 2)
exhaustive amidation with ethylenediamine. Generation 4.0 PPO-PAMAM block
copolymers with 16 amine ends present on each dendritic block were synthesized. The
synthesis of the block copolymer was confirmed through 1H-NMR and FTIR.
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Drug Loading. An oil/water emulsion technique was utilized to load a model
hydrophobic drug, triclosan, into preformed PPO-PAMAM micelles. Triclosan,
dissolved in dichloromethane, was added dropwise to an aqueous solution of PPO-
PAMAM. The emulsion was vigorously stirred and left open overnight for the
dichloromethane to evaporate. The final concentrations of the PPO-PAMAM and
triclosan in aqueous solution were 19 mg/ml and 5 mg/ml, respectively. The solution
obtained was centrifuged at 4500 rpm for 10 minutes. Any undissolved triclosan was
removed with a 0.45 ýtm PTFE syringe filter. To quantify the amount of drug in solution
for subsequent studies, the solution was analyzed by an Agilent 8453 UV-Visible
Spectrometer System (Palo Alto, CA). The characteristic absorbance of triclosan was
measured at 281 nm. For concentrated solutions of triclosan encapsulated by PPO-
PAMAM micelles, the solution was diluted with methanol in a 1:9 ratio. A calibration
curve applicable in the 0-100 pg/ml range for triclosan in 1:9 water:methanol mixtures
was used to determine the concentration (Y = 60.90*X - 1.22, r2 = .9973).
7.2.3 LbL Film Formation
LbL films were assembled with a modified programmable Carl Zeiss HMS slide
stainer. The films were constructed on quartz or silicon substrates approximately 1 cm
by 2 cm in size. The substrate was dipped into a PPO-PAMAM aqueous solution (1.9
mg/ml, with or without drug encapsulated) adjusted to pH 5.5 with dilute HCI for 10
minutes and then subsequently rinsed off in three water baths for 0.5, 1.0, and 1.0
minutes, respectively. Next, the substrate was dipped into an aqueous solution of PAA
adjusted to pH 5.0 with dilute HCI (20 mM based on repeat unit) for 10 minutes. The
substrate was rinsed off in three water baths for 0.5, 1.0, and 1.0 minutes, respectively.
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The dipping process was repeated until the number of layer pairs desired was achieved.
For LbL films containing pyrene, PPO-PAMAM micellar aqueous solutions were
incubated with 10-7 M pyrene overnight before being used for film formation.
7.2.4 LbL Film Characterization
Film thickness was measured with a Tencor P-10 Surface Profilometer. For film
fluorescence studies, the LbL films were formed on a quartz substrate, and a FluoroMax-
2 Spectrometer (Horiba Jobin Yvon) was used to obtain emission spectra. The emission
spectra were recorded over a range of 355 nm to 500 nm with an excitation wavelength of
333 nm. For detection of triclosan deposited in the LbL films on a quartz substrate, an
Agilent 8453 UV-Visible Spectrometer System was used.
Grazing Incidence Small Angle X-ray Scattering (GISAXS). LbL films of PAA and
PPO-PAMAM with or without triclosan on silicon substrates were examined with
GISAXS performed at the G1 beamline at the Cornell High Energy Synchotron Source
(CHESS). The wavelength of the incident beam was 1.239A, the sample to detector
distance was 1122 mm, and a 2-D area detector was used for data collection.21
Thermogravimetric Analyzer (TGA). LbL films were deposited onto polypropylene
substrates. Films composed of PAA and PPO-PAMAM with or without triclosan were
fabricated up to 150 layer pairs. The films were peeled from the substrate and tested on a
TA Instruments Q50 Thermogravimetric Analyzer. The films were equilibrated at 120
'C for 15 minutes before the temperature was ramped up at a rate of 5 'C per minute up
to 600 'C.
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Elemental Analysis. LbL films were prepared in the same fashion as the films used for
TGA analysis. The analysis was performed by Atlantic Microlab, Inc (Norcross, GA).
7.2.5 In Vitro Testing
Drug Release Studies. LbL films on silicon substrates composed of PAA and PPO-
PAMAM encapsulating triclosan were placed into vials of phosphate buffered saline
(PBS) at pH 7.4 and 37 'C. To maintain sink conditions, the films were moved to fresh
vials of PBS at appropriate time points. The PBS solutions were analyzed with UV-vis.
A calibration curve of triclosan in PBS from 0-9 pg/ml was used to calculate the
concentration of the solution and the amount of triclosan released (Y = 105.76*X -
0.0599, R2 = .99).
Kirby Bauer Test. A standard Kirby Bauer test was performed using Staphylococcus
Aureus (S. Aureus).22 Cation-adjusted Mueller Hinton broth was inoculated with S.
Aureus and cultured overnight. The culture was diluted to a concentration where with
UV-vis, the O.D. was 0.1 at 600 nm. The culture was then grown for an additional 4
hours, and then plated onto agar plates containing cation-adjusted Mueller Hinton broth.
LbL films of PAA and PPO-PAMAM with or without triclosan on 3 mm by 3 mm silicon
substrates were placed onto the plate. The plates were incubated at 37 "C overnight. A
zone of inhibition (ZOI) was measured for each sample and was calculated as:
= Outer Diameter of Inhibition - Diameter of SubstrateZOI = (7-1)2
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7.3 Results and Discussion
LbL films containing amphiphilic linear-dendritic block copolymers
encapsulating a hydrophobic bactericide were produced as a potential drug delivery
coating (see Figure 7-1). The LbL films produced are comprised of poly(acrylic acid)
(PAA) and PPO-PAMAM block copolymer micelles. The linear-dendritic block
copolymer is composed of a hydrophobic block of poly(propylene oxide) (PPO) flanked
by two hydrophilic dendritic poly(amidoamine) (PAMAM) blocks (Figure 7-2).
Generation 4.0 PPO-PAMAM linear-dendritic block copolymers, with 16 primary amine
ends on each block, were used to form charged micelles in aqueous solution with the PPO
block forming the core and the PAMAM block forming the corona of the micelle. Non-
cytotoxic materials were intentionally chosen for these LbL systems; PAA and PPO are
biocompatible, while PAMAM is non-cytotoxic when the primary amines are
complexed.23-2 5 For these studies, the micelles were used to encapsulate a hydrophobic
bactericide, triclosan. Triclosan has a log Pow (octanol-water) of 4.76 and a water
solubility of 10-2 mg/ml. As shown in a previous paper, the loading efficiency of
triclosan into PPO-PAMAM micelles is significantly high (86 w/w%) compared to the
loading efficiency of F127 (42 w/w%), a pluronic with similar PPO block length and
CMC value. 2o Loaded micelles were approximately 30 nm in diameter, as determined by
dynamic light scattering. It is hypothesized that the architecture of the linear-dendritic
block copolymer aids in increasing the loading capacity.
7.3.1 Formation and Characterization of Micelle-Containing LbL Films
The LbL films were formed through an alternating dipping process in which
the positively charged micelles acted as the counter-polyelectrolyte to PAA in the
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pH = 5.0
PPO-PAMAM Gen. 4.0
pH = 5.5 (pKa ~ 6, 9)
Figure 7-1. Schematic illustrating the formation of LbL films with positively charged
PPO-PAMAM micelles encapsulating either hydrophobic drug or pyrene and negatively
charged PAA.
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Figure 7-2. Chemical structure of PPO-PAMAM generation 4.0.
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assembly procedure.
The films were fabricated on either quartz or silicon surfaces, with the positively
charged micelles acted as the counter-polyelectrolyte to PAA in the assembly procedure.
The films were fabricated on either quartz or silicon surfaces, with the positively charged
PPO-PAMAM micelles deposited first from an aqueous solution. The solution
containing PPO-PAMAM micelles encapsulating triclosan was adjusted to a pH of 5.5 to
ensure that the primary amines and the tertiary amines on the PAMAM dendrimer were
protonated. The concentration of polymer was at 1.9 mg/ml, which is well above the
critical micelle concentration of approximately 10-5 M, and the concentration of drug in
solution was 0.5 mg/ml. After several rinse steps, the film was exposed to negatively
charged poly(acrylic acid) (PAA). The concentration of the PAA solution was 20 mM
based on the repeat unit, with a pH of 5 to yield a partially charged polymer. The dipping
process was repeated multiple times until the desired film thickness was achieved (Figure
7-1). Films were formed in a linear fashion from 4 bilayers up to 25 bilayers (Figure 7-
3). On average, a bilayer was approximately 108 nm thick. Previous experiments from
dynamic light scattering had determined the hydrodynamic diameter of generation 4.0
PPO-PAMAM micelles as 17 nm in pH 5.5 water. Assuming a perfectly spherical
micelle, the radius of gyration is calculated as 5.7 nm. TEM measurements indicated
micelle size to be approximately the same order of magnitude.20 The large bilayer
thickness suggests that either PAA is heavily deposited into the film, multiple layers of
micelles are added to the film, or both. It should be noted that similar large bilayer
thicknesses are observed for other polyamine/polyacid films when the pH values are
close to the pKa of the polyions. Examples include assembly of poly(allylamine
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hydrochoride) (PAH) and PAA, and linear polyethyleneimine (LPEI) and PAA. The
pKa of PAA is approximately 5.5 to 6.5.26 The pKa's of the tertiary and primary amines
in PAMAM have been observed as 3.9 and 6.9, respectively, by one group, 27 and
approximately 6 and 9, respectively, by another group.28 The construction of films from
partially charged weak polyelectrolytes tend to lead to polymer chains with thick, loopy
conformations within the multilayer. Additional polymer-polymer interactions such as
hydrogen bonding can also yield thicker films.
Film growth was also corroborated by measuring the UV-vis absorbance of the
triclosan incorporated into the film via the micelles as a function of the number of
bilayers in the film. As shown in Figure 7-4, triclosan was integrated into the films
linearly up to 25 bilayers.
To ensure the triclosan remained in the micelles during the LbL dipping process,
an indirect assessment was done by measurement of pyrene fluorescence in the films.
The use of pyrene fluorescence can confirm the presence of hydrophobic encapsulating
domains within the film. PPO-PAMAM micelles were equilibrated in an aqueous
solution with 10-7 M pyrene. The LbL films were fabricated with the PPO-PAMAM
micelles encapsulating pyrene on quartz substrates. The fluorescence emission spectra of
the films were measured, and the maximum emission at 393 nm was recorded. Similar to
the thickness and UV-vis measurements, there was a linear relationship between the
number of bilayers in the film and the fluorescence emission of the pyrene in the film
(Figure 7-5). Additionally, examining the vibronic band intensities of the fluorescence
emission spectrum can elucidate the nature of the pyrene environment.2 9 The ratio of the
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Figure 7-3. Growth curve of PAA
linear growth from 4 to 25 bilayers.
and PPO-PAMAM encapsulating triclosan indicating
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Figure 7-4. UV-vis measurements of triclosan at a characteristic wavelength of 281 nm
at varying number ofbilayers in a PPO-PAMAM-triclosan/PAA LbL film showing linear
incorporation of triclosan into the film.
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Figure 7-5. Fluorescence measurements of PPO-PAMAM-pyrene/PAA LbL films as a
function of the number of bilayers in the film.
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emission intensity at 383 nm to 373 nm (13/11) is indicative of the type of solvent-solute
interactions of pyrene and its environment; this ratio is higher in more hydrophobic
environments. In LbL films of PPO-PAMAM and PAA, the 13/1 ratio of pyrene was
0.91, while the I3/Il ratio of pyrene in an aqueous PPO-PAMAM solution above the
critical micelle concentration was 0.85. In contrast, the 13/11 ratio for pyrene in aqueous
solutions of PPO-PAMAM below the CMC was 0.73. The 13/I1 ratio indicates that
pyrene is in a hydrophobic environment that is at least as hydrophobic as the original
micelles in solution. Furthermore, films fabricated from aqueous solutions of linear
poly(ethyleneimine) (LPEI) with 10-7 M pyrene and solutions of PAA revealed no
integration of pyrene into the film, indicating that hydrophobic domains are needed for
pyrene incorporation (Figure 7-6).
To further confirm the presence of micelles in the LbL films, GISAXS was
performed on LbL films composed of PPO-PAMAM and PAA. The films contained
either empty micelles or micelles encapsulating triclosan. GISAXS allows for the
investigation of periodic structure within a thin film with respect to orientation. The off-
specular scattering can be analyzed for incidence angles close to the critical angle of total
external reflection of the composite, allowing for both lateral structure within the film
and structure normal to the substrate to be investigated. 30 From the GISAXS data, as
shown in Figure 7-7, it was established that there was regular spacing of 10.5 nm and
11.7 nm in the plane parallel to the substrate for the films with no drug and with drug,
respectively. Additionally, for the film containing drug, scattering in the angstrom length
scales indicate the presence of triclosan, which has crystallized within the micelles. As
reported in earlier work, the triclosan loading is unusually large in the linear-dendritic
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Figure 7-6. Pyrene emission spectra of LPEI/PAA films and PPO-PAMAM G4/PAA
films.
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Figure 7-7. GISAXS scattering data of a 10 bilayer LbL film composed of PPO-
PAMAM micelles and PAA. Scattering reveals there is regular spacing of 10.5 nm
spacing in the direction parallel to the substrate. There is some evidence of scattering in
the plane perpendicular to the substrate but is inconclusive.
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block copolymer micelles, yielding stabilized nanoparticles containing bulk drug within
the core of the micelle. There is also evidence of regular spacing on the nanometer
length scale of the same order of magnitude in the direction normal to the substrate,
which would correspond to the spacing of the micelles in the y-plane direction.
However, the scattering is less intense and inconclusive due to interference of the beam
stop and specular reflectance. The spacing in the LbL films revealed by GISAXS is of
the same order of magnitude as the size of the micelles determined in aqueous solution,
based on the calculated radius of gyration of 5.7 nm.
To ensure that the spacing determined from GISAXS was caused by regularly
spaced micelles, the volume fraction of each film component was calculated. The
volume fraction calculations were based on weight fractions assuming a density of 1
g/ml. Elemental analysis was performed on LbL films of PAA and PPO-PAMAM. The
volume percent which is equivalent to weight percent due to the density assumption was
51% for PAA and 49% for PPO-PAMAM in the film. These numbers closely match the
theoretical calculations for a configuration of 10 nm micelles closely packed to each
other in a layer as indicated by GISAXS (Figure 7-8). This configuration yields 48
(v/v)% of PAA and 52 (v/v)% of PPO-PAMAM. The differences calculated from
elemental analysis and the theoretical LbL structure can most likely be attributed to the
density assumption.
10 nm
Figure 7-8. Illustration of the possible configuration of PPO-PAMAM polymer micelles
within the LbL film with the spacing determined by GISAXS of 10 nm.
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Elemental analysis and TGA were also employed to determine the composition of
LbL films containing PAA and PPO-PAMAM micelles encapsulating triclosan. The
weight percent of each component was calculated by comparing the TGA data of the LbL
films to TGA data of bulk PAA, generation 4.0 PPO-PAMAM, and triclosan. There are
variations in the data between the two techniques because there is a larger error when
estimating film composition with TGA due to overlapping decomposition peaks of some
of the components. As seen in Table 7-1, the PPO-PAMAM content, ranging from 52-
57%, increased in comparison to films with no triclosan which had a PPO-PAMAM
content of 49%. The increase is most likely due to the increased hydrophobicity of the
PPO-PAMAM micelles encapsulating triclosan, which contributes to the driving force for
inclusion in the film. The weight percent of triclosan to PPO-PAMAM polymer in
solution was 26 (w/w)%. In comparison, in the film, the weight percent of triclosan to
PPO-PAMAM was 35%, calculated from both TGA and elemental analysis data. The
amount of drug loaded into the micelles before the dipping process was low in
comparison to the optimal loading capacity previously determined of 86%.20 Because the
micelles are not at their equilibrium loading capacity, the micelles incorporated into the
film are able to take up any free triclosan available in the PPO-PAMAM-triclosan
micellar dipping bath.
7.3.2 Drug Release and Efficacy
Drug release experiments were performed on the LbL film to determine the length
scales of drug release. LbL films (10 bilayers) on silicon substrates were placed in 0.1 M
PBS solutions at 37 OC. Sink conditions were maintained by changing the solutions
before the concentration of triclosan in the PBS was too high. As demonstrated in Figure
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7-9, the half-life of triclosan release was approximately 77 hours, with release lasting up
to 20 days.
Table 7-1. Composition of PAA and PPO-PAMAM with or without triclosan LbL films
as determined by two different methods.
PPO-PAMAM/PAA PPO-PAMAM*Triclosan/PAA
Film Component
Elemental Analysis TGA Elemental Analysis
PAA (wt %) 51 22 30
PPO-PAMAM G4 (wt %) 49 57 52
Triclosan (wt %) -- 20 18
According to the drug release profile, the mechanism of release from the film is
through diffusion. FTIR of a PPO-PAMAM/PAA film constructed with no drug and a
PPO-PAMAM-triclosan/PAA film after release show that the PPO-PAMAM remains in
the film as shown in Figure 7-10. The amide groups in the PAMAM block at 1650 and
1570 cm' are present after drug release. Furthermore, the relative intensities of these
peaks to the other peaks in the spectra are similar in magnitude. GISAXS further
indicates that the same spacing is maintained after drug release. Thus, with the film
remaining intact during the drug release process, the mechanism of diffusion release is
confirmed.
A Kirby Bauer assay was completed to determine the efficacy of the released
triclosan (Figure 7-11). LbL films (10 bilayers) of PAA and PPO-PAMAM with and
without triclosan on silicon substrates were tested against Staphylococcus Aureus. As the
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Figure 7-9. Drug release profile of triclosan in an LbL film composed of PPO-
PAMAM-triclosan/PAA. The release was performed at 37 OC in 0.1 M PBS.
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Figure 7-10. FTIR spectra of PPO-PAMAM/PAA films after triclosan release or PPO-
PAMAM/PAA films fabricated with no drug.
223
Figure 7-11. Agar plate of S. Aureus growth inhibited by release of triclosan from a 10
bilayer LbL film ofPPO-PAMAM micelles encapsulating triclosan and PAA.
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films are incubated with the bacterial agar plates, the drug diffuses out and leaves
a circular area free of bacteria called the zone of inhibition (ZOI). The ZOI for the film
containing drug was 14.6±0.3 mm while there was no ZOI of the film without drug.
7.4 Conclusions
An LbL film was fabricated incorporating micelles composed of a novel
amphiphilic linear-dendritic block copolymer. When compared to charged linear-linear
block copolymer micelles introduced into LbL films, as shown in other groups' past
studies' 4, 16, 31, drug encapsulation and release is superior in the case of PPO-PAMAM
micelles encapsulating triclosan due to the linear-dendritic architecture.20 The formation
of the PPO-PAMAM-triclosan/PAA film was shown to be linear after the initial first 4
bilayers. GISAXS and film composition measurements confirmed the presence of
micelles within the multilayer films. Additionally, in vitro tests indicated that the films
created are functional. Drug release studies show that there is prolonged release of drug
from the film over a period of several weeks. Due to the versatility of the LbL method,
the drug release time can be addressed by either changing the amount of drug
encapsulated within the micelles or by changing the number of times the substrate is
dipped into the electrolyte solutions, thereby controlling the total amount of drug within
the film. Kirby Bauer tests demonstrate that the drug released retains activity. The
results presented demonstrate the applicability of obtaining hydrophobic domains within
an LbL film by incorporating charged micelles in order to deliver hydrophobic drugs.
This could potentially be applied as a film coating to biomedical devices such as stents,
catheters, and other biomedical implants.
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CHAPTER 8: Conclusions and Future Work
The main objective of this thesis was to develop a novel amphiphilic linear-
dendritic block copolymer and explore its potential use as a drug delivery vehicle.
Previous work with linear-dendritic block copolymers developed polymers with
hydrophobic dendritic blocks that would form the core.1, 2 A feature unique to this
polymer system is the formation of micelles with the linear hydrophobic block forming
the core and the dendritic block facing the aqueous solution presenting dense functional
groups on the surface of the self-assembled micelles. The work detailed in this thesis is
summarized in the next section, going over the characterization of the polymer in an
aqueous environment and describing two potential applications where the linear-dendritic
architecture is used advantageously for drug delivery.
8.1 Thesis Summary
In Chapter 2, the synthesis and characterization of an amphiphilic linear-dendritic
block copolymer is described. The linear-dendritic block copolymer synthesized is
similar in structure to a pluronic, with a hydrophobic middle block composed of PPO
joined to outer hydrophilic dendritic blocks composed of PAMAM. A series of the PPO-
PAMAM block copolymers was synthesized with PAMAM generations varying from 1
through 6. To understand the linear-dendritic block copolymers' self-assembly behavior
in aqueous solution, the CMC was studied as a function of PAMAM generation, solution
pH, and the ionic strength. The generation of the PAMAM block was important to study
to determine the magnitude of the driving force for the self-assembly of the polymers and
whether the nanoparticles formed were stable enough for future use in vivo. The CMC as
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a function of pH and ionic strength were studied to understand the behavior of the block
copolymer in subsequent processing conditions and in vitro assay conditions, where the
block copolymers would experience a drop in pH moving from the environment of the
cell culture media to the environment of endosomes formed from receptor-mediated
endocytosis. The particle sizes of the self-assembled block copolymer nanoparticles were
also examined with dynamic light scattering and TEM. From these studies, it was found
that the nanoparticles formed were in the correct size range for systemic drug delivery
applications. Next, as an initial study, a model hydrophobic drug, triclosan, was used for
encapsulation by the PPO-PAMAM block copolymers. It was found that with the
presence of the PAMAM dendritic blocks, the encapsulation efficiency and the loading
capacity of triclosan was significantly higher compared to a pluronic counterpart. This
indicates that there are some synergies that are gained by introducing the dendritic block,
perhaps due to either triclosan being encapsulated in the PAMAM block or due to the
architecture of the linear-dendritic block copolymer. The results from Chapter 2 indicate
that the linear-dendritic block copolymers synthesized have solution-phase characteristics
that are within the design parameters for use as a circulating drug delivery nanoparticle
and have a lot of potential promise in that area.
Due to the interesting behavior found from the experiments detailed in Chapter 2,
Chapter 3 discusses molecular dynamics simulations of PPO-PAMAM unimers and
micelles to gain a better understanding of their atomistic details. Static light scattering
was performed to determine the aggregation number of the micelles, which was then used
to set up the micelle simulations. The results from the simulations indicated that the
unimers and micelles formed had high asphericity, and due to the asphericity, some water
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was observed in the core of these micelles. Furthermore, the amine terminal ends were
found to have some backfolding into the interior regions of the dendritic block, which
had previously been observed with simulations of full dendrimers. Last, from the
simulation that included triclosan in a micelle, it was found that triclosan did not localize
exclusively to the core but was present in the core and dendritic regions, which could
explain the high encapsulation data previously observed.
With the greater knowledge of the linear-dendritic block copolymers synthesized,
further studies to assess the potential benefits of utilizing the block copolymer
nanoparticles as systemic drug delivery vehicles were undertaken in Chapter 4. To take
advantage of the dense functional groups presented by the dendritic blocks on the outer
surface of the micelles, galactose was chosen as a targeting ligand due to its multivalent
binding behavior to the asialoglycoprotein receptor. Galactose was conjugated to PPO-
PAMAM of varying generations. Cytotoxicity studies indicated that the polymers
synthesized were not toxic and the concentrations that could be used for further testing
was well above the CMC. In vitro studies showed that the galactose-modified polymer
could bind to its corresponding receptor, the asialoglycoprotein receptor, and deliver
drugs to cells in a specific manner. The drug delivery efficiency improved drastically
with the addition of the galactose targeting ligand, ranging from a 2-15 fold decrease in
the IC5o over unmodified block copolymer micelle carriers. In comparison, linear
polymers such as HPMA, with galactose conjugated to its side chains only experienced a
4-5 fold improvement.3' 4 The in vitro studies detailed in this chapter show that there is a
lot of promise in utilizing these linear-dendritic block copolymers as multivalent drug
delivery carriers. Due to the length-scales of the dendrimer blocks, multivalent drug
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delivery is particularly suited for carbohydrate-lectin systems. A multitude of diseases
could be treated by taking advantage of the multivalent binding between carbohydrates
and lectins, such as colon and hepatic cancers, 5' 6 and hepatic inflammation. 7
With the positive in vitro results obtained in Chapter 4, improvements to the
linear-dendritic block copolymer system was presented in Chapters 5 and 6 that could be
implemented to increase the success of these systems when tested in vivo. Chapter 5
details a method to stabilize PPO-PAMAM micelles. The micelles were stabilized
through the physical entrapment of the core. Hydrophobic reactive methacrylate
monomers were introduced into the core of the PPO-PAMAM micelles through an
emulsion, and the monomers were polymerized with a UV-activated photoinitiator.
Fluorescence studies and dynamic light scattering revealed that the micelles were
stabilized at concentrations below the CMC and also in a solubilizing solvent condition.
Additionally, the monomers introduced into the micelle core led to higher drug
encapsulation and slower drug release. Although the results showed an improvement in
the drug delivery properties of the micelles, cytotoxicity tests revealed that the
introduction of the methacrylate monomers increased the cytotoxicity of the polymer. In
order to decrease the cytotoxicity, other reactive monomers would have to be explored.
Stabilizing the PPO-PAMAM micelles through physical entrapment yielded positive
improvements in the drug delivery characteristics of the micelles; however, some changes
would have to be made to decrease the cytotoxicity.
In Chapter 6, the synthesis and characterization of a new linear-dendritic block
copolymer was introduced. The chemical structure of the linear-dendritic block
copolymer is modified from what had been previously synthesized in the Hammond
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group.8, 9 This linear-dendritic block copolymer is composed of linear poly(P3-benzyl-L-
aspartate) (PBLA) and a polyester dendron. The PBLA block was introduced to have
greater affinity with the drug of interest, doxorubicin. Drug encapsulation studies
showed high encapsulation efficiency, and drug release from the nanoparticles formed
was slow and prolonged. Overall, the new block copolymers had an extremely low
CMC, which would reduce the need for further particle stabilization, and they self-
assembled in aqueous solution into micellar nanoparticles. The linear-dendritic block
copolymers synthesized also had PEG attached to the outer dendritic block. PEG was not
attached to the PPO-PAMAM block copolymers, since it was thought that the addition
would increase the polymers' CMCs and would make it impractical for in vivo use. With
this new linear-dendritic block copolymer design, even with the addition of PEG, the
CMC is still very low. The PEG is necessary to prolong the circulation of the
nanoparticles in the body by avoiding removal by the RES. Therefore, this new linear-
dendritic block copolymer has a lot of potential to be a successful targeted colloidal drug
delivery vehicle in vivo.
In Chapter 7, a different drug delivery application was explored for the PPO-
PAMAM micelles. In this application, the dendritic block is used as a densely charged
polyelectrolyte in the formation of a conformal coating created by the layer-by-layer
dipping process. The incorporation of linear-dendritic block copolymer micelles into an
LbL film was a general method offered to introduce hydrophobic domains into a
hydrophilic film for hydrophobic drug delivery. Through profilometry and fluorescence
studies, it was shown that the linear-dendritic block copolymer micelles formed films
with a counter-polyelectrolyte in a controlled and linear fashion. GISAXS and elemental
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analysis data confirmed that the linear-dendritic block copolymer micelles remained in
the film as micelles. Additionally, due to the exceptional loading capacity of triclosan in
PPO-PAMAM micelles, the LbL films created were unique in comparison to other LbL
films that had explored the use of block copolymer micelles. The amount of drug loaded
into the films was quite high, and the drug release out of the film was on the order of
weeks. Other groups had seen complete release of a model hydrophobic molecule in a
matter of minutes. '1, 11 Overall, the general approach that was suggested in this chapter
for incorporating hydrophobic domains into LbL films was shown to be a controllable
and a predictable method. Furthermore, the outstanding system that was fabricated which
could potentially be used as an antibacterial coating on biomedical implants gave greater
proof that this general method is a viable technique for hydrophobic drug delivery in LbL
films.
8.2 Future Work
In this section, future research directions related to studying and improving the
linear-dendritic block copolymer systems previously synthesized are discussed.
Improvements for the linear-dendritic block copolymer micelles used as both circulating
targeted colloidal drug delivery vehicles and as hydrophobic nanocontainers in a polymer
film coating are explored.
8.2.1 Improvements to the PPO-PAMAM System
One of the main issues encountered with the linear-dendritic PPO-PAMAM
system was that the system could possibly not be stable enough to maintain its structure
when administered systemically. In order to improve this aspect, either the hydrophobic
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block must be more insoluble or a method to crosslink the copolymer unimers has to be
determined. In order to increase the hydrophobicity of the block copolymer, a longer
PPO block could be used to decrease the HLB balance. Theoretically, the PPO block
could be synthesized to an unlimited molecular weight. However, for biological
applications, the PPO block would have to be limited to the size that could be removed
through kidney filtration since PPO can not be broken down degradatively. This size has
been cited as approximately 42-50 kDa for water-soluble polymers. 12
A method to stabilize the PPO-PAMAM micelles was suggested in Chapter 5
which involved physical entrapment of the PPO-PAMAM micelle core. However, direct
covalent bonding of the block copolymer backbone would be more desirable. Since PPO
does not have any reactive groups present, a scheme that would enable covalent bonding
would be to introduce another polymer block with reactive side chains. This could be
difficult to do since these side chains would have to be protected while the PAMAM
reactions are carried out to create the dendrimer. Furthermore, the protecting group
would have to be orthogonal to the methyl ester group, should the PAMAM synthesis end
in a half generation. Additionally, the reactive group on the side chains revealed after
deprotection should not be able to crosslink with the amines present on the PAMAM
dendrimer. A potential polymer block that could be introduced is polycysteine (Figure 8-
1). The amine on the PPO block could be used to initiate an N-carboxyanhydride (NCA)
ring opening polymerization, which reforms an amine at the terminus of the block. With
this, the PAMAM reactions could be carried forward as done previously with amine-
terminated PPO. With the introduction of the cysteine block, the block copolymer
micelles formed could be crosslinked in the shell region through oxidation of the thiol
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groups present on cysteine, or a dithiol linker could be introduced to ensure crosslinking
between unimers.
With the introduction of crosslinked disulfide bonds, the PPO-PAMAM system
would be more stable as micelles and would be biologically responsive. The primary
reducing agent for disulfide bonds in mammalian cells is glutathione. Glutathione is
abundant in the cell (in the millimolar range) while it is scarce in the blood plasma (in the
micromolar range). 13, 14 Therefore, the disulfide bonds could be used so that the drug
delivery vehicles would only destabilize and release drug in the cell, making the system
more specific and safer.
8.2.2 Improvements to the PBLA-B16-PEG System
The PBLA-B16-PEG linear-dendritic block copolymer has many of the desirable
attributes needed for circulating drug delivery nanoparticles. Furthermore, the design of
the linear-dendritic block copolymer allows for great flexibility. For example, the benzyl
side group on the polyaspartate block could be changed to include polymerizable vinyl
groups to further stabilize the micelles. However, with this strategy, crosslinking the
hydrophobic blocks would reduce the free volume in the core for encapsulation of
hydrophobic drugs. Here, a similar solution proposed in section 8.2.1 could be utilized
where an additional block could be introduced. The addition of another functional
polymer block would be even simpler with the use of another NCA-activated amino acid,
allowing for a one-pot reaction. For example, the B16 dendron could be used to initiate
the middle poly(amino acid) block, and once that reaction is complete, the NCA for the
terminal block could be added as shown in Figure 8-2.
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Figure 8-1. Synthetic scheme to create a triblock copolymer of PPO, polycysteine, and
PAMAM, where the polycysteine block adds a smart response component to the drug
delivery vehicle.
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Figure 8-2. Synthetic scheme for the synthesis of a triblock linear-dendritic block
copolymer with a polyester dendron, a linear PBLA end block, and a poly(amino acid)
middle block that could be used as either a proton sponge, biologically responsive
crosslinking system, or a covalently crosslinking system.
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With the formation of the triblock copolymer, many different functionalities could
be introduced. A feature that is lacking in the linear-dendritic block copolymer is a
stimulus-response mechanism where the drug release profile could be tuned. A method
that has been suggested in section 8.2.1 is to create a polycysteine middle block. Another
stimulus that is important in cancer therapies is pH. It has been found that tumors have a
lower pH than physiological pH ranging from 5.7 to 7.8.'5' 16 Moreover, for targeted drug
delivery vehicles, a pH responsive system is desirable. When targeted drug delivery
vehicles are taken up by cells through receptor-mediated endocytosis, vesicles called
endosomes form. The pH in endosomes is reduced by the protons that are pumped in. In
order to ensure complete drug release, a system created to destabilize and release drug at
low pH values is needed. The incorporation of polyhistidine into micelles as a way to
tune the response pH has been studied previously. 17' 18 It is hypothesized that histidine
can disrupt endosomes through the proton sponge effect due to the buffering capacity of
the imidazole groups present.19 The pKa of the histidine side chain is approximately 6.0
as measured by various methods.20 Therefore, histidine can absorb extra protons in the
endosome and act as a proton sponge. Additionally, histidine has been found to be
fusogenic as well, which could lead to the disruption the endosome membrane and the
release of its contents. 17 The introduction of the polyhistidine block would add multiple
benefits for the drug delivery vehicle by creating a stimulus-responsive system and
allowing for greater release of drugs from the endosomal compartment.
8.2.3 Multivalent Targeting
In addition to the galactose-functionalized system that was studied, another
multivalent system that could be explored is the folate-folate receptor system. This
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system is especially amenable for systemic targeted drug delivery. The folate receptor is
overexpressed in cancer cells and is clustered in lipid rafts for subsequent receptor-
mediated endocytosis.2 1  It has been found that folate receptors are clustered in
microdomains about 70 nm in size containing approximately 50 folate receptors.22 The
density of the folate receptors in the microdomain suggests that the receptors are spaced
apart in the nanometer length scale which would match the size of the drug delivery
vehicles that have been tested previously. This has been confirmed with folate-targeted
dendrimers, and multivalent interactions to the receptor have been observed.23
Approximately 3-4 folates were needed to achieve maximal binding.
The use of folate conjugated to the B16-PBLA-PEG linear-dendritic block
copolymer could yield a powerful multivalently targeting drug delivery system. The
synthesis of the block copolymer would only have to be slightly modified from the
synthesis of B16-PBLA-PEG-Gal (Figure 7-2). The y-carboxyl group of folate would
have to be modified to be an amine before reacting it with B16-PBLA-PEG-NHS as
shown in Figures 8-3 and 8-4.
OH
H-N N NN 
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DIPC/NHS
OH
CONH(CH2)nNH2
Figure 8-3. Activation of folate through conventional carbodiimide chemistry.
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the linear-dendritic block copolymer.
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With the two multivalent systems that have been proposed, galactose and folate, a
great deal is still needed to be explored. First, a more thorough study on the effects of
dendrimer generation and ligand density has to be undertaken. Previous studies with
dendrimers have shown that that there is an optimal density for the targeting ligand.2
3
, 
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With a self-assembled system, the trends observed may be more interesting. If the ligand
density and generation are varied, this may cause variations in the size of the particles
formed and different aggregation numbers of unimers in the nanoparticles. An additional
variable that needs to be studied is the PEG length. The PEG length influences the
multivalent binding behavior as well as the stability of the particles circulating in vivo.
An optimal PEG length should be determined to balance the destabilizing effect of an
increase in the CMC with increasing PEG length and increased RES removal with
decreasing PEG length.
8.2.4 PPO-PAMAM Micelles in LbL Films
PPO-PAMAM micelles were successfully incorporated into LbL films for
hydrophobic drug delivery. From the drug release profiles, the mechanism of release was
diffusion-controlled. Ideally, the drug release profile should be tunable. Further
experiments would have to be performed to determine how the drug release profile is
altered by varying the initial drug concentration encapsulated and the number of
multilayers fabricated. Most likely, the release curve should be similar, although the
length scales would be altered. A scheme to change the shape of the release curve is to
include degradable polyeletrolytes into the LbL film. Previous work in the Hammond lab
has demonstrated linear drug release profiles with a degradable polymer called Polyl.
25,' 26
Films containing tetralayers of PPO-PAMAM/PAA/Polyl/PAA have previously been
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constructed. However, these films expelled most of the drug content and most likely a
high concentration of PPO-PAMAM within the first 30 minutes of a drug release
experiment. This may be due to the disruption of the micelles by Polyl. Polyl has
hydrophobic domains that may interact with PPO-PAMAM. Additionally, it was
hypothesized that interdiffusion may play a role. Movement of LPEI through an LbL
film was observed, 27 and this may be occurring with PPO-PAMAM. Further exploration
of the fabrication conditions may lead to a more stable film. Possible factors that could
be tested include a different degradable polymer. Perhaps a polymer that is less
hydrophobic could be utilized. Another idea to explore is to vary the tetralayer structure.
For example, a film composed of [PPO-PAMAM/PAA]n/[Polyl/PAA], where n is 2 or
higher, may reduce the amount of interaction between PPO and Polyl. Another possible
way to reduce interdiffusion issues is to lightly crosslink the PPO-PAMAM/PAA bilayers
during the formation of the film.
By introducing a degradable polymer into the LbL film, the release rate of the
hydrophobic drug can be controlled in a more precise manner. Additionally, this may be
a way to gradually introduce circulating nanoparticles into the surrounding area. Ideally,
these nanoparticles would also be stabilized to ensure that they don't break apart due to
dilution effects. This application may be useful as a stent coating. Currently, stents are
being used to deliver hydrophobic drugs to the placement site. Additionally, there is lot
of injury induced in these areas, and previous studies have shown that nanoparticles
accumulate in arteries that have experienced balloon injury.28, 29 This may also be
applicable for treatment of ophthalmic neovascular diseases, where it has been reported
that micelles accumulate in the choroidal neovascularization sites in rat eyes.3o This
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delivery approach is promising for localized delivery and dispersion of drugs into the
affected area.
8.3 Concluding Remarks
This thesis demonstrated that linear-dendritic block copolymer micelles is a viable
drug delivery vehicle that could either be used as a circulating targeted nanoparticle or as
a nanoparticle embedded into a drug delivery film. It is hoped that the research presented
here contributed to the collective knowledge of the self-assembly behavior of these novel
amphiphilic linear-dendritic block copolymers and is a foundation for the further
acquisition of fundamental knowledge regarding multivalent binding behavior and drug
delivery. Additionally, it is hoped that the systems developed in this thesis provide a
foundation for the advancement in the design of drug delivery vehicles leading to the
creation of an optimized platform that is ultimately used to treat and cure important
diseases.
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